

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-001	The Kids Research Institute Australia	Murray Valley Encephalitis Virus	The researchers are aiming to produce a more effective vaccine against Murray Valley encephalitis virus and to test potential vaccines in mice.	Expired	8/03/2002	30/06/2007
DNIR-002	The University of Queensland	Investigate gene therapy for hypertension	The aim is to develop a new model for gene therapy by treating rats with hypertension (high blood pressure) with a gene which produces atrial natriuretic peptide.	Withdrawn		
DNIR-003	Institute of Medical and Veterinary Science	Construction of immortalized macrophage cell lines	This proposal aims to generate cell lines from macrophages isolated from patients who suffer from iron overload (haemochromatosis) to study the proteins involved in iron transport	Surrendered	21/01/2002	17/12/2002
DNIR-004	CSL Limited	Pilot Scale Fermentation and Processing of ESO-1 Antigen Expressed in Recombinant E.coli	The researchers will produce quantities of the protein coded for by the gene ESO-1, isolated from a human oesophageal carcinoma cell line, to be used to test the properties of the protein	Expired	4/02/2002	30/06/2009
DNIR-005	Murdoch University	Testing Protection of Cattle From Fluoroacetate	This proposal aims to test if cattle can be protected against fluoroacetate, a poison found in some native plants, by inoculating them with genetically modified bacteria.	Expired	11/02/2002	30/06/2004
DNIR-006	RMIT University	Evaluation of chimeric influenza virus, incorporating the fusion glycoprotein of respiratory syncytial virus	The researchers aim to generate a virus strain with potential as a live vaccine by replacing a gene from an influenza A virus strain with a gene from the respiratory syncytial virus.	Expired	15/02/2002	31/12/2004
DNIR-007	RMIT University	Cloning and inactivation of phospholipase gene from Clostridium perfringens to produce a non-toxic vaccine antigen - additional information received 13/02/02	The researchers are aiming to produce a vaccine against the chicken disease, necrotic enteritis, which is caused by the bacterium Clostridium perfringens.	Surrendered	5/03/2002	22/03/2012
DNIR-008	St Vincent's Hospital (Melbourne)	The role of Osteoclast Inhibitory Lectin in breast cancer metastases to bone	This research is to see if, in mice, an inhibitor of osteoclast formation can slow the spread of human breast cancer cells to bone.	Expired	18/02/2002	30/04/2003
DNIR-009	Novozymes Biopharma AU Limited	Production of humanised monoclonal antibodies from NSO cells	This proposal is to produce quantities of antibodies to be used in clinical trials.	Expired	11/03/2002	28/02/2003
DNIR-010	Australian Water Quality Centre	Rapid Methods for the Detection of Toxic Cyanobacteria	The aim of this project is to identify the genes associated with toxin synthesis in cyanobacteria and to construct cyanobacteria that don't produce the toxin.	Expired	2/04/2002	31/08/2006
DNIR-011	Westmead Institute for Medical Research	Cryptococcal phospholipases and secretion pathways: structure & potential targets for therapeutics	The structure and function of the phospholipase proteins in the fungus Cryptococcus neoformans will be studied and fungus without the proteins tested in mice and wax moth larvae Galleria mellonella	Licence issued	16/04/2002	31/03/2030
DNIR-012	Western Sydney Local Health District	Investigation of the roles of TNFa-related apoptosis-inducing ligand, TRAIL in the immune system	TRAIL is a molecule which is thought to specifically kill transformed and virus infected cells but not most normal human cells. The researchers are investigating the function of TRAIL within the immune system.	Surrendered	11/04/2002	10/02/2005
DNIR-013	Western Sydney Local Health District	Studies of cell growth & survival	The aim of the proposed dealing is to investigate the biological processes that regulate cell growth and survival.	Expired	16/04/2002	28/02/2008
DNIR-014	The Victor Chang Cardiac Research Institute	Transient overexpression of adrenergic receptors via the use of adenoviral vectors	The researchers will harvest and purify adrenergic receptors from rat livers to study the structure of the receptors.	Withdrawn		
DNIR-015	Novozymes Biopharma AU Limited	Production of NeoGARD antigens	The aim is to produce the antigens used in manufacturing a vaccine against neonatal scour in pigs.	Surrendered	2/04/2002	28/04/2006

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-016	Novozymes Biopharma AU Limited	Production of domain 1 of the human plasma protein Beta 2-glycoprotein 1	The project will produce recombinant protein which will be chemically modified for use in preclinical studies	Expired	18/02/2002	31/03/2003
DNIR-017	CSIRO	Reverse Genetics of Newcastle Disease Virus (NDV)	The researchers will determine the role of the matrix protein gene in NDV.	Expired	20/05/2002	30/06/2005
DNIR-018	CSIRO	Bone Repair	The aim is to identify genes and their most effective routes of administration to enhance bone repair.	Withdrawn		
DNIR-019	Deakin University	B55 gene over expression in Psammomys obesus	The researchers will study the effects on obesity and diabetes of over-expression of the B55 gene.	Expired	10/05/2002	31/08/2004
DNIR-020	Novozymes Biopharma AU Limited	Production of members of the inhibin hormone family in mammalian, insect, yeast and bacterial cells	The project will produce recombinant hormones for research reagents, clinical research and commercial biopharmaceuticals.	Surrendered	16/04/2002	28/04/2006
DNIR-021	QIMR Berghofer	HIV replication and gene expression	This project aims to determine the role of virus regulatory proteins in HIV replication and gene expression.	Surrendered	16/05/2002	12/03/2025
DNIR-022	Peter MacCallum Cancer Centre	Characterisation of the anti-apoptotic function of P-glycoprotein and transcriptional regulation of the MDR1 gene	The aim is to determine if the P-glycoprotein can protect tumour and normal cells against apoptosis (programmed cell death) produced by a variety of methods.	Surrendered	3/06/2002	29/06/2007
DNIR-023	St Vincent's Hospital (Melbourne)	The role of the cytokines receptor gp130 in prostate cancer	This study aims to determine whether the activation of gp130 in prostate cells influences the progression of prostate cancer.	Withdrawn		
DNIR-024	Novozymes Biopharma AU Limited	Production of recombinant proteins in mammalian, insect, yeast and bacterial cells	The project will produce a large range of recombinant proteins for research reagents, clinical research and commercial biopharmaceuticals.	Surrendered	25/06/2002	15/01/2008
DNIR-025	Royal Perth Hospital	Meningococcal virulence genes	The aim is to characterise the function and expression levels of virulence genes of the human bacterial pathogen Neisseria meningitidis.	Surrendered	5/07/2002	1/05/2007
DNIR-026	La Trobe University	The mechanisms of establishing and maintaining immunological memory	The aim is to investigate the development and maintenance of cytotoxic T lymphocyte (CTL) immunological memory against influenza virus proteins.	Surrendered	9/07/2002	18/07/2022
DNIR-027	University of Southern Queensland	Whooping Cough Vaccine IV	The aim is to create a safe non-invasive whooping cough vaccine which will neutralise consequences of the major toxin of Bordetella pertussis.	Surrendered	14/06/2002	30/11/2009
DNIR-028	University of Southern Queensland	Whooping cough vaccine V	The aim is to study Bordetella pertussis genes which are important in developing immune responses and protection from infection in mice.	Surrendered	5/07/2002	30/11/2009
DNIR-029	Australian National University	A drug screen for anti-viral compounds	The aim is to screen compounds for their ability to inhibit the human immunodeficiency virus (type 1) budding process.	Surrendered	19/07/2002	17/01/2006
DNIR-030	Biotron Limited	A drug screen for anti-viral compounds	The aim is to screen compounds for their ability to inhibit the human immunodeficiency virus (type 1) budding process.	Surrendered	19/07/2002	11/07/2007
DNIR-031	The University of Sydney	Porcine growth hormone production from recombinant E.coli	The aim is to model and optimise the production process of porcine growth hormone in 50 litre fermentations.	Withdrawn		
DNIR-032	CSIRO	In vivo analysis of modified myxoma virus for immunocontraception and vaccine development	The purpose of the proposed dealings is to produce recombinant myxoma viruses that could be used in the development of immunocontraceptives and/or vaccines.	Surrendered	24/07/2002	26/08/2005

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-033	Western Sydney Local Health District	Mechanisms by which CD44 variant exon 6 promotes disease progression in acute leukemia	The aim of the proposed dealings is to investigate the effect of the protein CD44v6 on the proliferation and survival of leukemic cells in culture and in mice.	Expired	12/07/2002	30/06/2006
DNIR-034	Australian National University	Modification of myxoma virus for immunocontraception and vaccine development	The purpose of the proposed dealings is to produce recombinant myxoma viruses that could be used in the development of immunocontraceptives and/or vaccines.	Surrendered	24/07/2002	27/02/2014
DNIR-035	Macfarlane Burnet Institute for Medical Research and Public Health	A replicon-based vaccine for Hepatitis C virus (HCV)	The purpose of the proposed dealings is to develop a vaccine for hepatitis C virus (HCV) using a novel RNA-based replicon system.	Surrendered	23/08/2002	17/10/2007
DNIR-036	Macfarlane Burnet Institute for Medical Research and Public Health	A cell culture system for Hepatitis C virus	The aim of the proposed dealings is to develop a mammalian cell culture system to study Hepatitis C virus using recombinant baculoviruses.	Surrendered	23/08/2002	17/10/2007
DNIR-037	Adelaide University	Replication of GB-Virus and related Chimeras	The aim of this study is to develop a mammalian cell culture system to study Hepatitis C virus (HCV) using chimerics of HCV and GB viruses.	Licence issued	23/08/2002	31/03/2027
DNIR-038	Macfarlane Burnet Institute for Medical Research and Public Health	Molecular interactions between HIV-1 and host gene products	The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture.	Licence issued	2/09/2002	22/12/2028
DNIR-039	Macfarlane Burnet Institute for Medical Research and Public Health	Impact of host gene products on HIV-1 replication in mammalian cells	The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture.	Integrated into DNIR-038		
DNIR-040	Macfarlane Burnet Institute for Medical Research and Public Health	Effect of host gene products that interact with HIV-1 reverse transcriptase on MoMLV replication	The aim of the proposed dealings is to test the impact of the expression of cellular proteins on HIV-1 and MLV replication in mammalian cell culture.	Integrated into DNIR-038		
DNIR-041	Peter MacCallum Cancer Centre	Characterisation of the signalling and cell biology of CD46 and the Dig family	The aim of the proposed dealing is to study the effects on immune cell function of the protein CD46 and its Dlg family in human and mouse cells.	Expired	2/09/2002	30/03/2006
DNIR-042	James Cook University	Cross infection of bacteriophages in Vibrio cholerae, Vibrio mimicus and Vibrio harveyi	The effect of swapping bacteriophages from one species of Vibrio to another will be examined. The aim is to see if the cholera pandemic of 1989 could be related to an outbreak of Vihrio harvevi in prawns.	Withdrawn		
DNIR-043	CSIRO	In vivo testing of immuno-contraceptive effects and species specificity of a recombinant murine cytomegalovirus (MCMV) expressing mouse ZP3	The aim of this dealing is to test the efficacy and specificity of a recombinant murine cytomegalovirus (MCMV) containing a mouse reproductive protein as an immunocontraceptive in house mice and a number of native and exotic rodent species.	Surrendered	7/08/2002	26/08/2005
DNIR-044	Baker Medical Research Institute	A viral mediated approach to examine Sgk in cellular function	This dealing aims investigate the role of Sgk (serum and glucocorticoid induced kinase) in heart disease using replication deficient adenoviruses in cell culture.	Withdrawn		
DNIR-045	Hospira Adelaide Pty Ltd	Production of recombinant PST and amino acid analogues of that hormone	The proposed dealings are to produce the protein pig somatotropin.	Surrendered	17/09/2002	13/02/2004
DNIR-046	Hospira Adelaide Pty Ltd	Production of recombinant MET - human growth hormone	The proposed dealings are to produce the therapeutic protein human growth hormone.	Surrendered	17/09/2002	13/02/2004

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-047	Hospira Adelaide Pty Ltd	Production of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and amino-acid analogues of this cytokine	The proposed dealings are to produce the therapeutic protein human granulocyte macrophage colony stimulating factor (GM-CSF) or analogue.	Surrendered	17/09/2002	13/02/2004
DNIR-048	Hospira Adelaide Pty Ltd	Production of recombinant human interleukin 5 (IL-5) and amino acid analogues of this cytokine	The proposed dealings are to produce the protein human interleukin 5 (IL 5).	Surrendered	17/09/2002	13/02/2004
DNIR-049	Western Sydney Local Health District	A preclinical model of pancreatic islet xenotransplantation as treatment for Type 1 Diabetes	This dealing aims to produce pig and mouse pancreatic islet cells that can avoid the human immune system.	Expired	26/09/2002	30/09/2007
DNIR-050	Western Sydney Local Health District	HIV immunopathogenesis and immune cell function	The aim of the proposed dealings is to study one possible mechanism whereby HIV depletes the immune cells in people.	Expired	26/09/2002	30/11/2007
DNIR-051	Western Sydney Local Health District	Growth of tissue culture cells genetically modified to express cytokine receptor subunit	The aim is to study the function of lymphocytes (white blood cells) and the effect of cytokine receptors on the development or treatment of severe combined immunodeficiency.	Expired	26/09/2002	30/11/2007
DNIR-052	Westmead Institute for Medical Research	Molecular pathogenesis of Bartonella henselae	The aim of the proposed dealings is to study Bartonella henselae, a bacterium which causes cat scratch disease.	Licence issued	26/09/2002	30/09/2027
DNIR-053	Novozymes Biopharma AU Limited	Commercial production of LongR3IGF-1 and IGF-1	The proposed dealings are to produce both native and variant forms of the protein IGF-1.	Withdrawn		
DNIR-054	Public and Environmental Health Reference Laboratories, Pathology Queensland	Cell complemented viruses as non-infectious diagnostic reagents and candidate vaccines. Australian Bat Lyssavirus	The dealings propose to produce diagnostic reagents and potential vaccines for the viral disease Australian Bat lyssavirus.	Surrendered	20/09/2002	6/05/2010
DNIR-055	Public and Environmental Health Reference Laboratories, Pathology Queensland	Cell complemented Hendra virus as a non-infectious diagnostic reagent and as a model for studying genetic and phenotypic changes affecting pathogenicity and host range	The dealings propose to produce diagnostic reagents and potential vaccines for the disease caused by Hendra virus.	Surrendered	20/09/2002	12/11/2007
DNIR-056	Public and Environmental Health Reference Laboratories, Pathology Queensland	Cell complemented viruses as non-infectious diagnostic reagents and candidate vaccines. Ross River Virus	The dealings propose to produce diagnostic reagents and potential vaccines for the disease caused by Ross River virus.	Expired	20/09/2002	28/02/2014
DNIR-057	The Walter and Eliza Hall Institute of Medical Research	Transfection of Plasmodium falciparum	These dealings aim to study the parasite which causes malaria, Plasmodium falciparum.	Surrendered	9/09/2002	7/11/2008
DNIR-058	The Walter and Eliza Hall Institute of Medical Research	Expression of genes in Leishmania	The aim of the proposed dealing is to study the parasite Leishmania and immune responses to the parasite in mice.	Expired	13/09/2002	30/09/2010
DNIR-059	The Walter and Eliza Hall Institute of Medical Research	Transduction of cells and tissue by adenoviral vectors for transplantation	The proposed dealing aims to develop tissues which may be able to be transplanted in people from pigs, mice and human cell lines and test these tissues in mice.	Withdrawn		
DNIR-060	The Walter and Eliza Hall Institute of Medical Research	Transduction of cells and tissue by lentivirus vectors for transplantation	The proposed dealing aims to develop tissues which may be able to be transplanted in people from pigs, mice and human cell lines and test these tissues in mice.	Withdrawn		
DNIR-061	The Walter and Eliza Hall Institute of Medical Research	Generation and use of recombinant Adenovirus	This project aims to develop a recombinant adenovirus vector system to deliver mouse genes into mouse tissue cultures and organs.	Withdrawn		

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-062	The Walter and Eliza Hall Institute of Medical Research	Adenovirus mediated gene transfer in murine models of rheumatoid arthritis	This project aims to use a mouse model of rheumatoid arthritis to test the effect of proteins thought to regulate inflammation of synovial tissue.	Withdrawn		
DNIR-063	The Walter and Eliza Hall Institute of Medical Research	Retroviral mediated gene transfer into murine haemopoietic cells	The researchers propose to transfer and study genes thought to be involved in cell growth, proliferation, apoptosis (programmed cell death) and differentiation in cell cultures.	Surrendered	26/09/2002	28/09/2007
DNIR-064	Peter MacCallum Cancer Centre	Negative regulation of haematopoiesis by P-selectin	The aim is to determine a signal transduction pathway and see how this results in suppression of blood cell production.	Expired	26/09/2002	30/04/2004
DNIR-065	Peter MacCallum Cancer Centre	Immunotherapy of cancer using recombinant viruses	This project aims to assess the anti-tumour potential of a melanocyte protein vaccine.	Surrendered	26/09/2002	24/08/2007
DNIR-066	CSIRO	Porcine adenovirus viral vectors	Adenovirus from pigs will be genetically modified for use as vaccines and therapeutics for a range of animal diseases.	Licence issued	26/09/2002	31/08/2027
DNIR-067	CSIRO	Development of Vaccines to protect against members of the pasteurallaceae	This project aims to develop vaccines against Pasteurellaceae associated diseases in production animal species.	Surrendered	26/09/2002	27/09/2013
DNIR-068	CSIRO	Fowl adenovirus recombinants	The proponents intend to construct and test different genetically modified fowl adenoviruses as potential vaccines against diseases in chickens and dogs.	Expired	26/09/2002	31/01/2024
DNIR-069	CSIRO	Identification of virulence factors for infectious bursal disease virus (IBDV)	The researchers are planning to identify what parts of the virus makes IBDV infectious to chickens.	Expired	26/09/2002	31/12/2005
DNIR-070	CSL Limited	Expression of Helicobacter pylori proteins in E.coli	The dealing is to produce quantities of proteins from the "stomach -ulcer" bacterium Helicobacter pylori for potential use as vaccines.	Expired	26/09/2002	31/12/2005
DNIR-071	Australian Defence Force Malaria and Infectious Disease Institute	JE CHIMERIVAX	The aim is to test the safety and efficacy of a yellow fever vaccine genetically modified to vaccinate against Japanese encephalitis in human volunteers.	Expired	26/09/2002	31/12/2010
DNIR-072	CSIRO	Construction of recombinant ranaviruses	Ranaviruses are viruses of fish, frogs and reptiles and this project aims to develop technology to genetically modify these viruses.	Surrendered	26/09/2002	28/09/2007
DNIR-073	Baker Medical Research Institute	Viral mediated approaches to examine the effects of dehydrogenase on cardiac function	The aim is to express four enzymes in cell culture and to test the effect of the enzymes on cultured heart cells.	Withdrawn		
DNIR-074	Baker Medical Research Institute	Signalling pathways in myocardial preparations	The aim is to study mechanisms which may be involved in sudden cardiac deaths.	Withdrawn		
DNIR-075	Baker Medical Research Institute	A viral mediated approach to examine SMAD in cellular functions	The researchers will study the role of specific proteins stimulated by Smad dependent mechanisms, by modulating Smad genes in wound healing, inflammation and cell development	Withdrawn		
DNIR-076	Murdoch University	Generation of infectious cucumber mosaic virus clones	Cucumber mosaic virus is a disease of lupins and many other plants. The researchers intend to study the interactions between the virus and lupins.	Expired	25/10/2002	30/04/2014
DNIR-077	Department of Primary Industries and Regional Development	Bioassay evaluation of bacteria expressing insecticidal genes	The aim is to identify proteins toxic to the rice bloodworm Chironomus tepperi from bacteria.	Surrendered	25/10/2002	13/06/2007

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-078	Department of Primary Industries and Regional Development	Toxicity of modified rice callus to Chironomus larvae	The aim is to insert and test proteins toxic to the rice bloodworm Chironomus tepperi in tissue cultures of rice.	Integrated into DNIR-077		
DNIR-079	Centenary Institute of Cancer Medicine and Cell Biology	Development of new vaccines against tuberculosis	The aim is to develop and test vaccines to protect against the human bacterial disease tuberculosis.	Expired	25/10/2002	31/12/2013
DNIR-080	Melbourne Health	Packaging of hepatitis delta virus (HDV) with modified envelope protein	The researchers propose to genetically modify hepatitis delta virus (HDV) so that it can infect cells other than liver cells, such as cancer cells, as a potential treatment.	Expired	8/11/2002	30/09/2021
DNIR-081	University of Wollongong	Molecular analysis of Streptococcus pyogenes	The aim is to understand the role of specific gene products of the bacteria Streptococcus pyogenes in the onset of disease and to develop vaccines to protect against the disease.	Expired	8/11/2002	31/10/2022
DNIR-082	University of Wollongong	Molecular analysis of Mycoplasma hyopneumoniae and vaccine development	The aim is to understand the role of specific gene products of the bacteria Mycoplasma hyopneumoniae in the onset of disease and to develop vaccines to protect against the disease.	Surrendered	8/11/2002	9/12/2013
DNIR-083	St Vincent's Hospital (Melbourne)	Breast cancer invasion and metastasis	Tagged breast cancer cells will be inoculated into mice to assess how tumours develop.	Surrendered	4/11/2002	11/07/2007
DNIR-084	Western Sydney Local Health District	The role of SDF-1 in normal leukemic pre-B cell interactions with bone marrow stroma	SDF-1 is thought to be a key regulator of the behaviour of cells involved in acute lymphoblastic leukemia and this project aims to study how it works.	Surrendered	8/11/2002	12/09/2006
DNIR-085	Western Sydney Local Health District	Analysis of the effects of CD44 variant exon 6 expression on adhesion and migration of human leukemia cells	CD44 is thought to affect cells involved in myeloid leukemia and this project aims to study how variations of CD44 act.	Surrendered	8/11/2002	7/01/2008
DNIR-086	Westmead Institute for Medical Research	HIV biology	The aim is to understand the biology of the human immune deficiency virus as the basis for better drug and vaccine development.	Licence issued	15/11/2002	20/09/2031
DNIR-087	Australian National University	Molecular genetic studies of Shigella virulence	Shigella can cause dysentery. They hope to find the genes which are involved in disease development.	Licence issued	15/11/2002	30/11/2027
DNIR-088	Monash University	Cloning of genes from Mycobacterium ulcerans in other mycobacteria	Mycobacterium ulcerans can cause skin ulcers in people. The ulcers are thought to be due to the production of mycolactone by the bacteria and the researchers are aiming to identify the genes responsible for mycolactone production.	Surrendered	29/11/2002	6/05/2010
DNIR-089	Monash University	Cloning of genes from Mycobacterium ulcerans	Mycobacterium ulcerans can cause skin ulcers in people. The ulcers are thought to be due to the production of mycolactone by the bacteria and the researchers are aiming to identify the genes responsible for mycolactone production.	Surrendered	29/11/2002	6/05/2010
DNIR-090	The University of Western Australia	Immunocontraception and antigen delivery by recombinant Cytomegaloviruses	The aim of this dealing is to genetically modify various cytomegaloviruses (CMVs) to contain reproductive proteins and other proteins and to test these GMOs as immunocontraceptives and vaccines in a number of animal species.	Surrendered	23/12/2002	16/11/2020

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-091	Harry Perkins Institute of Medical Research	Recombinant vaccinia virus encoding CMV or HCV genes	The aim is to examine the host response to cytomegalovirus and hepatitis C virus proteins to test for protective immune responses.	Expired	25/11/2002	30/06/2026
DNIR-092	Central Adelaide Local Health Network	Molecular Models of Bone and Tissue Remodeling	The aim is to introduce genes of interest into primary human and rodent cell lines of bone origin to study the effects of their forced expression on the formation of bone and other connective tissue	Surrendered	21/11/2002	30/10/2008
DNIR-093	Institute of Medical and Veterinary Science	Novel Retroviral Expression Cloning Strategies to Isolate Genes with Roles in Haemopoiesis and Stromal Biology	The aim is to isolate novel cDNAs which encode for proteins which regulate haemopoietic and stromal cell differentiation. This will be achieved using retroviral expression cloning techniques.	Surrendered	25/11/2002	30/06/2008
DNIR-094	St Vincent's Hospital Sydney Limited	Clinical Protocol HVDDT - NO1-AI-05395 - Fowlpox vaccine	The aim of this dealing is to determine the safety and immunogenicity of an HIV vaccine regimen.	Expired	27/11/2002	30/04/2006
DNIR-095	St Vincent's Hospital Sydney Limited	Clinical Protocol HVDDT - NO1-AI-05395 - DNA vaccine	The aim of this dealing is to determine the safety and immunogenicity of an HIV vaccine regimen.	Expired	18/11/2002	30/04/2006
DNIR-096	The University of Sydney	Investigation into the genes responsible for ochratoxin A production in Aspergillus carbonarius and Aspergillus niger	The aim of this dealing is to clone and sequence the biosynthetic pathway genes involved in ochratoxin A synthesis in Aspergillus carbonarius.	Surrendered	29/11/2002	25/05/2009
DNIR-097	Australian National University	Molecular biology of Phytophthora pathogenicity	The aim of this dealing is to identify Phytophthora genes that are involved in the infection of host plants.	Expired	29/11/2002	30/04/2013
DNIR-098	Royal Perth Hospital	Construction of vaccinia virus recombinants carrying HCV antigens and their use in detecting cytokine responses in human peripheral blood leucocytes	The aim of this dealing is to make recombinant vaccinia viruses that contain HCV genes and to use these viruses to observe the immunological responses of peripheral blood mononuclear cells (PBMCs) in vitro to endogenously synthesised HCV proteins.	Expired	27/11/2002	31/01/2007
DNIR-099	Royal Perth Hospital	Development and characterisation of viral hybrids containing various segments of flaviviridae genomes	The aim of this dealing is to make recombinant attenuated hepatitis C viruses and to use these viruses to elucidate the replicative mechanisms of hepatitis C virus.	Expired	29/11/2002	31/01/2005
DNIR-100	South Eastern Sydney Local Health District	Human and Ovine Adenovirus Vectors for Cancer gene therapy	The aim of this dealing is to examine the efficacy of a treatment for prostate cancer that uses adenoviral vectors, in the mouse model.	Surrendered	4/03/2003	20/08/2012
DNIR-101	Western Sydney Local Health District	The identification & investigation of virulence factors in legionella longbeachae	The aim of this dealing is to create a mutant strain of Legionella longbeachae (LL) lacking the pilD virulence gene and to study the role of this gene in the virulence of LL.	Surrendered	3/01/2003	31/07/2008
DNIR-102	Western Sydney Local Health District	Genetics and biochemical characterisation of cryptococcal phospholipases in relation to fungal virulence	The aim of this dealing is to first isolate the phospholipase gene from a particular cryptococcal strain and then study the role of this gene in the virulence of Cryptococcus neoformans by creating a mutant C. neoformans lacking the gene.	Surrendered	9/01/2003	31/07/2008
DNIR-103	Department of Primary Industries	Cloning the Complete Genomes of Alphaherpesviruses	The aim of this dealing is to produce recombinant herpesvirus vaccines through the utilisation of infectious clone technology.	Surrendered	15/01/2003	22/06/2007

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-104	The University of Melbourne	The Antigenicity and Replication of Hepatitis B Virus Vaccine and Lamivudine Resistant Mutants and Humoral Plus Cellular Immune Responses to Hepatic C Virus	The aim of this dealing is to study the antigenicity (ability of a substance to cause an immune response) and replication of hepatitis B virus mutants and to analyse the humoral (antibody) and cellular (T-cell) immune responses to hepatitis C virus.	Expired	16/01/2003	30/04/2020
DNIR-105	Melbourne Health	Studies of Replication of Hepatitis C Virus and Hepatitis C Virus in Mammalian Cells	The aim of this dealing is to infect liver cells using baculovirus containing hepatitis B and C viral DNA and to study the replication of hepatitis B and C virus in these cells.	Surrendered	16/01/2003	27/09/2013
DNIR-106	Monash University	Genetics and pathogenesis of the clostridia	The aim of this dealing is to study genes identified as potentially having a role in the pathogenesis, antibiotic resistance or gene transfer of C. perfringens, C. septicum and C. difficile.	Licence issued	22/01/2003	31/01/2028
DNIR-107	Central Adelaide Local Health Network	Virus Replication and Viral Pathogenesis	The aim of this dealing is to investigate the function of different viral genes and their role in regulating viral replication and viral pathogenesis.	Expired	24/01/2003	31/01/2013
DNIR-108	Central Adelaide Local Health Network	Targeted gene delivery for vascular and neoplastic disease	The aim of this dealing is to use targeted gene delivery to investigate pulmonary vascular disease, tumour vasculature and cancer.	Expired	24/01/2003	31/03/2025
DNIR-109	Peter MacCallum Cancer Centre	Signal transduction pathways in human cancers	The aim of this dealing is to understand the genetic and biochemical changes involved in the development of cancer using human and mouse cells as model systems for human disease.	Surrendered	29/01/2003	26/10/2007
DNIR-110	Peter MacCallum Cancer Centre	Novel approaches for activation and expansion of genetically engineered T cells in vivo	The aim of this dealing is to study the anti-tumour activity, expansion and survival of mouse and human primary lymphocytes (T cells) in vivo, that have been genetically modified to express single chain antibody receptors.	Expired	17/01/2003	31/01/2018
DNIR-111	Peter MacCallum Cancer Centre	Analysis of the molecular functions of perforin: a critical role in tumour immunosurveillance	The aim of this dealing is to express wildtype and mutant perforin cDNAs in perforin-deficient cell lines (rat mast cell line, RBL) and primary mouse T-lymphocytes to understand the structure/function relationship of the perforin molecule.	Surrendered	29/01/2003	26/10/2007
DNIR-112	Deakin University	Overexpression of diabetes/obesity related genes in cultured cells and animals using recombinant Adenovirus	The aim of this dealing is to study the roles of newly identified genes in the development of diabetes and obesity.	Expired	28/01/2003	31/12/2007
DNIR-113	Monash University	Infectious RNA of human caliciviruses	Infection of cultured cells by calicivirus particles has not been demonstrated and the researchers hypothesise this is due to defective virus particle attachment and entry. The aim of this dealing is to bypass this block by using viral nucleic acid.	Surrendered	29/01/2003	12/07/2007
DNIR-114	Institute of Medical and Veterinary Science	Generation of murine haemopoietic cells expressing human BCR/ABL	The aim of this dealing is to model human Chronic Myeloid Leukaemia (CML) in mice by delivering the leukaemogenic BCR/ABL DNA sequence to primary murine haemopoietic cells. Small molecule therapies for CML will also be examined.	Withdrawn		

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-115	The Walter and Eliza Hall Institute of Medical Research	Transfection and Gene Knockout/down of Plasmodium and Mammalian Cell Lines	The researchers propose to use short sequences of dsRNA produced by stable expression vectors to silence the expression of genes in either mammalian cell lines or malaria. They also propose to study the pathogenesis of P. berghei malaria in various murine gene knockout models.	Surrendered	14/02/2003	15/01/2008
DNIR-116	The Walter and Eliza Hall Institute of Medical Research	Functional Analysis of Malaria Parasite Proteins using Transfection of Plasmodium Species of Human and Rodent Origin	The aim of this dealing is to study the role of particular malaria proteins in various aspects of the parasite's lifecycle by transfecting the parasite with Plasmodium genes.	Expired	7/02/2003	28/02/2015
DNIR-117	Avexa Limited	Creation of a Recombinant Baculovirus Harboursing a Greater than Genome Length of the HIV Genome Capable of Transducing Hepatoma Cell Lines	The aim of this dealing is to create a recombinant baculovirus that harbours a greater than full length copy of the HBV genome and to use this virus to transfect cell lines. The transfected cells will be used to screen for antiviral compounds.	Surrendered	7/02/2003	21/11/2007
DNIR-118	Avexa Limited	Construction of Recombinant HIV Clones and Viruses	The aim of this dealing is to construct and grow molecular clones of HIV in E. coli and to produce and grow HIV and recombinant HIV in mammalian cell lines. The viruses produced will be used in assays for the development of antiviral compounds.	Surrendered	12/02/2003	29/08/2011
DNIR-119	CSL Limited	Expression of Human papilloma virus antigens	The aim of this dealing is to express human papillomavirus protein antigens in E. coli and to purify these proteins in order to formulate a vaccine.	Surrendered	12/02/2003	29/08/2011
DNIR-120	Peter MacCallum Cancer Centre	Role of SMC6 in cell growth, DNA damage repair, cell cycle control and chromosome stability	The aim of this dealing is to suppress the expression of SMC6 in human and mouse cells by transforming the cells with retroviruses capable of producing small interfering RNAs (siRNAs).	Withdrawn		
DNIR-121	The University of Adelaide	Cereal Transformation	The researchers intend to introduce various genes into rice callus tissues. They aim to improve gene transfer efficiency and understand the effects of targeted modification of the rice glutelin gene on its expression and stability in transgenic plants.	Withdrawn		
DNIR-122	CSL Limited	Pilot scale fermentation and processing of antibody fragments expressed in GMOs	The aim of this dealing is to produce antibody fragments using GMOs and to evaluate them for the treatment of a variety of animal and human disease conditions.	Surrendered	28/02/2003	26/02/2008
DNIR-123	Melbourne Health	Studies on the replication of hepatitis C virus (HCV)	The aim of this dealing is to produce a DNA copy of HCV that contains only the regions of the virus necessary for the virus to replicate. The researchers intend to study HCV replication and design and test antiviral compounds that stop this process.	Surrendered	10/02/2003	22/06/2007
DNIR-124	Melbourne Health	Replication of hepatitis B virus, duck hepatitis B virus and woodchuck hepatitis virus and the testing of antiviral agents	The aim of this dealing is to study the replication of HBV, DHBV and WHV and to investigate the growth of these viruses in the presence of antiviral agents. Variants of HBV associated with resistance to antiviral agents will also be studied.	Surrendered	21/02/2003	27/09/2013

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-125	Melbourne Health	Studies of the replication of hepatitis B virus using recombinant HBV/adenovirus as a delivery system for mammalian cells and studies of HBV and HCV co-infection using HBV/adenovirus and HCV clones	The aim of this dealing is to study the replication of HBV by infecting liver cells with HBV using a modified adenovirus containing HBV DNA. HCV genetic material will also be introduced to HBV infected cells to investigate HBV and HCV co-infection.	Surrendered	28/02/2003	27/09/2013
DNIR-126	University of New South Wales	Molecular Regulation of Cell Lifespan and Malignant Transformation	The aim of this dealing is to investigate the molecular regulation of cell lifespan and malignant transformation by genetically modifying mammalian cells with genes of interest.	Surrendered	14/02/2003	21/12/2007
DNIR-127	The University of Queensland	Development of a gene transfer vector for banana	The aim of this dealing is to develop a gene transfer vector for the banana plant and other plant species.	Expired	19/02/2003	28/02/2018
DNIR-128	Harry Perkins Institute of Medical Research	Expressing Hemopoietic Regulators in Cells using Amphotropic Retroviruses.	The aim of this dealing is to transfer genes associated with haemopoietic regulation into cells using a replication defective retrovirus, and to study the effects of this altered gene expression on haematopoiesis.	Surrendered	6/03/2003	21/09/2007
DNIR-129	Queensland University of Technology	Cloning of Genes from Potentially Toxigenic Risk Group Two Bacteria	The aim of this dealing is to analyse genes from a variety of risk group 2 bacteria for commonalities.	Surrendered	7/03/2003	7/01/2008
DNIR-130	Royal Perth Hospital	Use of retroviral and lentiviral gene delivery systems for the expression of HCV proteins in cell culture	The aim of this dealing is to use retroviruses and lentiviruses to express various HCV proteins. These viruses will be used to study the replication of HCV in cell culture.	Surrendered	7/03/2003	26/02/2008
DNIR-131	Institute of Medical and Veterinary Science	Expression of the GM-CSF Receptor Alpha and Beta Chains from a Single Retroviral Construct	The aim of this project is to test agents known to block the action of GM-CSF on mice containing bone marrow cells that express the human GM-CSF receptor.	Withdrawn		
DNIR-132	University of Southern Queensland	Whooping Cough Vaccine VI	The aim of this dealing is to develop a genetically modified non-toxic whooping cough vaccine.	Surrendered	13/03/2003	31/03/2008
DNIR-133	University of Southern Queensland	Pasturella Multocida Type A Genes and Gene Products - 1	The aim of this dealing is to study the role of various genes and gene products in the pathogenesis of P. multocida.	Surrendered	13/03/2003	31/03/2008
DNIR-134	University of Southern Queensland	Mechanisms of Immunity in Salmonellosis	The aim of this dealing is to characterise the immunoregulating factors produced by mice vaccinated with two attenuated strains of Salmonella typhimurium.	Integrated into DNIR-132		
DNIR-135	Central Adelaide Local Health Network	Conditionally Replicative Adenoviruses for Neoplastic Disease	The aim of this dealing is to generate adenoviruses that will only replicate in the presence of specific tumour cell proteins. The adenoviruses will be tested for their impact on cell function.	Expired	29/04/2003	30/04/2013
DNIR-136	Orica Australia Pty Ltd	Production of Pesticide Degrading Enzymes Using Recombinant E.coli	The aim of this dealing is to produce commercial quantities of pesticide-degrading enzymes using recombinant E. coli.	Expired	6/03/2003	31/01/2008
DNIR-137	Progen Industries Limited	Geneswitch	The aim of this dealing is to produce large amounts of plasmid that will be purified and formulated into a drug product (EPO) for clinical investigation in humans.	Expired	24/03/2003	31/03/2008
DNIR-138	Hospira Adelaide Pty Ltd	Large Scale Production of Recombinant Peptides or Proteins	The aim of this dealing is to produce a sufficient quantity of specific recombinant peptides or proteins to supply product for clinical trials and/or commercialisation.	Surrendered	26/03/2003	25/03/2008
DNIR-139	CSIRO	Recombinant Canine Herpesvirus as Vaccine Vector	The aim of this dealing is to construct a recombinant canine herpesvirus to be used as a vaccine vector.	Surrendered	31/03/2003	26/08/2005

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-140	The University of New England	Characterisation of DNA Region Associated With the Virulence of D. nodosus	The aim of this dealing is to identify genes which control virulence of D. nodosus, and to use this information to assist in the diagnosis, treatment or prevention of footrot.	Expired	2/04/2003	15/05/2014
DNIR-141	CSIRO	Molecular Virology	The viruses under investigation pose a significant risk to tomato, cotton and viticulture industries. The aim of this dealing is to characterise the roles of viral genes in viral replication and to assess the use of virus derived gene constructs for preventing disease.	Withdrawn		
DNIR-142	Agen Biomedical	Thromboview Cell Culture	The aim of this dealing is to produce enough material from cell culture to support later Phase Trials and to develop large-scale manufacturing procedures.	Surrendered	4/04/2003	21/12/2007
DNIR-143	Peter MacCallum Cancer Centre	The Role of Sialomucins in the Regulation of Haemopoiesis	The aim of this dealing is to study the role of sialomucin cell surface adhesion molecules in the regulation of haemopoiesis, by expressing them in a range of mouse and human cell types.	Surrendered	4/04/2003	12/06/2007
DNIR-144	Peter MacCallum Cancer Centre	The Role of Hyaluronic Acid in Normal and Aberrant Stem Cell Biology	The aim of this dealing is to analyse the role of hyaluronic acid in leukaemiagenesis by over expressing or inhibiting hyaluronic acid synthase genes in primary human leukaemic cells.	Surrendered	4/04/2003	29/06/2007
DNIR-145	CSIRO	Expression and Vaccine systems Using Viruses Expressing Zona Pellucida Genes	The aim of this dealing is to produce recombinant myxoma and vaccinia viruses that express ZP proteins for use in rabbit immunocontraceptive trials and assays respectively.	Surrendered	8/04/2003	26/08/2005
DNIR-146	Monash University	Adenovirus Mediated Transient Expression of Cre Recombinase in Rodent Cells	The aim of this dealing is to transiently express Cre recombinase in rat and mouse stem cells and to use these cells to produce transgenic and knockout rats and mice.	Withdrawn		
DNIR-147	Monash University	Lentivirus Mediated RNAi Technology	The aim of this dealing is to develop lentivirus-mediated RNAi (RNA interference) technology to inactivate genes in rats and mice at the mRNA (messenger RNA) level.	Withdrawn		
DNIR-148	CSIRO	A Viral Vectored Mouse Immuno-Contraceptive	The aim of this dealing is to infect mice with a GM virus that will induce an autoimmune response which targets the developing oocyte within the ovary and renders female mice infertile.	Surrendered	10/04/2003	26/08/2005
DNIR-149	Avexa Limited	Generation of Wild Type and Mutant Hepatitis B Virus (HBV) Capsid and Polymerase Proteins For Use In In Vitro Assays	The aim of this dealing is to generate HBV mutant and wild type capsid and polymerase proteins that can be used in in vitro assays to measure the sensitivity of mutant and wild type HBV polymerases to potential inhibitors of HBV replication.	Surrendered	15/04/2003	21/11/2007
DNIR-150	The University of Queensland	Lentiviral Delivery of Genes and/or DNA to Cells	The aim of this dealing is to use various replication defective lentiviruses to introduce genetic information into cells.	Surrendered	16/04/2003	18/10/2007

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-151	Central Adelaide Local Health Network	Construction and in vitro and in vivo testing of recombinant fowlpox virus vectors that express human or rat prostatic acid phosphatase with or without co-expression of human interleukin-2, AND Induction of auto-immune prostatitis in rats and mice using recombinant vaccinia virus vectors that encode human or rat prostatic acid phosphatase	The aim of this dealing is to investigate the immune response to recombinant fowlpox virus vectors in laboratory strains of mice and rats and in primary human peripheral blood mononuclear cell cultures.	Surrendered	16/04/2003	4/07/2016
DNIR-152	Institute of Medical and Veterinary Science	Induction of Autoimmune Prostatitis in DA Rats and B6 Mice Using Recombinant Vaccinia Virus Vectors That Encode Human, Rat or Murine Prostatic Acid Phosphatase	The aim of this dealing is to induce experimental prostatitis in laboratory strains of rats by infecting them with recombinant vaccinia virus vectors containing the gene for human prostatic acid phosphatase	Integrated into DNIR-151		
DNIR-153	CSIRO	Isolation and expression of genes from endogenous soil microorganisms	The aim of this dealing is to clone various genes from soil microorganisms. The gene products will be investigated for use in the degradation of pesticide residues/toxins or for their insecticidal properties	Expired	23/04/2003	30/04/2013
DNIR-154	Monash University	Novel Virulence Determinants of Enterohemorrhagic Escherichia coli	The aim of this dealing is to identify and characterise bacterial genes in EHEC that may be required for colonisation of the host.	Expired	24/04/2003	30/04/2008
DNIR-155	Progen Industries Limited	MPT64	The aim of this dealing is to generate recombinant protein (MPT64) that will be purified and formulated into a topical drug for clinical investigation in humans.	Expired	28/04/2003	30/04/2008
DNIR-156	The University of Western Australia	Gene Mediated Cell Death in Ovarian Cancer	The aim of this dealing is to study gene mediated cell death in ovarian cancer by infecting human cancer cells with viral particles containing the Y81 gene. The Y81 protein is hypothesised to slow the growth of the infected cells.	Expired	30/04/2003	30/04/2006
DNIR-157	The University of Queensland	Molecular Analysis of Cucumber Mosaic Virus Host Range Factors	The aim of this dealing is to study CMV replication, symptom development and host range by inoculating plants with CMV and recombinant CMV RNA.	Surrendered	22/04/2003	19/07/2017
DNIR-158	Western Sydney Local Health District	Focal Modification of Cardiac Conduction By Gene Transfer	The aim of this dealing is to introduce specific genes into human and animal cells in order to induce electrical conduction between these cells in network.	Surrendered	1/05/2003	8/04/2008
DNIR-159	Australian National University	Flavivirus Host/Pathogen Interactions	The aim of this dealing is to study flaviviral host/pathogen interactions in mice and mammalian and mosquito cell lines.	Expired	1/05/2003	31/05/2013
DNIR-160	The University of Queensland	Metabolic Engineering of Hyaluronic Acid (HA) Production	HA forms the capsule of some Group A and C streptococci. The aim of this dealing is to identify and study genes involved in the regulation of HA production.	Surrendered	6/05/2003	6/12/2024
DNIR-161	Queensland University of Technology	Expression of Adhesins From Bacterial Pathogens in Non-Pathogenic Lactic Acid Bacteria	The aim of this dealing is to genetically modify non-pathogenic lactic acid bacteria to express adhesin molecules from pathogenic organisms.	Surrendered	7/05/2003	22/01/2009
DNIR-162	Queensland University of Technology	Investigation of Host Range Determinants in Papaya Ringspot Virus	There are two types of PRSV (P & W) that differ in host range – ie. one infects papaya and another does not. The aim of this dealing is to determine the gene sequence/s that allow PRSV to infect papaya.	Expired	8/05/2003	31/10/2008
DNIR-163	Queensland University of Technology	The Development of Glycine Mosaic Comovirus (GMV) as a Vector for Heterogenous Gene Expression in Plants	The aim of this dealing is to test GMV-based vectors for high level expression of genes in plants.	Expired	8/05/2003	30/06/2006

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-164	CSIRO	Small RNA viruses of insects	The aim of this dealing is to study the potential use of small RNA viruses of insects for pest control and biotechnological purposes.	Expired	9/05/2003	31/05/2013
DNIR-165	Xenome Limited	Isolation and Characterisation of Venom Peptide Genes	The aim of this dealing is to investigate venom peptides for therapeutic potential.	Surrendered	12/05/2003	14/10/2010
DNIR-166	Mater Research Ltd	Retroviral Expression Cloning to Discover New Molecules Expressed by Leucocytes	The aim of this dealing is to isolate novel gene sequences from leukocytes (white blood cells) to better understand immune function.	Expired	12/05/2003	31/05/2008
DNIR-167	CSIRO	Production of Recombinant Proteins By Vaccinia Virus For In Vitro Uses	The aim of this dealing is to express proteins in vaccinia virus that will be used in serological assays.	Surrendered	12/05/2003	26/08/2005
DNIR-168	Hunter Grain Pty Ltd	Yellow Corn Import	The applicant intends to import grain from the USA for processing as stockfeed. Since there are commercial crops of GM corn in the USA, the shipment may contain GM corn.	Expired	2/01/2003	30/04/2003
DNIR-169	Hunter Grain Pty Ltd	Importation of soybeans for processing into soy oil and stockfeed	The applicant intends to import soybeans from the USA for expelling and solvent extraction to produce soybean meal to be used for stockfeed purposes and soybean oil to be used for human consumption as margarines and cooking oils (approved by FSANZ in 2000). Since there are commercial crops of GM soybeans in the USA, the shipment may contain GM soybeans.	Expired	3/01/2003	30/09/2003
DNIR-170	Johnson & Johnson Research Pty Ltd	A randomized Phase II, double blind, controlled trial to evaluate the safety and efficacy of autologous CD34+ hematopoietic progenitor cells transduced with either a delivery gene construct (LNL6) or LNL6 that contains an anti-HIV-1 ribozyme (QZ1) in patients with HIV-1 infection	The proposed dealing is to modify progenitor haematopoietic cells taken from HIV-1 infected patients to carry either a retroviral vector containing an anti-HIV-1 ribozyme or only the retroviral vector.	Surrendered	13/05/2003	19/01/2007
DNIR-171	Macquarie University	Comparative Genomics of Equine Herpesviruses	The aim of this dealing is to analyse gene functions of EHV-1 and EHV-4 which are genetically closely related but have different cell culture host ranges and disease outcomes.	Expired	2/05/2003	31/01/2007
DNIR-172	CSIRO	Myxoma Virus/ Kunjin Replicon Vaccine System	The aim of this dealing is to produce a recombinant Myxoma/ Kunjin virus that expresses genes encoding reproductive proteins. This recombinant virus will be tested as an immuno-contraceptive delivery system in rabbits.	Surrendered	14/05/2003	26/08/2005
DNIR-173	The University of Adelaide	Molecular Breeding Of Grapevines for Resistance to Major Root Pests	The aim of the proposed dealings is to develop transgenic grapevines that are resistant to root pests by incorporating the genes for cyanogenic glucoside biosynthesis into these plants or by altering the expression of plant genes involved in root pest feeding sites.	Expired	15/05/2003	30/11/2009
DNIR-174	The University of Sydney	Cloning of Duck Hepatitis B Virus	The aim of this dealing is to clone naturally occurring variants of DHBV and to assess the infectivity of these variants in cell cultures and ducklings.	Expired	23/05/2003	30/06/2007
DNIR-175	Virax Holdings Limited	Clinical Trial of Fowlpox Virus Vaccines Expressing HIV-1 Antigens and Human Interferon-gamma	The aim of this dealing is to express HIV antigens and interferon-gamma in fowlpox virus and to use this virus to elicit an immune response to these antigens in HIV infected individuals.	Expired	10/06/2003	31/10/2013

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-176	The University of Western Australia	Characterisation of Haemolysin produced in <i>Vibrio alginolyticus</i>	The aim of this dealing is to characterise the haemolysin produced by <i>Vibrio alginolyticus</i> and determine its relationship to other previously reported haemolysins.	Expired	10/06/2003	30/06/2008
DNIR-177	Children's Medical Research Institute	Immortalisation of human cells	The aim of this dealing is to use human cells transformed with genes that may alter their growth properties to study how normal cells become cancer cells.	Surrendered	10/06/2003	15/02/2008
DNIR-178	The Children's Hospital Westmead	Functional and Molecular Analysis of Defects of the Mitochondrial Electron Transport Chain	The aim of this dealing is to study immortalised human cells that have a metabolic defect of the mitochondrial energy production pathways to determine on which chromosome the disease causing gene is located.	Expired	6/06/2003	30/06/2006
DNIR-179	The Children's Hospital Westmead	Ex-Vivo Retroviral Transduction of CD34+ Selected Haemopoietic Stem Cells for Clinical Gene Therapy Trials	The aim of this dealing is to introduce genes into CD34+ haemopoietic stem cells to treat patients with X-linked Severe Combined Immunodeficiency and to provide resistance to alkylating drugs used in cancer therapy.	Expired	10/06/2003	30/06/2013
DNIR-180	The University of Queensland	Functional Analysis of Cloned Avirulence/Pathogenesis Genes From Plant Pathogenic Microbes	The aim of this dealing is to determine the function of cloned genes encoding putative avirulence and pathogenesis determinants in pathogenic fungi and oomycetes.	Expired	30/06/2003	30/06/2014
DNIR-181	Sugar Research Australia Limited	Transposition and Marker Exchange Mutagenesis of <i>Leifsonia xyli</i> Subspecies to Study Pathogenesis on Sugarcane	The aim of these dealings is to identify the genes from <i>Leifsonia xyli</i> involved in the interaction of this pathogen with sugarcane, in order to identify targets for antimicrobial compounds or antibodies.	Surrendered	11/06/2003	5/12/2012
DNIR-182	Sugar Research Australia Limited	Development of a Virus Based Assay system to Elucidate Gene Function in Sugarcane	The aim of this dealing is to produce a virus-based vector containing sugarcane virus gene sequences that will be used in further studies to elucidate the function of sugarcane genes.	Surrendered	11/06/2003	17/12/2007
DNIR-183	La Trobe University	Nucleotide Sequences of The Coat Protein of Johnsongrass Mosaic Virus (JGMV) Determining Host Specificity	The aim of this dealing is to identify the critical changes in the amino acids of the JGMV coat protein that allowed the recent evolution of a <i>Krish</i> sorghum-infecting strain of JGMV.	Expired	5/06/2003	31/12/2004
DNIR-184	Ludwig Institute for Cancer Research Ltd	Induction of Tumour Formation and Tumour Regression by Adenoviral -Mediated Gene Transfer	The aim of this dealing is to introduce genes that are involved in tumour formation and suppression into cultured cells and mice to mimic and/or reverse the sporadic genetic alterations that occur in adults with colorectal cancer.	Expired	13/06/2003	30/06/2008
DNIR-185	CSIRO	Use of Virus Vectors For Gene Silencing in Plants (Virus Induced Gene Silencing)	The aim of this dealing is to infect plants of interest with viruses containing RNA sequences that will silence specific genes in the plants in order to identify agronomically important genes.	Expired	16/06/2003	30/04/2014
DNIR-186	Macfarlane Burnet Institute for Medical Research and Public Health	Molecular Virology of HIV-1 and SIV	This dealing aims to understand the regulation and role of the various SIV, HIV-1 and HIV-2 genes in virus production and pathogenesis by comparative analysis of generated mutant variants of these viruses.	Licence issued	13/06/2003	31/01/2028

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-187	Macfarlane Burnet Institute for Medical Research and Public Health	Viral Assembly of MoMLV, M-PMV, HFV and ASLV	The aim of this dealing is to understand the role of various Moloney murine leukaemia virus, Mason-Pfizer monkey virus, human foamy virus or avian sarcoma/leukosis virus genes by transfecting mammalian cells with mutated or wild type clones of these retroviruses.	Licence issued	16/06/2003	31/01/2028
DNIR-188	Macfarlane Burnet Institute for Medical Research and Public Health	Pathogenesis of macrophage-tropic HIV-1	The aim of this dealing is to examine the ability of HIV-1 strains to induce cell killing by transfecting mammalian cell lines with HIV-1 DNA.	Expired	16/06/2003	30/06/2006
DNIR-189	Johnson & Johnson Research Pty Ltd	In vitro Murine and Human Cell Transformation or Mouse Reconstitution for a Gene Therapy approach to Acute Myeloid leukaemia	The aim of this dealing is to develop a model for leukemia (or lymphoma) development by oncogene activation and to use the model to assess the effects of tumour suppressor genes in arresting leukemia (or lymphoma) development.	Surrendered	17/06/2003	26/06/2008
DNIR-190	Macfarlane Burnet Institute for Medical Research and Public Health	Cellular immunity to HIV and HCV	The aim of this dealing is to examine cellular immunity to HIV and HCV by expressing part of the HIV or HCV genome in vaccinia virus and infecting human cells with this virus.	Expired	16/06/2003	30/06/2012
DNIR-191	Australian National University	Signalling pathways for the induction and maintenance of tolerance to islet allografts and xenografts and for the re-establishment of tolerance to islet beta cells in NOD mice	The aim of this dealing is to assess the tolerance of mice to pancreatic islet transplants following the delivery of immunoregulatory genes to the donor tissue or pre-treatment of the mice with cells expressing the same genes.	Withdrawn		
DNIR-192	Australian National University	Immunoregulatory gene studies and vaccine vector library development	The aim of this dealing is to develop an ongoing library of vaccine vectors for use in vaccine development and the study of immunoregulatory molecules.	Licence issued	18/06/2003	30/09/2028
DNIR-193	The University of Queensland	Studies on the immune response to recombinant vaccinia virus	The aim of this dealing is to use vaccinia viruses containing papillomavirus genes to study the processes governing immune activation or tolerance to DNA tumour viruses and to improve the quality of immune responses against human papillomavirus proteins.	Expired	16/06/2003	30/06/2012
DNIR-194	Monash University	Evaluation of cellular immunological function with recombinant virus	The aim of this dealing is to evaluate if treatment can augment or sustain the cellular anti-HIV response of HIV positive patients and help further define the mechanisms involved.	Surrendered	5/06/2003	25/11/2008
DNIR-195	Flinders University	Intracellular calcium signalling and liver disease	The aim of this dealing is to introduce genes involved in calcium channels into primary rat hepatocyte tissue culture cells.	Withdrawn		
DNIR-196	Flinders University	Transplantation of corneal and limbal stem cell allografts	The aim of this dealing is to infect the eye of rats or sheep with an adenovirus carrying genes encoding specific proteins that may prevent corneal and limbal stem cell graft rejection.	Withdrawn		
DNIR-197	CSIRO	DNA Viruses of Invertebrates	The aim of this dealing is to produce recombinant insect DNA viruses to improve understanding of their properties and characteristics and to assess their suitability as biological control agents for insect pests.	Expired	20/06/2003	31/05/2013
DNIR-198	Macfarlane Burnet Institute for Medical Research and Public Health	The expression of leukocyte antigens	The aim of this dealing is study the role of a variety of leukocyte antigens, especially cell surface antigens in leukocyte function.	Expired	18/06/2003	31/12/2008

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-199	CSIRO	Tracking soil micro-organisms using marker genes	The aim of this dealing is to study the ecology of soil microbes that have been selected for their beneficial effects on crop plant growth using marker genes to monitor their activities.	Withdrawn		
DNIR-200	University of Canberra	Mutagenesis of vaccine antigen genes and related proteins in bacterial respiratory pathogens	The aim of this dealing is to disrupt genes encoding candidate vaccine antigens and related proteins in bacterial respiratory pathogens to gain a better understanding of their function.	Surrendered	20/06/2003	30/06/2008
DNIR-201	The University of Melbourne	The Mechanisms of Tolerance and Immunity in Systemic Rheumatic Diseases	The aim of this study is to examine immunological tolerance to self antigens when they are encountered during an infection by infecting mice with vaccinia viruses containing genes encoding self or foreign antigens	Surrendered	20/06/2003	19/10/2010
DNIR-202	The University of Melbourne	Gene Regulation in Osteoclastogenesis	The aim of this project is to examine the action of candidate genes on the process of osteoclast generation from precursor cells by infecting these cells with adenoviruses/retroviruses containing the candidate genes	Surrendered	20/06/2003	21/08/2007
DNIR-203	The University of Melbourne	Construction and use of Herpes simplex virus mutants	The aim of this dealing is to determine how minor changes to the HSV viral protein gB will alter the response of cytotoxic T lymphocytes by infecting mice with HSV-1 gB mutants.	Surrendered	19/06/2003	22/09/2011
DNIR-204	The University of Melbourne	Molecular Biology of retroviral Replication, Pathogenesis and Productive Infection	The aim of this dealing is to study the RNA elements that modulate the expression of HIV proteins and to develop drugs that target these elements .	Expired	20/06/2003	20/08/2017
DNIR-205	The University of Melbourne	Nucleic Acid (DNA and RNA) and Viral Vectored Vaccines for HIV	The aim of this dealing is to develop a safe and effective vaccine against HIV by injecting animals with DNA plasmids, a recombinant fowlpoxvirus or a recombinant sindbis virus containing HIV or SIV genes	Surrendered	20/06/2003	30/11/2012
DNIR-206	CSIRO	Effect of growth hormone transgenesis on wool, meat and milk production in sheep	The aim of this dealing is to modify a growth hormone gene and insert it into the genome of sheep to determine its effects on wool, meat and milk production .	Withdrawn		
DNIR-207	The University of New England	Molecular Aspects of Plant -Pathogen Interactions - Thielaviopsis	The aim of this dealing is to identify genes in T. basicola (a pathogen causing black root disease in plants) which may be involved in virulence .	Expired	1/07/2003	31/12/2008
DNIR-208	Harry Perkins Institute of Medical Research	Recombinant Murine Cytomegalovirus Encoding Hepatitis Virus C Proteins	The aim of this dealing is to use MCMV as a delivery vehicle to express HCV proteins in murine liver.	Licence issued	20/06/2003	30/06/2030
DNIR-209	The University of Western Australia	Assessment of Outcrossing Under Idealised Conditions for Chickpeas	The aim of this dealing is to interplant chickpea plants containing the bar gene with non-transgenic chickpea plants and assessing the seed from non-transgenic plants for the presence of the bar gene after insect pollination	Withdrawn		
DNIR-210	The University of Western Australia	Use of Vaccinia Virus as a Vector for Antigens and Cytokines in Murine Tumour Models	The aim of this dealing is to determine if recombinant Vaccinia virus can induce long term protection against tumour growth and induce tumour regression .	Licence issued	20/06/2003	31/05/2027

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-211	The University of Sydney	Construction and Manipulation of an Infectious cDNA clone of Enterovirus 71 and Coxsackievirus A16	The aim of this dealing is to investigate the molecular basis of human enterovirus 71 virulence by inserting genome regions from related viruses of low virulence into its genetic background. The virulence of these chimeras will be studied in the mouse model.	Expired	18/06/2003	20/02/2018
DNIR-212	The University of Adelaide	Pathogenicity and virulence genes of the barley pathogen Rhynchosporium secalis	The aim of this dealing is to identify and isolate pathogenicity determinant genes from the barley pathogen R. secalis.	Surrendered	20/06/2003	20/09/2004
DNIR-213	Alpharma Animal Health Pty Ltd	Porcine growth hormone	The aim of this dealing is to continue the commercial production of porcine somatotropin which is sold into Australian and international markets under the tradename Renorcinâ.	Surrendered	15/08/2003	7/01/2008
DNIR-214	CSIRO	Adenoviruses as Gene Delivery Vectors	The aim of the proposed dealings is to develop and characterise human and ovine adenovirus vectors for use in gene therapy and vaccine development.	Expired	20/06/2003	30/06/2011
DNIR-215	The University of Queensland	Gene therapy of hypertension tumor sensitisation to radiotherapy	The aim is to develop gene therapy strategies using replication defective viral vectors for the treatment of hypertension and tumours.	Surrendered	19/03/2003	9/07/2015
DNIR-216	The University of Melbourne	Development of Trichoderma harzianum for biocontrol of plant pathogens	The aim of this dealing is to improve the biocontrol efficacy of Trichoderma harzianum by inserting the chitinase gene into its genome.	Expired	28/07/2003	31/03/2004
DNIR-217	The University of Western Australia	Structure/activity of novel toxins from native venomous organisms (jellyfish)	The aim of this dealing is to produce milligram quantities of toxic jellyfish and snake venom proteins by expressing them in Escherichia coli. The structure and activity of these proteins will then be investigated.	Surrendered	1/08/2003	4/01/2007
DNIR-218	CSIRO	Generation of Recombinant Canine Herpesvirus	The aim of this dealing is to develop recombinant CHVs that express heterologous antigens derived from genomic, viral, protozoan or bacterial genes. These viruses will be used as experimental vaccines to immunise foxes, dogs and ferrets against infectious diseases and/or to reduce their fertility.	Surrendered	4/08/2003	26/08/2005
DNIR-219	Centenary Institute of Cancer Medicine and Cell Biology	Recombinant mycobacteria as new anti-tuberculosis vaccines	The aim of this dealing is to express mycobacterium tuberculosis antigens in the vaccine strain Mycobacterium bovis BCG to develop a potential tuberculosis vaccine.	Surrendered	4/08/2003	21/12/2007
DNIR-220	Menzies School of Health Research	Cloning of Streptococcal DNA to and from Streptococcal species	The aim of this dealing is to understand how streptococcal gene products contribute to the pathogenesis of streptococcal infections by inserting the genes of interest into strains of streptococci that do not normally harbour these genes.	Surrendered	6/08/2003	3/06/2008
DNIR-221	QIMR Berghofer	Cloning of DNA Between Group A Streptococcal Strains	The aim of this dealing is to understand how group A streptococcal (GAS) gene products contribute to the pathogenesis of streptococcal infections by inserting the genes of interest into GAS strains that do not normally harbour these genes.	Expired	6/08/2003	31/05/2021

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-222	QIMR Berghofer	Expression of Virus Encoded Antigens Using Vaccinia Expression System	The aim of this dealing is to study in vitro T lymphocyte responses to cells infected with recombinant vaccinia viruses expressing Cytomegalovirus (CMV) or Epstein-Barr Virus (EBV) proteins	Licence issued	6/08/2003	31/05/2028
DNIR-223	Central Adelaide Local Health Network	Identification of novel molecular targets in angiogenesis	The aim of this dealing is to identify genes involved in endothelial cell function by overexpressing genes of interest in human endothelial cells and mice using viral vectors.	Surrendered	8/07/2003	20/01/2012
DNIR-224	Macfarlane Burnet Institute for Medical Research and Public Health	Molecular virology of hepatitis A, B and E viruses	The aim of this dealing is to investigate the role of various hepatitis genes and gene products in the gene expression, replication, virus particle assembly and pathogenesis of hepatitis A, B and E	Expired	14/07/2003	24/12/2019
DNIR-225	Ludwig Institute for Cancer Research Ltd	Mouse models of colorectal cancer using a TVA-based retroviral gene transfer system	The aim of this dealing is to investigate the role of various genes in colorectal cancer by transferring candidate oncogenes and a tumour suppressor gene directly into the intestinal epithelium of mice using an avian retrovirus	Surrendered	13/08/2003	29/11/2012
DNIR-226	Department of Jobs, Precincts and Regions	Molecular Breeding Of Grapevines for Resistance to Major Root Pests	The aim of the proposed dealings is to challenge transgenic grapevines with root pests and monitor their response.	Expired	15/05/2003	30/06/2005
DNIR-227	The University of Western Australia	Structure/activity of novel toxins from native venomous organisms (Brownsnake)	The aim of this dealing is to introduce genes encoding brown snake venom proteins into bacterial and/or eukaryotic hosts to produce milligram quantities of these proteins for biophysical and functional studies	Integrated into DNIR-217		
DNIR-228	Queensland University of Technology	The development of tobacco mosaic virus (TMV) as a vector for heterologous gene expression	The researchers intend to use TMV to deliver heterologous genes to plants with the purpose of expressing high levels of these genes in the plants.	Withdrawn		
DNIR-229	Queensland University of Technology	Development of a tobacco rattle virus-based RNA amplification system in tobacco	The researchers intend to use non-infectious RNA components of Tobacco rattle virus to deliver heterologous genes to tobacco plants with the purpose of enhancing the expression of these genes in the plants	Withdrawn		
DNIR-230	Adelaide University	Pathogenesis, prevention and treatment of Shiga toxigenic Escherichia coli (STEC) infections	The aim of this dealing is to clone and characterise STEC genes involved in the pathogenesis of disease in order to identify novel drug targets and develop vaccines against STEC infection	Licence issued	26/06/2003	31/05/2029
DNIR-231	The University of Adelaide	Pathogenesis and prevention of pneumococcal disease	The aim of this dealing is to clone and characterise Streptococcus pneumoniae genes involved in the pathogenesis of pneumococcal disease in order to identify novel drug targets and develop vaccines against pneumococcal disease.	Integrated into DNIR-230		
DNIR-232	The University of Newcastle	HIV vaccine design and development teams	The aim of this dealing is to develop a safe and effective vaccine against HIV using a mouse model using DNA vaccines and recombinant fowlpoxvirus vaccines to induce both mucosal and systemic HIV-specific immune responses	Surrendered	7/07/2003	3/05/2004

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-233	Murdoch University	Mutation of an infectious clone of BIV R29	The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues.	Expired	28/08/2003	31/08/2008
DNIR-234	Murdoch University	Transcomplementation of vif deleted BIV with bovine lentivirus	The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues.	Integrated into DNIR-233		
DNIR-235	Murdoch University	Use of an infectious clone of BIV R29	The aim of this dealing is to identify the role of the bovine immunodeficiency virus (BIV) genes vif and tmx in viral replication and pathology and to assess the ability of homologous genes from the related Jembrana disease virus (JDV) to act as functional homologues.	Integrated into DNIR-233		
DNIR-236	Women's and Children's Health Network Incorporated	Functional analysis of genes involved in haemopoiesis by retroviral expression in human cells and cell lines	This project aims to investigate the function of various genes involved in normal and abnormal growth of human blood cells.	Expired	9/07/2003	31/07/2008
DNIR-237	Department of Primary Industries	Vaccination of cattle with recombinant bovine herpesvirus 1	DNA from bovine pestivirus will be inserted into the genome of bovine herpesvirus 1 and cattle will be inoculated with the modified virus in order to elicit protective immune responses to both viruses.	Withdrawn		
DNIR-238	Murdoch University	Mutational Analysis of the Australian Strain of Porcine circovirus type 1	The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2.	Expired	16/09/2003	31/08/2007
DNIR-239	Murdoch University	Production of an infectious clone from the Australian Strain of Porcine circovirus type 1	The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2.	Integrated into DNIR-238		
DNIR-240	Murdoch University	Mutational Analysis of the Australian Strain of Porcine circovirus type 2	The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2.	Integrated into DNIR-238		
DNIR-241	Murdoch University	Production of an infectious clone from the Australian Strain of Porcine circovirus type 2	The aim of these dealings is to analyse the effect of mutations introduced into the coding regions of the Rep and capsid open reading frames of porcine circovirus (PCV)- 1 and PCV-2.	Integrated into DNIR-238		
DNIR-242	The University of Queensland	Investigating the molecular pathways controlling cell survival in acute and chronic renal failure	The aim of this dealing is to modify renal disease processes by using replication defective lentiviruses to overexpress various genes associated with apoptosis (programmed cell death) in the rats and mice.	Surrendered	7/07/2003	28/07/2016

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-243	The University of Melbourne	Investigating the biological requirements for prion formation	The aim of this dealing is to transform bacterial, fungal and mammalian cells with the gene encoding the prion protein (PrP) and use these cells to study PrP function and metabolism	Expired	12/08/2003	30/06/2007
DNIR-244	CSIRO	Development of daughterless carp technology (Zebrafish)	The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population.	Withdrawn		
DNIR-245	CSIRO	Development of daughterless carp technology (Mosquitofish)	The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population.	Withdrawn		
DNIR-246	CSIRO	Development of daughterless carp technology (Medaka)	The aim of these dealings is to use RNA interference technology in zebrafish, carp and mosquito fish to sex bias these fish as a means of controlling their population.	Withdrawn		
DNIR-247	Virax Holdings Limited	GMP Manufacturing of recombinant fowlpox viruses vectored vaccines	The researchers intend to undertake large-scale production of recombinant fowlpox virus vector-based vaccines from tissue cultured avian cells.	Expired	30/09/2003	30/09/2008
DNIR-248	Pfizer Australia Pty Ltd	Production of Neovac antigens	The aim of this dealing is to produce four types of recombinant pili antigens to be used in the manufacture of a vaccine against neonatal scours in pigs.	Expired	30/09/2003	30/09/2012
DNIR-249	The University of Adelaide	Studies of avian hepatitis B viruses - virulence, replication and pathogenesis	The aim of this dealing is to introduce mutations into cloned genomes of avian hepatitis B virus isolates and then compare the replication and pathogenesis of the wild type and mutant strains in vitro and in vivo.	Expired	1/07/2003	30/06/2013
DNIR-250	The University of Adelaide	Cellular interactions between HBV and HCV	The aim of this dealing is to transfect cultured liver cells containing a non-infectious hepatitis C virus (HCV) replicon with hepatitis B virus (HBV) and investigate the effect of HBV replication on HCV replication, cell growth, cell viability and cellular gene expression.	Expired	2/10/2003	31/07/2013
DNIR-251	Monash University	Function of Dichelobacter nodosus genes	The aim of this dealing is to isolate and characterise genes that may have a role in conferring virulence and pathogenesis in Dichelobacter nodosus the causative agent of footrot in sheep, cattle and goats.	Surrendered	23/06/2003	24/06/2008
DNIR-252	University of Technology Sydney	Paralysis Tick Vaccine Development	The aim of this dealing is to produce recombinant forms of Australian paralysis tick (Ixodes holocyclus) salivary proteins for the development of a veterinary vaccine.	Expired	9/07/2003	30/11/2011
DNIR-253	St Vincent's Hospital Sydney Limited	HIV biology	The aim is to understand the biology of the human immune deficiency virus as the basis for better drug and vaccine development.	Expired	21/10/2003	31/10/2017
DNIR-254	The University of Western Australia	Evaluation on the effects of apoptosis and necrosis on tumour antigen presentation and anti-tumour response	The aim of this dealing is to determine whether induction of different types of cell death mechanisms in tumours can increase the immune response to these tumours.	Surrendered	3/10/2003	4/04/2007
DNIR-255	Griffith University	Studies on the virulence and physiology of Burkholderia pseudomallei	The aim of this dealing is to identify and characterise virulence genes in the pathogen B. pseudomallei, including those involved in adherence to epithelial cells, and to develop diagnostic and preventative strategies.	Expired	8/08/2003	30/09/2015

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-256	CSIRO	Genetics of Clostridium perfringens pathogenesis	The aim of this dealing is to investigate the role of specific, defined toxin proteins in the pathogenesis of C. perfringens.	Expired	6/11/2003	30/06/2008
DNIR-257	CSIRO	Live bacterial vectors for delivery of recombinant proteins to the chicken gut	The aim of this dealing is to use benign bacterial strains isolated from the chicken gut to deliver therapeutic proteins such as cytokines, bacteriocins, single chain antibodies and vaccine antigens to the chicken gut.	Withdrawn		
DNIR-258	Australian Red Cross Blood Service - Endeavour	Cell mediated immune responses against blood borne viral pathogens	This study aims to express genes from the human pathogenic viruses HIV and HCV in mammalian cell cultures for use as targets in cytotoxic T lymphocyte (CTL) activity assays or antigen presenting cells to stimulate virus-specific CTLs in vitro.	Surrendered	5/08/2003	31/07/2008
DNIR-259	Department of Primary Industries	Study of plant Virus interactions using fluorescence tagged viruses	The aim of this dealing is to study the function of viral genes in virus movement and host interaction in resistant and susceptible plants.	Surrendered	30/10/2003	22/02/2005
DNIR-260	Royal Perth Hospital	Use of Adenovirus and Adenovirus associated virus gene delivery systems for the expression of HCV proteins	Recombinant adenovirus and adeno-associated viruses carrying hepatitis C virus (HCV) genes will be used to produce HCV proteins in cell cultures and mice. This will enable studies on the structure and function of the proteins and act as a source of HCV protein for immune studies.	Surrendered	30/10/2003	3/09/2013
DNIR-261	EnGeneIC Limited	Novel Gene Delivery Vector	The aim of this dealing is to develop a novel drug delivery vector that combines drug biosynthesis and targeted delivery.	Expired	31/10/2003	30/04/2017
DNIR-262	Peter MacCallum Cancer Centre	Molecular analysis of cell cycle and polarity in development and tumourigenesis	The aim of this dealing is to generate cells and mouse tissues modified to express or down-regulate genes involved in the pRB/E2F and Scrib/Dlg/Lgl pathways and study their role in tumour development.	Withdrawn		
DNIR-263	University of Technology Sydney	Development of recombinant immunotoxins	The aim of this dealing is to develop a recombinant cytotoxic agent (which is not a GMO) that can be tested as a therapeutic agent for cancer.	Expired	9/09/2003	31/01/2008
DNIR-264	Western Sydney Local Health District	Liver cell biology and liver injury, metabolic liver disease and mitochondrial dysfunction in drug-induced liver disease	The aim of this dealing is to use mice and rats with experimentally induced liver injury to identify cellular proteins that mediate important liver injury resulting from medical conditions or after exposure to alcohol and drug toxins.	Surrendered	19/09/2003	30/09/2008
DNIR-265	University of New South Wales	Transformation of human cells by human Papillomavirus transforming genes	The aim of this study is to discover the functions of human papillomavirus E6 and E7 proteins by introducing the genes encoding these proteins into normal and/or immortalised human cells.	Withdrawn		
DNIR-266	Melbourne Health	Construction of influenza viruses by reverse genetics for diagnostic and research purposes.	The aim of this project is to employ a technique known as reverse genetics to produce Influenza viruses synthetically in order to derive potential Influenza virus vaccine candidates in a more rapid and reproducible manner.	Surrendered	27/11/2003	14/10/2013

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-267	Queensland University of Technology	Chimeric Dengue vaccines	The aim of this dealing is to elicit an immune response against multiple Dengue virus serotypes in mice using a recombinant Dengue virus or a plasmid containing Dengue virus envelope protein genes from two or more serotypes.	Surrendered	18/11/2003	16/05/2007
DNIR-268	Queensland University of Technology	The development of a novel resistance strategy against ssDNA plant viruses	The aim of this dealing is to develop resistance to single stranded DNA viruses in several plant species by introducing a gene to these plants that will trigger the death of infected cells when exposed to a particular viral protein.	Surrendered	27/11/2003	30/04/2007
DNIR-269	Murdoch Children's Research Institute	Characterisation of genes involved in haematopoietic stem cell growth and regulation	This project will examine the role of known and novel genes in human blood cell growth with the aim of learning more about normal blood cell development and what goes wrong in this process to cause leukaemia.	Surrendered	12/12/2003	25/11/2008
DNIR-270	The Walter and Eliza Hall Institute of Medical Research	Retroviral and adenoviral mediated gene transfer into murine mammary cells and breast cancer cell lines	The aim of this dealing is to study the role of specific genes in cell growth, mammary gland development and oncogenesis.	Surrendered	18/12/2003	28/09/2007
DNIR-271	University of Technology Sydney	Investigations on parasite virulence using cross complementation	The goal of this project is to use a genetic approach to investigate the regions of the parasitic proteins GRA2 and GRA6 involved in Toxoplasma gondii and Neospora caninum virulence.	Expired	10/12/2003	31/12/2008
DNIR-272	The University of Queensland	Delivery of replication defective lentiviruses into mice	The aim of this dealing is to develop novel anticancer treatments against both skin cancers and cancers caused by viruses, using a mouse model.	Surrendered	10/12/2003	8/10/2008
DNIR-273	Western Sydney Local Health District	Repression of hepatic drug metabolism by solid tumours	The aim of this dealing is to investigate how the inflammatory factors released by tumours into the blood reduce hepatic levels of enzymes involved in drug metabolism.	Surrendered	9/12/2003	13/06/2007
DNIR-274	Australian Defence Force Malaria and Infectious Disease Institute	Experimental Infection of Culex annulirostris, Ochlerotatus vigilax and Culex gelidus with Japanese encephalitis virus vaccine candidate ChimeriVax™-JE	The aim of this dealing is to assess the potential of the ChimeriVax™-JE vaccine to infect and replicate in Australian mosquitoes.	Surrendered	29/01/2004	12/02/2007
DNIR-275	Biotron Limited	Viral protein gene function in whole virus for screening anti-viral compounds	The aim of this dealing is to screen for novel compounds which disrupt viral replication using whole recombinant viruses.	Surrendered	22/01/2004	11/03/2011
DNIR-276	QIMR Berghofer	Functional analysis of DNA damage responsive genes by retroviral transfections	The aim of this dealing is to overexpress or inhibit the expression of genes encoding proteins involved in DNA damage repair. This will allow the proponents to determine the function and importance of these genes in keeping the genome intact and preventing cancer.	Surrendered	18/12/2003	17/10/2007
DNIR-277	Cargill Australia Limited	Importation and Processing Soybeans	The applicant intends to import soybeans from the USA, Argentina, and Brazil for processing as oil and stockfeed. Since there are commercial crops of GM soybeans in these countries, the shipment may contain GM soybeans.	Expired	19/12/2003	31/07/2023
DNIR-278	The University of Newcastle	Analysis of oncogenes and their protein products, and investigation of drug resistance mechanisms.	The purpose of this dealing is to investigate specific genes involved in the onset of cancers and characterise various mechanisms of cancer cell drug resistance to conventional and new cancer therapies.	Surrendered	23/12/2003	17/12/2008

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-279	QIMR Berghofer	Expression of virus encoded antigens using vaccinia/fowlpox expression system	The aim of this dealing is to study cell lines infected with vaccinia and fowlpox viruses containing genes encoding Epstein-Barr virus (EBV) and cytomegalovirus antigens.	Withdrawn		
DNIR-280	University of New South Wales	Production of Recombinant Proteins in Chinese Hamster Ovary (CHO) cells	The aim of this dealing is to produce large-scale amounts of recombinant proteins of commercial value in Chinese hamster ovary (CHO) cells.	Surrendered	10/03/2004	21/12/2007
DNIR-281	Murdoch University	Development of a subterranean clover mottle virus as a gene-silencing vector	The aim of this dealing is to use subterranean clover mottle virus as a vector for silencing plant genes in vivo and in vitro.	Expired	27/02/2004	31/10/2008
DNIR-282	Monash University	Modification of the HIV-1 genome in order to visualize the HIV-1 preintegration complex (PIC) and HIV-1 component subcellular trafficking	The aim of this dealing is to elucidate the mechanism used by HIV-1 to gain access to the nucleus of infected cells by investigating a nucleoprotein (PIC) that mediates entry of HIV-1 DNA into the nucleus.	Withdrawn		
DNIR-283	Queensland University of Technology	Generation of an infectious clone of taro bacilliform virus (TaBV)	The aim of this dealing is to determine if taro plant disease can be caused by infection with TaBV alone by infecting taro plant with infectious clones of this virus.	Expired	2/02/2004	30/06/2007
DNIR-284	Griffith University	Cloning and characterisation of Campylobacter spp pathogenicity genes in E.coli and construction of a vector dedicated to cloning and expression of Campylobacter spp. Dna functional in E.coli and Campylobacter spp	The aim of this dealing is to develop a system for the expression of Campylobacter spp. genes functional in both Campylobacter spp. and E. coli and to characterise genes from C. jejuni that encode potential pathogenicity determinants.	Surrendered	10/03/2004	2/12/2008
DNIR-285	Centenary Institute of Cancer Medicine and Cell Biology	Gene transfer into cells of human, non-human primate or rodent origin using replication-incompetent lentiviral vectors	The proponents intend to transfer genes of interest into human or animal cells using lentiviral-based gene delivery systems with the aim of applying these techniques to gene therapy.	Withdrawn		
DNIR-286	The University of Queensland	Retroviral expression of known and potential growth-regulatory genes in human and murine cell lines	The aim of this dealing is to understand how certain oncogenes actively cause or contribute to cancer and to identify new oncogenes involved in leukaemia and breast cancer.	Surrendered	22/04/2004	18/10/2007
DNIR-287	Monash University	Subcellular trafficking of the Dengue virus NS5 protein	The aim of this research is to describe the localisation of the Dengue virus non-structural protein 5 (NS5) during infection of cultured mammalian and insect cells.	Expired	28/05/2004	31/05/2009
DNIR-288	Avexa Limited	Cell Lines Expressing Hepatitis B Virus	The aim of this dealing is to study the formation and release of lamivudine resistant and normal Hepatitis B virus in liver cells.	Expired	24/05/2004	30/06/2009
DNIR-289	Flinders University	Asexual Genetic Exchange in Rhynchosporium secalis, the causal agent of barley scald	The aim of this dealing is to investigate whether genes can be exchanged between isolates of R. secalis in the absence of a sexual cycle.	Surrendered	25/05/2004	8/05/2007
DNIR-290	Australian National University	Temporary storage of Ross River virus mutants	The proponents intend to store Ross River virus mutants for future use.	Expired	20/07/2004	31/07/2009
DNIR-291	South Eastern Sydney Local Health District	Analysis of cytomegalovirus (CMV) genes involved in antiviral susceptibility, replication and cell tropism.	The aim of this dealing is to determine the role of different gene regions of CMV in infection and growth of the virus and inhibition of growth by antiviral drugs, focussing on the DNA polymerase and protein kinase mutations.	Licence issued	26/05/2004	18/09/2030

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-292	QIMR Berghofer	Kunjin replicon virus like particles for delivery of cytokines into mice	The proponents intend to deliver immune response modulating genes into mice using Kunjin replicons with the aim of effecting tumour regression and preventing transplant rejection.	Expired	30/07/2004	31/07/2014
DNIR-293	The University of Queensland	Viral delivery of genes or siRNA involved in adipogenesis or insulin signaling to cells	The aim of this dealing is to examine the effect of increasing or reducing the expression of factors involved in the body's response to insulin and in human fat tissue development in mammalian cells.	Surrendered	30/07/2004	18/10/2007
DNIR-294	CSIRO	Expression of alpha mannosidase in human RD rhabdomyosarcoma cells	The aim of this dealing is to produce RD rhabdomyosarcoma cells expressing alpha mannosidase that can be encapsulated and used in guinea pig trials of an experimental enzyme replacement therapy.	Withdrawn		
DNIR-295	Murdoch Children's Research Institute	Somatic cell genetic studies of mitochondrial respiratory chain disorders	The aim of this dealing is to determine the genetic basis of human diseases caused by mitochondrial energy generation disorders.	Expired	30/07/2004	31/10/2011
DNIR-296	University of Technology Sydney	Characterisation of vaccine, drug and diagnostic targets in apicomplexan parasites	The aim of this dealing is to characterise molecules implicated in the survival and infection of apicomplexan parasites and to determine their suitability as targets for drug and vaccine development.	Withdrawn		
DNIR-297	Australian Defence Force Malaria and Infectious Disease Institute	Development of in vitro liver stage drug susceptibility assays for Plasmodium vivax, P. falciparum, P. yoelii, and P. cynomolgi.	The aim of this dealing is to develop an in vitro assay for evaluating the effectiveness of new drugs and vaccines against the liver stage of malarial parasites.	Expired	30/08/2004	30/06/2009
DNIR-298	CSIRO	A Phase I/IIa, two centre, open-label, dose escalation study to assess the safety, tolerability and efficacy of FP253 in combination with fludarabine phosphate.	The aim of this dealing is to assess the safety, tolerability and efficacy of a candidate cancer therapeutic in a Phase I/IIa clinical trial in prostate cancer patients.	Expired	23/09/2004	28/02/2015
DNIR-299	Monash University	Characterisation of replication competent hepatitis B viruses	The aim of this dealing is to characterise HBV viral DNA sequences present in blood samples from different animal species.	Expired	22/09/2004	30/09/2014
DNIR-300	Western Sydney Local Health District	Expression of CD44 variants in ALL cells	The aim of this dealing is to examine the roles of the cell surface proteins CD44 and VLA-4 in the interaction of leukemic cells with the bone marrow.	Withdrawn		
DNIR-301	Intervet Australia Pty Ltd	Fermentation, processing and inactivation of M.haemolytica cultures	The aim of this dealing to produce large-scale quantities of recombinant M. haemolytica for use in an inactivated veterinary vaccine.	Licence issued	28/06/2004	30/06/2027
DNIR-302	Avexa Limited	Generation of stable cell lines expressing Hepatitis B Virus using the ViraPower lentiviral expression system.	The aim of this dealing is to generate recombinant liver cells that express hepatitis B virus.	Surrendered	3/09/2004	29/08/2011
DNIR-303	Westmead Institute for Medical Research	Production of recombinant Vaccinia viruses for viral disease: immunogenicity studies and vaccine development	The purpose of the dealing is to study the immunogenicity of HIV and Herpes simplex virus proteins in vitro	Expired	3/09/2004	30/09/2024
DNIR-304	Western Sydney Local Health District	Storage of GMOs	The proponents intend to store recombinant mouse and human cell lines for future use.	Withdrawn		
DNIR-305	Peter MacCallum Cancer Centre	Wnt/FZD in human cancer	The aim of this dealing is to define the role of two particular proteins in colon cancer metastasis by modulating the expression of these proteins in colon cancer cell lines in vitro.	Surrendered	5/10/2004	12/06/2007

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-306	University of New South Wales	Study of human immunity against Hepatitis C virus	The aim of this dealing is to investigate specific immune responses against hepatitis C virus that allow some individuals to clear infection, others to become chronically infected and others to have a rapid disease progression.	Surrendered	3/09/2004	20/08/2012
DNIR-307	Macfarlane Burnet Institute for Medical Research and Public Health	Molecular studies of HIV and HCV replication	The proponents intend to study the fusion and entry of human immunodeficiency virus and hepatitis C virus into human cell lines in vitro in order to develop antivirals and vaccines targeting this process.	Licence issued	5/11/2004	30/11/2029
DNIR-308	University of Canberra	Storage and maintenance of bacterial strains and plasmids for future use	The aim of this dealing is to store and maintain an array of bacterial strains and plasmids for future use.	Surrendered	5/11/2004	30/06/2008
DNIR-309	The University of Adelaide	Diagnosis and management of eutypa dieback	The aim of this dealing is to improve disease management strategies for the grapevine pathogen Eutypa lata by using DNA probes to detect the pathogen in infected grapevines and to analyse variations in the fungus.	Withdrawn		
DNIR-310	Institute of Medical and Veterinary Science	Mechanisms of cell survival and apoptosis in multiple myeloma	The aim of this dealing is to investigate the role of various proteins involved in apoptosis and cell survival in multiple myeloma cells and to identify potential targets for therapy.	Surrendered	9/11/2004	30/06/2008
DNIR-311	Department of Primary Industries and Regional Development	DNA adenine methylase salmonella vaccines	The aim of this dealing is to evaluate the cross protective efficacy of the DNA adenine methylase deficient Salmonella typhimurium vaccine strain in calves.	Withdrawn		
DNIR-312	The University of New England	Interactions between beneficial bacteria and wheat	The aim of this dealing is to investigate the interactions between wheat and beneficial bacteria that suppress fungal diseases of wheat.	Withdrawn		
DNIR-313	Institute of Medical and Veterinary Science	Study of breast cancer tumour suppressor genes	The aim of this dealing is to investigate the function of breast tumour suppressor genes and their interacting proteins in human breast cell lines in vitro.	Surrendered	18/11/2004	30/06/2008
DNIR-314	Peter MacCallum Cancer Centre	Viral mediated approaches to examine cell growth, cell proliferation and cell death.	The aim of this dealing is to use viral vectors to introduce genes into cultured cells and animals to determine their role in cancer.	Expired	19/11/2004	30/11/2019
DNIR-315	Peter MacCallum Cancer Centre	Expression and function of HIN 200 proteins.	The aim of this dealing is to use viral vectors to introduce genes encoding HIN-200 proteins into mice and cultured cells to determine their role in cellular differentiation.	Surrendered	26/11/2004	26/10/2007
DNIR-316	The University of Adelaide	Storage (Salmonella GMOs)	The storage of genetically modified Salmonella enterica Serovar Typhimurium.	Surrendered	29/11/2004	3/07/2008
DNIR-317	Progen Industries Limited	Deltavasc	The aim is to generate large amounts of plasmid that will be formulated into a drug product for a US based Biotechnology company.	Expired	22/09/2004	28/02/2006
DNIR-318	Flinders University	Analysis of the M-flax rust resistance gene in transgenic flax and tobacco.	The aim is to use transgenic plants to study the control of expression and function of disease resistance proteins.	Withdrawn		
DNIR-319	IDT Australia Limited	Randomised, double blind, placebo controlled phase II dose-ranging study of the safety, tolerability and immunogenicity of live attenuated ChimeriVax™-JE vaccine (lyophilised).	The aims of this study are to assess the safety, tolerability and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with the placebo.	Surrendered	5/11/2004	17/10/2006

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-320	Melbourne Health	Randomised, double blind, placebo controlled phase II dose-ranging study of the safety, tolerability and immunogenicity of live attenuated ChimeriVax™-JE vaccine (lyophilised).	The aims of this study are to assess the safety, tolerability and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with a placebo.	Surrendered	5/11/2004	17/10/2006
DNIR-321	The Walter and Eliza Hall Institute of Medical Research	Storage of GM Cell Lines that would require a licence if dealings with those GMOs were undertaken.	Storage of GM cell lines that would require a licence if dealt with. The GMOs will be stored in certified facilities or in other restricted access areas (such as a locked freezer or liquid nitrogen store).	Surrendered	3/12/2004	28/09/2007
DNIR-322	CSL Limited	Pilot scale fermentation and processing of merozoite surface proteins (MSP) expressed in recombinant Escherichia coli (E.coli)	The aim is to use genetically modified bacteria to express proteins normally made by the malaria parasite to test as anti-malarial vaccines.	Expired	4/01/2005	31/07/2008
DNIR-323	Griffith University	Development of novel gene transfer vectors for gene therapy.	The aims are to develop new mechanisms and vectors for gene therapy of respiratory diseases and cancers.	Expired	7/01/2005	31/08/2013
DNIR-324	The University of Queensland	Complementation of mutations to genes that play a role in virulence in intestinal and extraintestinal bacteria.	This work will examine the processes important to adherence, colonisation, survival and pathogenesis employed by bacteria that cause enteric and urinary tract infections in humans.	Surrendered	7/01/2005	18/10/2007
DNIR-325	The University of Queensland	Genetic analysis of X. albilineans.	This project explores the molecular basis for albicidin antibiotic biosynthesis and resistance in Xanthomonas albilineans.	Surrendered	7/01/2005	18/10/2007
DNIR-326	St Vincent's Hospital (Melbourne)	Storage of GMOs that are a licensed dealing.	Storage of GMOs related to licenced dealings	Withdrawn		
DNIR-327	Mater Research Ltd	Retroviral expression of genes and small inhibitory RNA.	This study aims to use retroviral vectors to generate stable and transient expression of human and rodent genes in human and rodent cell lines.	Expired	7/01/2005	31/01/2010
DNIR-328	Macfarlane Burnet Institute for Medical Research and Public Health	Immunotherapy for hepatitis C virus infection.	The aim is to treat HCV-infected individuals who have failed conventional interferon-based therapy, with activated dendritic cells.	Expired	27/01/2005	31/01/2015
DNIR-329	The University of Melbourne	Identification of virulence determinants of Leptosphaeria maculans and sclerotinia sclerotiorum.	The aims are to identify the genes that allow L. maculans and S. sclerotiorum, two fungal pathogens, to cause disease in canola.	Surrendered	25/01/2005	21/08/2007
DNIR-330	The University of Melbourne	Novel approaches to vaccination against bacterial diseases.	The purpose of this dealing is to construct attenuated Salmonella strains for use as potential Salmonella vaccines and to study the immunobiology of Salmonella infection and the efficacy of the attenuated Salmonella strains as vaccine delivery vehicles for foreign antigens.	Surrendered	22/07/2005	23/08/2007
DNIR-331	The University of Melbourne	Investigation of the virulence of Klebsiella pneumoniae: development of a vaccine and immunotherapeutics.	The aims are to investigate the properties of the bacterium K. pneumoniae which allow it to cause pneumonia, urinary tract infections and sepsis.	Surrendered	24/01/2005	21/08/2007
DNIR-332	The University of Melbourne	Identification of virulence-associated determinants and protective antigens in bacterial pathogens.	This dealing aims to identify novel virulence-associated determinants in several bacterial pathogens of humans and to investigate whether these factors can be used as targets for therapeutic or prophylactic vaccines.	Surrendered	27/01/2005	28/08/2007

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-333	The University of Melbourne	Manipulation of Influenza A viruses using reverse genetics to study both cellular, humoral and molecular characteristics of viral immunity.	The aims are to use reverse genetics on Influenza A virus to determine the cellular, humoral and molecular characteristics of anti-viral immunity.	Surrendered	28/01/2005	23/08/2007
DNIR-334	University of New South Wales	Storage of GMOs that are a licensed dealing.	The aim of this dealing is to store or dispose of pre-existing GMOs generated by several GMAC dealings.	Surrendered	27/01/2005	21/12/2007
DNIR-335	University of New South Wales	The role of quorum sensing in biofilm formation, virulence factor expression and environmental adaptation.	The aims are to study the role of quorum sensing, quorum sensing genes and quorum sensing controlled factors in the processes of biofilm formation, environmental adaptation and infection.	Surrendered	27/01/2005	21/12/2007
DNIR-336	University of Technology Sydney	Use of wild type, gene knock-out, and transgenic mice, and recombinant viruses to study cytokine biology.	The aims are to investigate the roles of immune cell activating proteins in the immune response to virus infection.	Expired	28/01/2005	31/01/2020
DNIR-337	CSL Limited	Pilot scale fermentation and processing of hepatitis C polyprotein expressed in recombinant saccharomyces cerevisiae.	The aims are to produce pilot-scale quantities of Hepatitis C virus polyprotein from S. cerevisiae for purification and vaccine formulation.	Surrendered	25/01/2005	8/10/2009
DNIR-338	Western Sydney Local Health District	Use of transgenic and gene knock-out mice and recombinant viruses to study tumour necrosis factor (TNF)-family molecule biology.	The aims are to investigate the role of TNF-related apoptosis inducing ligand (TRAIL) in the immune system.	Withdrawn		
DNIR-339	The University of Melbourne	Virulence genes of avian pathogenic Escherichia coli.	This study aims to identify the genes responsible for virulence in avian pathogenic Escherichia coli and to examine the efficacy of mutants with these genes deleted or disrupted as vaccine candidates.	Surrendered	8/02/2005	21/08/2007
DNIR-340	Western Sydney Local Health District	(1) Regulation of secretion of the fungal virulence determinant, phospholipase B. (2) Fungal phospholipases: exploring a new target for drug discovery.	The aims are to determine the mechanisms regulating cryptococcal Phospholipase B (PLB) synthesis and secretion and to develop new antifungals based on the inhibition of PLB.	Withdrawn		
DNIR-341	Women's and Children's Health Network Incorporated	Functional analysis of genes involved in haemopoiesis by retroviral expression in human cells and cell lines.	This project aims to investigate the function of various genes with regard to the normal and abnormal growth of human blood cells.	Surrendered	24/02/2005	7/11/2008
DNIR-342	The Children's Hospital Westmead	Use of wild type, gene knock-out, and transgenic mice, and recombinant viruses to study cytokine biology.	The aims are to investigate the roles of immune cell activating proteins in the immune response to virus infection.	Surrendered	28/01/2005	22/09/2009
DNIR-343	Macquarie University	Production of TMV-GFP viral vector.	The aim of this project is to produce assembled TMV-GFP viral vector from RNA transcript in young plants.	Withdrawn		
DNIR-344	Harry Perkins Institute of Medical Research	Studying the regulation of gene transcription using amphotropic retroviruses.	The aims of this project are to use replication defective amphotropic retroviruses to transfer genes into mammalian cell lines and primary cells.	Surrendered	30/03/2005	21/09/2007
DNIR-345	The University of Sydney	Function of Dichelobacter nodosus genes and production of recombinant antigens.	The purpose of the dealings is to investigate the function of potential virulence genes in Dichelobacter nodosus, the causative agent of footrot and, to produce recombinant antigens.	Expired	6/04/2005	30/04/2015

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-346	South Eastern Sydney Local Health District	Cellular Antiviral Immunity (including HIV and HCV)	The aim of this dealing is to study cellular immunity of human peripheral blood mononuclear cells to Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) by expressing HIV and HCV antigens using Vaccinia virus (VV) recombinant vectors and conducting in vitro assays that measure cytotoxic T cell activity, lymphoproliferative activity and cytokine production.	Surrendered	4/05/2005	25/05/2009
DNIR-347	University of Wollongong	Storage of GMOs that are GMAC, NLRD and DNIR dealings	The purpose of this dealing is to store GMOs that were previously covered under GMAC, NLRDs and DNIRs.	Expired	5/05/2005	30/11/2010
DNIR-348	CSIRO	Production of anti-CD59 Fab fragments using recombinant E. coli	The purpose of this dealing is to produce large-scale quantities of recombinant Escherichia coli expressing anti-CD59 antibody fragments and to purify the recombinant protein.	Surrendered	14/04/2005	15/03/2010
DNIR-349	The University of Queensland	Investigation into the role of novel genes at the level of the cell and animal	The purpose of this dealing is to understand the role of genes of interest in disease specifically inflammation, tissue regeneration and congenital abnormalities.	Expired	12/05/2005	31/05/2010
DNIR-350	University of Technology Sydney	Development of Chimeric and Humanized forms of a mouse monoclonal antibody	The aims of this dealing are to produce large-scale quantities of chimeric and humanised forms of the murine monoclonal antibody mKap.	Expired	27/05/2005	31/05/2007
DNIR-351	The University of Melbourne	Cell wall metabolism in mycobacteria	The aim of this dealing is to investigate the cell wall metabolism of Mycobacterium tuberculosis, the causative agent of tuberculosis.	Surrendered	27/06/2005	11/09/2014
DNIR-352	Seqirus Pty Ltd	Preparation of influenza vaccines of genetically modified, attenuated influenza A strains with a PR8 [A/Puerto Rico/8/1934 (H1N1)] background	The aim of the dealing is to prepare batches of inactivated human influenza vaccine from strains of attenuated avian influenza	Licence issued	6/04/2005	31/03/2030
DNIR-353	Queensland University of Technology	Investigation of Host Range Determinants in Papaya Ringspot Virus	To use an artificial infection system for PRSV-P and W using cloned components to identify amino acids involved in host range through generation of recombinants representing mixtures of different regions of the two genomes and in vitro mutagenesis	Withdrawn		
DNIR-354	Murdoch Children's Research Institute	Analysis of telometric structure and function in human marker chromosomes.	This project aims to determine the structure and function of the ends (telomeres) of human cytogenetic marker chromosomes	Withdrawn		
DNIR-355	Department of Primary Industries and Regional Development	Function of Dichelobacter nodosus genes.	The purpose of this dealing is to examine the function of potential virulence genes in Dichelobacter nodosus, the causative agent of footrot, through in vivo testing on sheep (Ovis aries).	Expired	3/06/2005	30/06/2010
DNIR-356	QIMR Berghofer	Expression and characterization of novel genes from Australian snakes.	The aims of this research are to clone and express venom proteins from Australian elapid snakes in relation to the treatment of envenomation victims or as therapeutic agents.	Expired	16/08/2005	31/08/2015
DNIR-357	The University of Queensland	Investigation into the role of genes in neural development and repair.	The aims of this research are to use replication defective lentiviral vectors as a tool to investigate the function of genes that are involved in neural development and repair.	Expired	22/08/2005	31/08/2015

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-358	CSIRO	Immun contraceptive effects of recombinant murine cytomegaloviruses expressing mouse zona pellucida subunit 3 protein.	The purpose of this dealing is to test the efficacy and safety of recombinant Murine cytomegalovirus expressing immun contraceptive proteins.	Expired	30/06/2005	30/11/2013
DNIR-359	CSIRO	Storage of GMOs that are licensed dealings.	The purpose of this dealing is to store GM cell lines that are no longer being worked on but for which the researchers wish to maintain stocks.	Expired	30/06/2005	30/11/2013
DNIR-360	The University of Queensland	Identification of virulence determinants in encephalitic flaviviruses	The aims of this research are to investigate the role of flaviviral genes and untranslated genomic regions in the virulence and pathogenicity of encephalitic flaviviruses.	Surrendered	7/10/2005	15/06/2010
DNIR-361	Peter MacCallum Cancer Centre	Viral mediated approaches to examine cell proliferation, differentiation transformation and death.	The aim of this research is to utilise replication defective viral vectors for the delivery of tumour-suppressor genes and oncogenes in order to study the proliferation, differentiation, transformation and death of mammalian cultured cells.	Withdrawn		
DNIR-362	University of New South Wales	The role of quorum sensing and biofilm related genes in environmental adaptation by marine Vibrio spp.	The aim of this project is to study those genes that appear, under laboratory conditions, to be essential for biofilm development and grazing resistance under real life conditions in the marine environment where the bacteria are exposed to natural variations in nutrients, light, and temperatures.	Withdrawn		
DNIR-363	Flinders University	Storage of GMO's associated with the DNIR project.		Withdrawn		
DNIR-364	University of Technology Sydney	Generation and characterisation of poxvirus Tumour Necrosis Factor Receptor (TNF-R) homologues orfs in subversion of cellular TNF-R signalling.	The aims of this research are to investigate how poxvirus tumour necrosis factor receptor-like proteins are able to inhibit the death of infected cells.	Surrendered	25/10/2005	12/12/2024
DNIR-365	Western Sydney Local Health District	Infusion of Ad5F35pp65-stimulated, donor-derived cytotoxic T lymphocytes for the prevention of CMV reactivation and infection following allogeneic stem cell transplantation.	The aim of this dealing is to conduct a clinical trial in patients undergoing blood or bone marrow transplantation. The trial will involve the use of a recombinant adenovirus as an antigen source	Withdrawn		
DNIR-366	PPD Australia Pty Ltd	Phase III clinical trials of ChimeriVax™-JE	The aims of this dealing are to conduct two phase III clinical trials of ChimeriVax™-JE a live, attenuated, genetically modified vaccine against Japanese encephalitis (JE).	Expired	26/09/2005	30/06/2009
DNIR-367	Australian National University	Molecular characterisation of the biogenesis and action of cholera toxin and related enterotoxins	The purpose of this dealing is to clone and express the cholera toxin of Vibrio cholerae and related enterotoxins of Escherichia coli, and to analyse their interactions with mammalian cells, for potential use in therapeutics	Expired	30/11/2005	30/11/2010
DNIR-368	Monash University	Measurement of cell entry mediated by HIV-1 particles pseudotyped with hepatitis C virus (HCV) envelope proteins.	The aims of this dealing are to investigate the entry into human liver cells in vitro of HIV-1 particles pseudotyped with Hepatitis C virus (HCV) envelope proteins	Surrendered	6/12/2005	25/08/2016
DNIR-369	St Vincent's Hospital Sydney Limited	A Multicentre, Double-blind, randomised, placebo-controlled phase II proof-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in adults at high risk of HIV-1 infection.	The aims of the dealing are to test the safety, efficacy and tolerability of a recombinant adenovirus vaccine containing genes from HIV-1 to act as a prophylactic vaccine to prevent HIV-1 infection of HIV-1 seronegative individuals.	Expired	6/02/2006	31/01/2011

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-370	St Vincent's Hospital Sydney Limited	A randomised study of therapeutic immunization and treatment interruption among subjects who began potent antiretroviral therapy within 16 days of diagnosis of acute or recent HIV infection	The aims of the dealing are to test the safety, efficacy and tolerability of a recombinant adenovirus containing genes from HIV-1 as a therapeutic vaccine to suppress viral replication and lower the viral load in patients who have been diagnosed with acute or recent HIV-1 infection and who have been receiving antiretroviral therapy.	Integrated into DNIR-369		
DNIR-371	Harry Perkins Institute of Medical Research	Generation of assay cell lines		Withdrawn		
DNIR-372	Melbourne Health	The Effect of Hepatitis B Virus surface antigen mutations on Hepatitis Delta Virus assembly and release.	The aims of this research are to study the effect of mutations encoded by the Hepatitis B virus envelope genes on the assembly and release of Hepatitis delta virus.	Expired	9/02/2006	28/02/2011
DNIR-373	The Children's Hospital Westmead	Studies of human cell immortalisation using adeno-associated virus (AAV) vectors		Withdrawn		
DNIR-374	CSL Limited	Fermentation and Processing of a Recombinant Antibody Expressed in Recombinant Chinese Hamster Ovary Cells.	The purpose of this dealing is to produce and purify pilot-scale quantities of recombinant, chimeric anti-cancer antibodies from Chinese Hamster Ovary cells	Expired	20/02/2006	31/05/2011
DNIR-375	The University of Adelaide	Adenoviruses as a delivery vector of exogenous protein expression in cultured cells and livers of mice	The aim of the proposed dealing is to use an adenovirus gene-delivery and over-expression system to evaluate the role that several cellular gene products, previously identified through microarray analysis of HCV-infected tissue, play in the progression of HCV-related liver disease.	Withdrawn		
DNIR-376	The University of Sydney	RCAS gene transmission to TVA transgenic mice and cells	This study aims to identify human and mouse genes that are responsible for maintaining a normal differentiation program in keratinocytes.	Expired	10/04/2006	30/04/2016
DNIR-377	The University of Sydney	Regulation of keratinocyte differentiation	The aim of the proposed dealings is to identify genes that are responsible for maintaining a normal differentiation program in keratinocytes, determine whether they are aberrantly expressed in cancers of the skin and head and neck region and to assess the carcinogenic consequences of aberrantly expressing themThe aim of the proposed dealings is to identify genes that are responsible for maintaining a normal differentiation program in keratinocytes, determine whether they are aberrantly expressed in cancers of the skin and head and neck region and to assess the carcinogenic consequences of aberrantly expressing them	Withdrawn		
DNIR-378	University of Tasmania	Therapeutic Potential of shRNA's in Leukemic Cells		Withdrawn		
DNIR-379	University of Tasmania	Storage of GMO's that are licenced dealing		Withdrawn		
DNIR-380	Griffith University	Engineering anaerobic bacteria for multimodal cancer therapy	The aims of this study are to investigate the potential of utilising anaerobic bacteria that express recombinant immunotoxins as treatments for solid tumours in animal models.	Expired	9/05/2006	31/10/2011
DNIR-381	The University of Melbourne	Biological requirements for prion formation	The aims of this research are to express isoforms of human, mouse and hamster prion protein to identify regions of the protein that modulate the infection process.	Surrendered	16/05/2006	31/05/2011

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-382	The University of Melbourne	Mutations in humans prion diseases	The aims of this research are to express isoforms of human, mouse and hamster prion protein to identify regions of the protein that modulate the infection process.	Integrated into DNIR-381		
DNIR-383	The University of Melbourne	Analysis of HIV vaccination strategies	The aims of the dealing are to compare the efficacy of HIV vaccination strategies by the use of live recombinant vaccinia and influenza viruses expressing HIV antigens in mice in vivo and to develop a vaccination strategy based on the influenza virus	Withdrawn		
DNIR-384	Peter MacCallum Cancer Centre	Analysis of molecular signalling for growth of blood vessels and lymphatic vessels using adenoviral gene transfer	The purpose of this dealing is to transfer genes using adenoviral vector and to analyse the expressed proteins for growth of blood and lymphatic vessels in cultured mammalian cells and mice	Expired	31/05/2006	31/05/2021
DNIR-385	Royal Perth Hospital	Construction of recombinant plasmids carrying HCV viral genome inserts.		Withdrawn		
DNIR-386	Sanofi-Aventis Australia Pty Ltd	Clinical trials of ChimeriVax™ Tetravalent Dengue Vaccine	The purpose of this dealing is to conduct a Phase IIa clinical trial of ChimeriVax™-DEN, a tetravalent, live, attenuated, chimeric, genetically modified vaccine against dengue virus.	Expired	24/07/2006	31/12/2012
DNIR-387	CSIRO	Identification of virulence factors for infectious bursal disease virus (IBDV)	Recombinant strains of infectious bursal disease virus (IBDV) will be used to identify the virulence factors that make IBDV pathogenic to chickens.	Licence issued	21/07/2006	31/07/2029
DNIR-388	Baker Heart & Diabetes Institute	Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo	This project utilises virus-based gene delivery to examine the processes that control the function of the heart and circulation in health and disease.	Expired	1/09/2006	31/08/2012
DNIR-389	Griffith University	Mechanisms of Ross River viral disease	The aim of the proposed dealings is to study the pathogenesis of Ross River virus-induced polyarthritis in a mouse model.	Licence issued	1/09/2006	19/12/2026
DNIR-390	La Trobe University	Identification of virulence determinants of <i>Venturia inaequalis</i> , <i>Botrytis cinerea</i> and <i>Sclerotinia sclerotiorum</i>		Withdrawn		
DNIR-391	Bioproperties Pty Ltd	Production of Neovac antigens	The aim of this dealing is to produce four types of recombinant pili antigens to be used in the manufacture of a vaccine against neonatal scours in pigs.	Expired	16/10/2006	31/10/2012
DNIR-392	The University of Western Australia	Plasmids in <i>Neisseria</i> sp	The aims of this dealing are to identify and study the expression and function of genes involved in pathogenicity/virulence of <i>Neisseria meningitidis</i> and <i>N. gonorrhoeae</i>	Surrendered	2/11/2006	4/10/2011
DNIR-393	University of New South Wales	Evolution of Hepatitis C Virus (HCV) in Cell Culture		Withdrawn		
DNIR-394	The University of Newcastle	Generation of low-pathogenic enteroviral full-length infections clones	The purpose of this dealing is to generate full-length infectious clones of several low-pathogenic enteroviruses of the picornaviridae for characterisation of the virus genome(s) by in vitro studies	Surrendered	10/11/2006	30/11/2010
DNIR-395	Institute of Medical and Veterinary Science	The use of lenti-viral vectors as delivery systems for the knock-down of proteins involved in gastric vagal afferent mechanosensitivity		Withdrawn		

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-396	The University of Queensland	Analysis of invertebrate virus genomes	This dealing aims to analyse the function of various invertebrate viral genomes by mutagenesis and subsequent analysis of virus function in vitro and in vivo.	Surrendered	21/11/2006	8/06/2016
DNIR-397	Seqirus Pty Ltd	Development of improved attenuated H5 influenza virus for production of killed influenza vaccine	The aim of the proposed dealings is to use reverse genetics to produce an improved, attenuated H5 influenza vaccine strain with increased levels of surface haemagglutinin (HA) through modification of the HA gene	Surrendered	28/11/2006	19/12/2014
DNIR-398	QIMR Berghofer	Large Scale Production of a Human/Chimeric IgG4 Antibody for Clinical trials	The purpose of this dealing is to produce large scale quantities of a chimeric IgG4 antibody via cell culture for clinical use	Expired	9/11/2006	30/11/2011
DNIR-399	La Trobe University	Mechanisms of cell death		Withdrawn		
DNIR-400	Cargill Australia Limited	Canadian canola seed import for further processing at Newcastle	The aim of the dealing is to import Canadian canola seed into Newcastle, NSW, Australia for crushing in order to supply domestic oil and meal demands.	Expired	22/09/2006	30/09/2021
DNIR-401	Westmead Institute for Medical Research	Transmissible genetic elements in bacteria	The purpose of this dealing is to characterise antibiotic resistance-associated genetic loci such as resistance genes and mobile genetic elements in bacteria.	Licence issued	23/01/2007	20/01/2027
DNIR-402	Clinical Network Services (CNS) Pty Ltd	Single armed, multicentre, open label clinical study evaluating the safety and tolerability of NovaCaps in patients with inoperable pancreatic carcinoma	The aim of this dealing is to conduct a phase I clinical trial of an encapsulated cell therapy product (NovaCaps) that activates the prodrug ifosfamide in patients with inoperable pancreatic carcinoma	Surrendered	16/01/2007	7/11/2008
DNIR-403	Progen Industries Limited	Large scale production of Mannan Fusion Protein		Withdrawn		
DNIR-404	The University of Sydney	A Gene Therapy Strategy for Prion Disease using Lentiviral Vector Delivery of Short Hairpin RNA (shRNA) Targeting the PrP ^C Gene		Withdrawn		
DNIR-405	The University of Queensland	Overexpression and mutant complementation in <i>Cryptococcus</i>	The aim of this dealing is to investigate mating and growth regulators in <i>Cryptococcus</i> species.	Surrendered	5/03/2007	22/01/2009
DNIR-406	Imugene Limited	Construction and testing of porcine adenovirus (PAV) vectors expressing foreign DNA	The aim of this dealing is to develop and conduct in vitro tests of potential vaccines and therapeutics for the poultry and pork industries	Surrendered	5/04/2007	25/01/2013
DNIR-407	Imugene Limited	Construction and testing of fowl adenovirus (FAV) vectors expressing foreign DNA	The aim of this dealing is to develop and conduct in vitro tests of potential vaccines and therapeutics for the poultry and pork industries	Surrendered	5/04/2007	25/01/2013
DNIR-408	Institute of Medical and Veterinary Science	Binding and replication studies of Norovirus		Withdrawn		
DNIR-409	The University of New England	Is XprG a global regulator of fungal virulence?		Withdrawn		
DNIR-410	Women's and Children's Health Network Incorporated	New approaches to understanding bone fusion		Withdrawn		
DNIR-411	Murdoch University	Pathogenicity determinants of <i>Septoria</i> (<i>Stagonospora</i>) <i>nodorum</i>		Withdrawn		
DNIR-412	Queensland University of Technology	Population dynamics of arboviruses		Not Issued		

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-413	The University of Melbourne	Analysis of malaria proteins and regulatory DNA sequences through disruption and complementation		Withdrawn		
DNIR-414	The University of Queensland	Characterisation of Cytomegalovirus chemokine receptor homologues	The purpose of this dealing is to investigate the function of mouse and human viral chemokine receptors in promoting virus replication and dissemination during infection	Surrendered	13/06/2007	3/03/2025
DNIR-415	The University of Western Australia	A phase I/II human gene therapy trial to establish the base line safety and efficacy following a single subretinal injection of rAAV.sFlt-1 for the treatment of exudative age related macular degeneration (AMD)	The purpose of this dealing is to conduct a phase I/II clinical trial of a genetically modified replication defective Adeno-associated virus in patients suffering exudative age related macular degeneration	Surrendered	2/07/2007	12/05/2015
DNIR-416	Ludwig Institute for Cancer Research Melbourne-Austin Branch	Dissecting the mechanism of immunodominance hierarchy		Withdrawn		
DNIR-417	Macfarlane Burnet Institute for Medical Research and Public Health	Studies of dengue type 2 virus replication		Withdrawn		
DNIR-418	Biotron Limited	Anti Viral Drugs	The purpose of this dealing is to use GM viruses to understand how novel anti-HIV drugs act against HIV-1 and confirm the target site of drug activity	Expired	17/09/2007	15/02/2015
DNIR-419	Institute of Medical and Veterinary Science	Designing novel vaccination approaches to provide protection against vaccinia virus infection		Withdrawn		
DNIR-420	Central Adelaide Local Health Network	Determining the relative packaging efficiency of HIV-1 and HIV-1 derived vector genomes	The purpose of the dealing is to determine the relative packaging efficiencies of wild-type HIV-1 genomic RNA and the genomic RNA of attenuated HIV-1 derived gene vectors	Surrendered	5/10/2007	22/09/2011
DNIR-421	Sanofi Pasteur Pty Ltd	Recombinant, live attenuated Japanese encephalitis vaccine (ChimeriVax™-JE)		Withdrawn		
DNIR-422	Westmead Institute for Medical Research	Pathogenesis of hepatitis C virus	The aim of the project is to understand how hepatitis C virus causes disease in infected people, including fatty liver, inflammation and scarring of the liver, liver failure and liver cancer	Licence issued	8/11/2007	31/08/2027
DNIR-423	QIMR Berghofer	The biology of arbovirus fitness in arthropod hosts	The purpose of this dealing is to study the replication of genetically modified Ross River virus strains in mosquitoes	Expired	16/11/2007	30/11/2012
DNIR-424	Women's and Children's Health Network Incorporated	Evolution and selection of complement-resistant VSV-G variants	The purpose of this dealing is to isolate a complement-resistant variant of the Vesicular stomatitis virus (VSV)-G glycoprotein that can be used to pseudotype lentiviral vectors	Surrendered	16/11/2007	22/09/2011
DNIR-425	Seqirus Pty Ltd	Influenza viruses	The aim of the dealing is to construct influenza viruses by reverse genetics for research purposes	Licence issued	16/11/2007	30/06/2031
DNIR-426	Griffith University	Characterising virulence in enteric pathogens	The purpose of these dealings is to study the function of bacterial molecules that enter into and alter host cells in order to understand disease progression and identify targets for therapeutics	Surrendered	21/12/2007	9/02/2011
DNIR-427	CSIRO	Molecular identification and characterisation of the virulence and host range determinants of SARS and SARS-like coronaviruses	The aims of this dealing are to investigate the role of virulence and host-range determinants in vitro in Severe Acute Respiratory Syndrome (SARS) and SARS-like coronaviruses	Licence issued	7/02/2008	30/11/2027

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-428	CSIRO	Identification of virulence factors for Henipaviruses	This study aims to generate recombinant Hendra virus and Nipah virus that include mutations or deletions in viral genes or the non-coding regions to determine their role in Heninavirus pathogenesis and transmission	Surrendered	7/02/2008	15/11/2011
DNIR-429	Cargill Australia Limited	Importation of US Corn for further processing into stockfeed	The aim of this dealing is to import corn which potentially includes GM lines into Newcastle and Melbourne for processing to produce domestic stockfeed.	Surrendered	21/02/2008	15/08/2025
DNIR-430	The University of Melbourne	Gene transfer of neurotrophins for survival and reconnection of regenerating auditory nerves		Withdrawn		
DNIR-431	Women's and Children's Health Network Incorporated	Lentiviral-mediated gene therapy	Development and testing of lentiviral HIV-1 vector systems for the treatment of monogenic diseases	Surrendered	11/03/2008	10/11/2016
DNIR-432	University of Technology Sydney	Insulin storage and release from liver hepatocytes	The purpose of the proposed dealings is to develop a somatic cell gene therapy system using lentiviral vectors for the treatment of diabetes.	Licence issued	31/03/2008	31/08/2027
DNIR-433	University of Technology Sydney	Insulin storage and release from liver hepatocytes using a new lentiviral vector		Withdrawn		
DNIR-434	CSIRO	Generation of new vaccines to Marek's disease virus		Withdrawn		
DNIR-435	Flinders University	Lentivirus-mediated gene transfer to prolong corneal graft survival	The aims of these dealings are to investigate the potential for lentiviral and adenoviral (var-6526) mediated gene therapy to improve the survival of corneal grafts in animal models	Surrendered	2/04/2008	1/12/2015
DNIR-436	Institute of Medical and Veterinary Science	The effects of BCR-ABL and BCR-ABL mutants on transporter expression and function		Withdrawn		
DNIR-437	QIMR Berghofer	Cleanroom manufacturing of a chemotherapeutic drug delivery technology for use in cancer therapy	The purpose of this dealing is to produce large scale preparations of a drug delivery vehicle for use in cancer therapy	Surrendered	29/04/2008	25/05/2009
DNIR-438	Royal Prince Alfred Hospital	Phase 1 safety study in subjects with severe Hemophilia B (Factor IX Deficiency) using adeno-associated viral vector to deliver the gene for Human Factor IX into the liver coupled with transient immunomodulation	The purpose of this dealing is to conduct a phase I clinical trial of a genetically modified, replication defective Adeno-associated viral vector in patients suffering Hemophilia B in combination with immunosuppressive therapy	Surrendered	20/06/2008	7/01/2013
DNIR-439	The University of Queensland	Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo	The aim of the proposed dealings is to investigate the regulation of cardiac function in vivo by the delivery of cardiac regulatory genes into rodents using replication-defective viral vectors	Licence issued	30/06/2008	31/03/2028
DNIR-440	The University of Queensland	Mechanisms of growth hormone signalling II	This project will investigate how growth hormone signals via the growth hormone receptor and other genes to control growth and metabolism, and its role in the development of cancer	Licence issued	30/06/2008	30/04/2028
DNIR-441	QIMR Berghofer	Characterizing Host Immunity to Plasmodium	The aims of this dealing are to characterise Plasmodium antigens in vitro and in vivo, to assess their suitability in the development of a malaria vaccine	Expired	15/07/2008	31/07/2019
DNIR-442	Women's and Children's Health Network Incorporated	Lentivirus Gene Transfer to Treat Cystic Fibrosis Airway Disease	The purpose of this dealing is to test lentiviral HIV-1 vector systems for the treatment of cystic fibrosis.	Surrendered	21/07/2008	10/11/2016

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-443	CSIRO	Avian Influenza: A Study of Molecular Pathogenesis	The purpose of this dealing is to identify sequence changes in H5N1 influenza viral genes that cause differences in the severity of disease symptoms in avian and mammalian hosts.	Expired	7/08/2008	31/10/2021
DNIR-444	The Bionics Institute of Australia	Gene transfer of neurotrophins for survival and reconnection of regenerating auditory nerves	This study aims to utilise adenoviral and adeno-associated viral vector gene therapy to determine whether locally expressed neurotrophins can promote nerve survival and nerve regeneration in the inner ear of animals	Expired	4/04/2008	30/04/2013
DNIR-445	CSIRO	Characterisation of pathogenicity determinants of <i>Fusarium oxysporum</i>		Withdrawn		
DNIR-446	The Queen Elizabeth Hospital	Transduction of islets with Adenovirus and Adeno associated virus expressing marker and/or therapeutic genes to improve islet survival and function following transplantation		Withdrawn		
DNIR-447	CSIRO	Characterisation of putative pathogenicity determinants in <i>Fusarium</i> species by gene knockout and complementation		Withdrawn		
DNIR-448	O'Brien Institute	Targeting NADPH oxidase in angiogenesis in vivo		Withdrawn		
DNIR-449	Peter MacCallum Cancer Centre	Phase I study of autologous T lymphocytes with an anti LeY chimeric receptor gene for patients with Multiple Myeloma, AML or high-risk MDS	The purpose of this dealing is to analyze the safety and efficacy of autologous administration of genetically modified T-lymphocytes expressing an anti-Lewis Y antibody for the treatment of cancer in patients enrolled in a Phase I clinical trial	Expired	6/11/2008	31/12/2012
DNIR-450	Monash University	Polymyxin resistance in Gram-negative bacteria		Withdrawn		
DNIR-451	Central Adelaide Local Health Network	Expression of lysosomal enzymes and shRNA from a lentiviral vector and gene therapy for MPS	The purpose of this dealing is the development of gene therapies for the treatment of lysosomal storage diseases using lentiviral vectors.	Expired	11/12/2008	4/04/2014
DNIR-452	The University of Queensland	Genome wide overexpression and knockdown of mRNA transcripts at the level of the cell	The purpose of this dealing is to use replication defective lentiviral vectors encoding gene silencing constructs to study gene expression in mammalian cells in vitro	Surrendered	22/12/2008	20/08/2012
DNIR-453	The University of Queensland	Investigations into the role of novel genes at the level of the cell and animal	The purpose of this dealing is to use replication defective lentiviral vectors in vitro and in vivo as a tool to investigate the function of genes involved in eukaryotic tissue, organ and organism development	Surrendered	19/04/2009	11/01/2016
DNIR-454	University of New South Wales	Development of a pseudo-typed NoV to investigate NoV replication in cell culture	The purpose of this dealing is to develop a pseudo-typed murine Norovirus to investigate Norovirus replication in cell culture.	Expired	24/02/2009	13/06/2014
DNIR-455	PPD Australia Pty Ltd	Clinical Study MI-CP178 - A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants		Withdrawn		
DNIR-456	The University of Western Australia	Development of a prime-boost anti-cancer vaccine	The purpose of this dealing is to test prime-boost anti-cancer vaccines using in vivo murine tumour models.	Expired	19/03/2009	31/03/2019

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-457	The Walter and Eliza Hall Institute of Medical Research	Knockdown of gene expression in human and mouse cells using lentiviral libraries	The purpose of these dealings is to use replication defective lentiviral vectors encoding gene silencing constructs to study cellular behaviour in vitro.	Surrendered	20/03/2009	20/08/2012
DNIR-458	CSIRO	Pathogenicity of J paramyxovirus (JPV) and Beilong paramyxovirus (BeiPV)	The purpose of this dealing is to generate recombinant J Paramyxovirus and Beilong Paramyxovirus that including changes in viral genes or non-coding regions to determine their influence on pathogenicity	Expired	6/04/2009	30/04/2014
DNIR-459	Women's and Children's Health Network Incorporated	Molecular mechanisms of bone growth	The purpose of this dealing is to use replication defective lentiviral vectors in vitro and in vivo as a tool to investigate the function of genes involved in bone growth or repair.	Expired	14/04/2009	30/04/2014
DNIR-460	Peter MacCallum Cancer Centre	Use of a short hairpin microRNAi (shRNA-mir) lentiviral based library for small and large scale functional genomics screens	The purpose of these dealings is to use replication defective lentiviral vectors encoding gene silencing constructs to study cellular behaviour in vitro.	Expired	20/03/2009	31/03/2024
DNIR-461	Amgen Australia Pty Ltd	Clinical trials to evaluate the efficacy and safety of treatment with GM human herpes virus 1 (talimogene laherparepvec)	The purpose of the dealings is to undertake the Australian arm of multi-national clinical trials in melanoma patients.	Expired	26/06/2009	31/03/2019
DNIR-462	University of Technology Sydney	Roles for TNF-family molecules in anti-viral immunity		Withdrawn		
DNIR-463	Griffith University	Engineering anaerobic bacteria for multimodal cancer therapy	The purpose of the dealings is to generate anaerobic bacteria that express recombinant immunotoxins specific for solid tumours and to test the oncolytic activity of the GMO in vitro and in vivo.	Expired	30/09/2009	30/09/2025
DNIR-464	QIMR Berghofer	Investigation of malaria parasite proteins		Withdrawn		
DNIR-465	South Eastern Sydney Local Health District	Investigation of polymerase (PB1) fidelity from different influenza strains	The purpose of the dealing is to construct reassorted influenza viruses by reverse genetics for research purposes.	Licence issued	6/09/2009	30/09/2027
DNIR-466	Peter MacCallum Cancer Centre	Regulation of Tumor Suppression		Withdrawn		
DNIR-467	St Vincent's Institute of Medical Research	The role of LIMK1 and its interacting proteins in cancer metastasis	The purpose of this dealing is to identify novel proteins involved in cancer metastasis and explore the role of these and LIM kinases in tumour cell invasiveness.	Surrendered	13/10/2009	13/11/2013
DNIR-468	QIMR Berghofer	Investigation of malaria parasite proteins	The aim of the proposed dealings is to investigate the function of characterised and uncharacterised DNA sequences in the erythrocytic stage rodent and human malaria parasite Plasmodium	Expired	30/10/2009	31/10/2019
DNIR-469	The University of Melbourne	Complementation of Mycobacterium spp and Streptomyces spp with genes required for the synthesis of mycolactones	The aim of the proposed dealing is to understand how mycobacteria produce mycolactones	Expired	26/10/2009	31/10/2024
DNIR-470	The University of Melbourne	Pathogenesis in Staphylococcus aureus	The purpose of this dealing is to understand: 1) how S. aureus strains develop low-level resistance to the antibiotic vancomycin; and 2) the role of S. aureus protein toxins in disease	Licence issued	13/11/2009	30/11/2029
DNIR-471	The University of Sydney	Adeno-associated virus expression of immunosuppressive genes in rodent livers	This study aims to utilise adeno-associated viral vector gene therapy to determine whether a locally expressed immunosuppressive genes can promote the acceptance of transplanted organs in animal transplanted models	Expired	16/10/2009	30/10/2019

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-472	The University of Queensland	Identification of virulence determinants of flaviviruses	The aims of this dealing are to investigate the role of flaviviral genes and untranslated genomic regions in the neurovirulence and/or pathogenicity of flaviviruses	Licence issued	9/11/2009	30/11/2029
DNIR-473	The University of Melbourne	Cardiovascular reactivity to stress: role of redox signaling in the hypothalamus and brainstem	The purpose of this dealing is to use replication defective lentiviral vectors in vivo to investigate the role of redox signalling genes in the cardiovascular response to stress.	Surrendered	21/12/2009	25/03/2013
DNIR-474	The University of Melbourne	The Impact of influenza A virus PB1-F2 protein on host immunity and potential for therapeutic targeting	The purpose of this dealing is to determine the mechanisms by which the protein PB1 F2 contributes to the virulence of Influenza A virus.	Expired	15/01/2010	31/01/2015
DNIR-475	O'Brien Institute	Targeting NADPH Oxidase in angiogenesis	The purpose of this dealing is to study the importance of the enzyme NADPH oxidase in the growth of blood vessels and tumours that depend on the blood vessel growth.	Surrendered	15/02/2010	15/02/2012
DNIR-476	Murdoch Children's Research Institute	Developing lentiviral vectors for gene therapy of Friedreich ataxia	The purpose of the dealing is to develop replication defective lentiviral vectors for gene therapy of Friedreich Ataxia.	Surrendered	2/03/2010	6/05/2013
DNIR-477	Adelaide University	Human immunodeficiency vaccine studies	The aim of the proposed dealings is to test the efficacy of vaccines against HIV in mice by challenge with ecotropic HIV (EcoHIV), a genetically modified (GM) HIV that specifically infects rodents	Expired	12/04/2010	30/04/2026
DNIR-478	University of Canberra	Interferon-adjuvanted flavivirus vaccine	The proposed dealings are to introduce an interferon gene into the genome of Murray Valley encephalitis virus or chimeric Murray Valley encephalitis virus that has had two structural genes replaced with those of Dengue virus, with an aim to create interferon-adjuvanted flavivirus vaccines	Expired	23/03/2010	31/03/2025
DNIR-479	The University of Melbourne	Modulation of brain activity for understanding cardiovascular diseases	The purpose of this dealing is to use replication defective lentiviral vectors to deliver genes to brain regions of rodents to examine the role of specific neurons in the regulation of cardiovascular function	Surrendered	30/03/2010	16/10/2012
DNIR-480	The University of Queensland	In vivo modification of target cell populations to study signalling pathways	This study aims to use retroviral vectors to investigate signalling pathways involved in stem cell differentiation and the onset of metastasis in a whole animal context.	Expired	5/05/2010	31/05/2015
DNIR-481	CSL Limited	Rescue of Influenza B viruses by reverse genetics for research purposes		Withdrawn		
DNIR-482	The Kids Research Institute Australia	Comparative analysis of human and kangaroo Leishmania: defining human pathogenicity genes.	The purpose of this dealing is to use Australian Leishmania as a tool to identify genes involved in pathogenesis of human Leishmania species.	Expired	28/05/2010	31/05/2019
DNIR-483	The University of Queensland	Manipulation of the immune system in mouse skin using immunoregulatory cytokines	This study aims to use genetically modified Fowlpox virus to investigate the ability of immunomodulatory molecules to enhance the action of an anti-cancer vaccine.	Surrendered	1/06/2010	4/07/2014
DNIR-484	CSL Limited	Rescue of Influenza A viruses by reverse genetics for research purposes		Withdrawn		
DNIR-485	QIMR Berghofer	Mouse studies using EcoHIV	The purpose of the dealings is to generate and use a genetically modified HIV that specifically infects rodents to analyse the role of specific host genes or drugs in regulating anti-viral immunity and virus replication	Surrendered	15/07/2010	27/05/2025

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-486	Calimmune Australia Pty Ltd	Gene Therapy for HIV	This study aims to test an in vitro model for HIV gene therapy, by challenging transgenic cells expressing potential anti-HIV genes with GM HIV virions.	Expired	20/07/2010	31/07/2015
DNIR-487	Harry Perkins Institute of Medical Research	The use of short hairpin microRNAi lentiviral based constructs and libraries for functional analysis	The purpose of this dealing is to use lentiviral mediated short hairpin RNAi sequences to identify genes and/or pathways involved in various diseases such as cancer and diabetes, as well as immunological and neurological disorders.	Licence issued	25/08/2010	31/08/2030
DNIR-488	CSIRO	Identification of determinants of virulence and vector competence factors in Bluetongue virus	The purpose of the dealings is to use reverse genetics to produce genetically-modified Bluetongue virus to identify determinants of virulence and vector competence.	Expired	30/08/2010	31/08/2015
DNIR-489	St Vincent's Institute of Medical Research	The Role of micro-RNAs in Cancer Models	This study aims to use replication-defective lentiviral vectors to study genes and micro-RNAs involved in tumour invasion and metastasis.	Surrendered	1/09/2010	8/07/2012
DNIR-490	CSIRO	Identification of determinants of virulence and vector competence factors in ephemeroviruses	The purpose of the dealings is to produce genetically modified insect-vectored animal Rhabdoviruses to identify determinants of virulence and vector competence.	Expired	22/10/2010	31/10/2015
DNIR-491	Australian Institute of Marine Science	Cloning and over-expression of a metalloprotease implicated in the virulence of a coral pathogen vibrio coralliilyticus	This study aims to elucidate the mechanism of action of a virulence factor from the coral pathogen Vibrio coralliilyticus. The virulence factor, a metalloprotease, will be overexpressed in an attenuated vaccine strain of V. cholerae.	Expired	31/10/2010	31/10/2015
DNIR-492	CSIRO	Construction of a Taura syndrome virus infectious clone	The purpose of the dealings is to use reverse genetics to produce genetically modified (GM) Taura syndrome virus to identify virulence determinants.	Expired	28/10/2010	30/11/2016
DNIR-493	The University of Queensland	Molecular analysis of Streptococcus pyogenes	The aim of the dealing is to gain an understanding of the role of S. pyogenes gene products in streptococcal infection and disease.	Expired	24/11/2010	30/11/2015
DNIR-494	Peter MacCallum Cancer Centre	Regulation of tumour suppression	This the purpose of this study is to use replication-defective lentiviral vectors to study regulation of the p53 tumour suppressor pathway.	Expired	29/11/2010	30/11/2015
DNIR-495	CSIRO	Generation of recombinant Rabbit Caliciviruses	The purpose of this project is to study the biology of rabbit caliciviruses by generating GM caliciviruses and developing GM cell lines.	Expired	22/12/2010	31/12/2020
DNIR-496	CSIRO	Characterisation of the molecular determinants of host range and pathogenicity for Henipaviruses	This the purpose of this study is to generate and characterise, in vivo and in vitro, genetically modified (GM) Hendra virus and Nipah virus. Viral genes and non-coding regions will be mutated, deleted or replaced in order to determine their role in pathogenesis, host range and transmission.	Licence issued	5/01/2011	31/01/2031
DNIR-497	The University of Queensland	Expression and characterization of novel genes from Australian snakes	This study aims to use clone and express venom proteins from 20 Australian elapid snakes that may useful in the treatment of envenomation victims or as therapeutic agents.	Expired	13/01/2011	31/01/2021

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-498	Western Sydney Local Health District	Isolation and characterisation of genes involved in antifungal drug metabolism including drug resistance in pathogenic yeasts	The aim of the proposed dealings is to elucidate the mode of action of the antifungal drug miltefosine in pathogenic yeasts, ie <i>Cryptococcus neoformans</i> and <i>Candida</i> species.	Surrendered	19/01/2011	12/06/2014
DNIR-499	The Walter and Eliza Hall Institute of Medical Research	Augmenting anti-viral immunity		Withdrawn		
DNIR-500	Macfarlane Burnet Institute for Medical Research and Public Health	Xenotropic murine leukemia virus-related virus (XMRV) and prostate cancer		Withdrawn		
DNIR-501	Central Adelaide Local Health Network	A phase 1 study of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma	A clinical trial assessing the feasibility, safety and efficacy of GM autologous T cells for the treatment of metastatic melanoma.	Surrendered	21/07/2011	10/01/2014
DNIR-502	Harry Perkins Institute of Medical Research	Lentiviral gene overexpression and knock-down using short hairpin micro RNAi		Withdrawn		
DNIR-503	The University of Melbourne	Functional analysis of <i>Schistosoma</i> spp egg-secreted proteins using vector-based RNAi	This study aims to use replication-defective lentiviral vectors to generate GM <i>Schistosoma</i> spp to analyse the function of egg-secreted proteins at different stages of the <i>Schistosoma</i> life cycle	Surrendered	10/08/2011	19/12/2013
DNIR-504	Virax Holdings Limited	Clinical study of the efficacy and safety of intra-tumoural injection of TG1042 in nodular basal cell carcinoma	This clinical trial aims to test the efficacy and safety of TG1042 for the treatment of nodular basal cell carcinoma	Expired	3/08/2011	4/08/2013
DNIR-505	Adelaide University	Lentiviral vectors to assess HIV vaccine efficacy	The purpose of the proposed dealings is to use lentiviral vectors to express HIV genes in mice as a model of HIV infection.	Licence issued	26/08/2011	29/08/2026
DNIR-506	CSIRO	Expression of a fatty acid modifying enzyme in <i>Candida tropicalis</i>	The purpose of this dealing is to determine whether it is possible to use GM <i>Candida tropicalis</i> to produce industrial quantities of Omega-hydroxyfatty acids	Expired	9/09/2011	30/09/2014
DNIR-507	The University of Sydney	The use of virus vectors for research in plants		Withdrawn		
DNIR-508	Flinders University	Investigation of Dengue virus replication and pathogenesis		Withdrawn		
DNIR-509	Griffith University	The role of host and viral factors in chikungunya virus disease	The applicant aims to genetically modify structural proteins of Chikungunya virus to understand their role in viral infection.	Licence issued	22/12/2011	31/12/2026
DNIR-510	Australian National University	Recombinant Mucosal Vaccines		Withdrawn		
DNIR-511	Public and Environmental Health Reference Laboratories, Pathology Queensland	Investigation of replication and virulence determinants in Alphaviruses	In this study, the applicant plans to genetically modify proteins implicated in replication and virulence of pathogenic Ross River virus and assay for resulting changes in genotypic or phenotypic traits <i>in vivo</i> .	Licence issued	6/12/2011	31/12/2031
DNIR-512	Deakin University	Molecular Virology of HIV-1	The aim of the proposed dealings is to generate replication defective (RD) GM HIV-1 viral particles pseudotyped with envelope proteins of different viruses and use them for <i>in vitro</i> studies to investigate how these GM viruses gain entry into cells	Surrendered	23/12/2011	11/01/2018
DNIR-513	Intervet Australia Pty Ltd	Innovax ILT - Vaccine Seed Production		Withdrawn		

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-514	Queensland University of Technology	Identification of novel virulence determinants of pathogenic Legionella pneumophila 130b using an avirulent environmental Legionella isolate	The applicant proposes to use GM Legionella to identify and analyse virulence determinants from L. pneumophila.	Surrendered	3/05/2012	23/12/2014
DNIR-515	Queensland University of Technology	Effect of genetically modified bananas enriched in carotenoids on postprandial carotenoid and vitamin A levels	The applicant proposes to conduct a human nutritional study to determine how efficiently pro-vitamin A is absorbed and converted to vitamin A (retinol) following consumption of genetically modified bananas with elevated levels of pro-vitamin A carotenoids.	Expired	3/05/2012	31/12/2014
DNIR-516	The University of Queensland	Analysis of developmentally important genes involved in disease	This study aims to use genetically-modified retroviral and lentiviral vectors to identify genes that induce or accelerate tumour formation in the brain.	Expired	15/06/2012	19/06/2017
DNIR-517	CSIRO	Genomic Analysis of the Canonical Case of Virulence Evolution: Myxomatosis in Australia		Withdrawn		
DNIR-518	The University of Queensland	Isolation, expression and characterization of the toxins expressed by the Australian paralysis tick (Ixodes holocyclus).	This study will use GM bacteria and yeast to express putative toxin proteins from the Australian paralysis tick, for the purpose of developing a vaccine against tick bite for companion animals.	Licence issued	26/09/2012	30/09/2026
DNIR-519	The University of Melbourne	Infection of monkeys with SHIV (HIV / SIV chimera)	In this study, macaque monkeys will be infected with a GM lentivirus to test the effectiveness of experimental vaccines against Human Immunodeficiency Virus.	Surrendered	10/11/2012	13/05/2025
DNIR-520	The University of Melbourne	Testing of novel replication competent immunomodulatory viruses as vaccine candidates	The applicant proposes to test the efficacy of GM Vaccinia virus and GM Fowlpox virus as vaccine candidates.	Surrendered	5/11/2012	13/05/2025
DNIR-521	University of Canberra	Generation of recombinant, attenuated hepatitis D viruses		Not Issued		
DNIR-522	Clinical Network Services (CNS) Pty Ltd	Clinical investigation of NT-501, encapsulated human NTC-201 cell implants releasing Ciliary Neurotrophic Factor (CNTF)		Withdrawn		
DNIR-523	Royal Prince Alfred Hospital	A clinical trial to treat Hemophilia B using AAV-based gene therapy	The applicant is planning to conduct a clinical gene therapy trial using a GM adeno-associated viral vector encoding human Factor IX to treat patients with severe Hemophilia B.	Surrendered	10/04/2013	29/05/2017
DNIR-524	Macfarlane Burnet Institute for Medical Research and Public Health	Bat Retroviruses	The aim of the dealings is to create genetically modified replication defective viral particles to study the properties of endogenous bat beta- and gamma-retroviruses.	Licence issued	22/10/2013	25/10/2028
DNIR-525	The University of Melbourne	The role of gut-resident T cells in protecting against enteric Listeria infection	In this study, GM Listeria monocytogenes will be used to study the role of gut-resident T cells in protecting against intestinal Listeria infection.	Licence issued	26/04/2013	30/04/2028
DNIR-526	Melbourne Health	Replication of Hepatitis B virus, duck hepatitis B virus (DHBV) and woodchuck hepatitis B virus and the testing of antiviral agents.		Withdrawn		
DNIR-527	The University of Melbourne	Influenza A virus PB1-F2 protein: A virulence factor and initiator of inflammation	In this study, the applicants will use GM Influenza A virus to study the effect of PB1-F2 on the host response to influenza infection.	Licence issued	4/06/2013	7/06/2028
DNIR-528	Zoetis Australia Research & Manufacturing Pty Ltd	Evaluation of a cytolysin expressed in Corynebacterium glutamicum	The applicant proposes to evaluate a cytolysin expressed in Corynebacterium glutamicum	Surrendered	10/05/2013	13/04/2016

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-529	Adelaide University	Recombinant Viral Vaccines to Treat and Prevent Cancer, Allergy and Infectious Diseases	The aim of this dealing is to generate GM Vaccinia virus and GM lentiviral vectors and evaluate their efficacy as vaccine candidates against target antigens.	Licence issued	28/05/2013	30/09/2028
DNIR-530	University of South Australia	Recombinant Viral Vaccines to Treat and Prevent Peanut Allergy	DNIR 529, 530 and 531 applications considered together and issued as one licence - DNIR 529.	Integrated into DNIR-529		
DNIR-531	University of South Australia	Recombinant viral vaccines to treat and prevent skin cancer	DNIR 529, 530 and 531 applications considered together and issued as one licence - DNIR 529.	Integrated into DNIR-529		
DNIR-532	University of New South Wales	HCV founder virus evolution: evolution and vaccine targets	The aim of the dealings is to use genetically modified HIV to study the evolution of Hepatitis C Virus (HCV) during infection.	Surrendered	4/07/2013	26/07/2017
DNIR-533	University of New South Wales	HCV founder viruses as vaccine targets: vector LucR-E-	DNIR 532 and 533 applications considered together and issued as one licence - DNIR 532.	Integrated into DNIR-532		
DNIR-534	QIMR Berghofer	A Phase 1 study of haploidentical haematopoietic stem cell transplantation with add-back of donor T cells transduced with inducible caspase 9 suicide gene in patients with poor risk haematological malignancies		Withdrawn		
DNIR-535	Griffith University	Investigation of malaria parasite proteins	The aim of the dealings is to use genetically modified Plasmodium species to investigate the function of Plasmodium proteins.	Licence issued	26/08/2013	31/08/2028
DNIR-536	Ascend Biopharmaceuticals Pty Ltd	Clinical study of the efficacy and safety of intra-tumoural injection of ASN-002 in basal cell carcinoma	The aim of the dealings is to investigate the efficacy and safety of intra-tumoural injection of genetically modified ASN-002 in basal cell carcinoma in a clinical study.	Licence issued	29/10/2013	5/11/2028
DNIR-537	CSIRO	The molecular basis of the pathogenicity of Newcastle disease in chickens	The aim of the dealings is to generate and use GM ND viruses to study the role of individual ND viral genes, or combinations of genes and determine their role in the pathogenicity of the disease	Expired	2/12/2013	31/01/2019
DNIR-538	University of New South Wales	HIV biology	The aim of the dealings is to use GM lentiviruses based on Human immunodeficiency virus (HIV) and Simian immunodeficiency virus to study aspects of HIV biology.	Licence issued	4/07/2014	12/07/2029
DNIR-539	Queensland University of Technology	Development and use of a banana streak virus-based virus vector to investigate banana-Fusarium interactions	The aim of the dealings is to use genetically modified banana streak virus-based vectors to introduce genetic material related to Fusarium disease development or resistance into banana plants in order to identify key genes in banana-Fusarium interactions.	Surrendered	6/01/2014	11/06/2021
DNIR-540	Flinders University	Mouse model for studies of B cells migration into the eye	The aim of the dealings is use genetically modified lentiviral vectors to study B-cell mediated inflammation in the eye.	Surrendered	17/12/2013	5/08/2016
DNIR-541	Advanced Analytical Australia Pty Ltd	R & D for Norovirus and Hepatitis A.		Withdrawn		
DNIR-542	CSIRO	The molecular determinants of pathogenicity, tissue tropism and transmissibility of influenza A virus.	The aim of the dealings is to generate GM Influenza A viruses for the in vitro and in vivo study of viral genes and their role in disease.	Licence issued	30/01/2014	28/02/2029
DNIR-543	University of New South Wales	HIV Biology of Latency and Assembly	The aim of the dealing is to use GM RD HIV-1 to study its latency and assembly	Licence issued	21/02/2014	20/02/2029
DNIR-544	Western Sydney Local Health District	Plasmid ecology and microbial husbandry in the Enterobacteriaceae		Withdrawn		

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-545	Australian National University	Using Aspergillus nidulans as a heterologous host for mining the secondary metabolomes of fungal phytopathogens		Withdrawn		
DNIR-546	Macquarie University	Investigation of the role of glia in the control of blood pressure	The aim of the dealings is generate GM lentiviral vectors encoding the light chain of tetanus toxin to investigate the role of glia in the control of blood pressure.	Expired	28/05/2014	31/05/2019
DNIR-547	Zoetis Australia Research & Manufacturing Pty Ltd	Evaluation of toxin expression in Pichia pastoris and Chinese hamster ovary cells (Cricetulus griseus).	Evaluation of toxin expression in Pichia pastoris and Chinese hamster ovary cells (Cricetulus griseus).	Surrendered	14/08/2014	13/04/2016
DNIR-548	Zoetis Australia Research & Manufacturing Pty Ltd	Evaluation of toxin expression in Chinese hamster ovary cells (Cricetulus griseus)	DNIR 547 and 548 applications considered together and issues as one licence - DNIR-547.	Integrated into DNIR-547		
DNIR-549	Treidlia Biovet Pty Ltd	Manufacture of Foot Rot Vaccine for sheep and goats.	The aim of the dealings is to use genetically modified Pseudomonas aeruginosa in the manufacturing of a foot rot vaccine for sheep and goats.	Licence issued	12/09/2014	12/09/2029
DNIR-550	Harry Perkins Institute of Medical Research	Generation of fluorescent lentiviral transduced tumour cell lines	The aim of the dealings is use genetically modified lentiviral vectors to produce fluorescent-labelled tumour cell lines, for use in a range of in vitro and in vivo experiments.	Expired	2/10/2014	15/10/2019
DNIR-551	Monash University	Human Immunodeficiency Virus anti-viral development	The aim of the dealings is use genetically modified HIV, which specifically infects rodents, to investigate the properties of new anti-viral drugs.	Licence issued	2/12/2014	30/11/2029
DNIR-552	Western Sydney University	Use of N11 murine microglia for drug discovery	The aim of the dealings is to use a GM mouse cell line (N11) that secretes a GM retrovirus to screen plant and fungal extracts for anti-inflammatory compounds.	Licence issued	19/12/2014	19/12/2029
DNIR-553	Australian National University	Assessing HIV vaccine efficacy	The aim of the dealings is use genetically modified HIV, which specifically infects rodents, to investigate the efficacy of HIV vaccines.	Surrendered	3/12/2014	4/04/2019
DNIR-554	QIMR Berghofer	Production and clinical trial of a genetically modified Plasmodium falciparum blood stage vaccine	The aim of the dealings is to assess genetically-modified Plasmodium falciparum for safety, immunogenicity and efficacy as a malaria vaccine in healthy human volunteers.	Expired	17/02/2015	17/02/2025
DNIR-555	Griffith University	New studies on the virulence and physiology of Burkholderia pseudomallei	The aim of the dealings is to study virulence factors in GM B. pseudomallei for the development of a diagnostic assay.	Expired	11/06/2015	11/05/2025
DNIR-556	Monash University	Factors controlling developmental transitions in the fungus Candida albicans	The aim of the dealings is use genetically modified Candida albicans to identify and characterise factors and mechanisms that enable this organism to produce pathogenic morphological structures.	Expired	17/04/2015	17/04/2025
DNIR-557	Monash University	An investigation of a single intranasal administration of the interferon alpha compound "DEF201" in longtail macaques.	Project aim is to determine the bio distribution and potential toxic effects of GM replication defective adenovirus DEF201 in fascicularis macaques.	Expired	3/07/2015	3/07/2020
DNIR-558	The University of Melbourne	Generation of protein for structural studies of membrane-bound pore forming toxins	The aim of this study is to clone and express bacterial pore-forming toxin genes so as to purify the toxin proteins and carry out structural studies.	Licence issued	31/07/2015	4/08/2030
DNIR-559	Amgen Australia Pty Ltd	Evaluation of the efficacy and safety in the treatment of solid tumours with talimogene laherparepvec	The aim of the dealings is to conduct clinical trials to study safety and efficacy of a GMO in the treatment of different types of solid tumours.	Surrendered	4/11/2015	30/05/2024
DNIR-560	RMIT University	Generation of recombinant toxin molecules	A project using chimeras of naturally occurring proteins for potential therapeutic use.	Licence issued	10/12/2015	10/12/2030

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-561	Griffith University	Development of an Alphaviral vector to deliver bioactive factors to bone. Potential use to treat diseases resulting in severe reduction of bone density	The aim of the dealings is to develop a GM Ross River Virus and conduct in vitro and in vivo experiments to investigate its potential as a vector delivering bioactive factors to bone tissue and potentially treat bone or joint diseases.	Expired	21/12/2015	22/12/2025
DNIR-562	Centenary Institute of Cancer Medicine and Cell Biology	Molecular changes and therapies for Hepatitis B virus infection		Withdrawn		
DNIR-563	Curtin University	Expression of genes from plant pathogenic fungi into a model fungus, Parastagonospora nodorum.	The applicant proposes to use GM P. nodorum in in vitro and in vivo experiments to develop an understanding of fungal pathogenicity and fungicide resistance.	Licence issued	24/06/2016	24/06/2031
DNIR-564	CMAX Clinical Research Pty Ltd	Phase I/IIa Study of DVC1-0101 in subjects with intermittent claudication secondary to peripheral artery disease	The Phase I/IIa clinical trial would assess the safety and tolerability of genetically modified (GM) Sendai virus as a therapeutic agent to stimulate the growth of new blood vessels in individuals who experience limb pain as a result of peripheral artery disease.	Surrendered	29/04/2016	6/09/2021
DNIR-565	Baker Heart & Diabetes Institute	Using adeno-associated virus vectors to study striated musculature and related tissues in vitro and in vivo	To use GM AAV to study changes in striated musculature when exposed to single cytokines, to aid in development of treatment for muscle wasting caused by disease or injury.	Surrendered	21/07/2016	19/07/2019
DNIR-566	Monash University	Biochemical Studies of Cholesterol Dependent Cytolysin Proteins	The aim of this study is to clone and express bacterial pore-forming toxin genes so as to purify the toxin proteins and analyse in vitro using imaging and biophysical techniques.	Licence issued	5/08/2016	5/08/2026
DNIR-567	Acura Bio Pty Ltd	Expression of PRS060 protein by recombinant Corynebacterium glutamicum	Use GM C. glutamicum to overexpress a genetically modified Anticalin protein (PRS060) on a large scale for the purposes of manufacturing a human therapeutic product.	Expired	1/09/2016	1/09/2021
DNIR-568	Queensland University of Technology	Development and use of a Cucumber mosaic virus-based vector to investigate banana-Fusarium interactions	The aim of the dealings is to use a genetically modified Cucumber mosaic virus vector to identify key genes related to virulence or resistance in Fusarium wilt disease of banana.	Surrendered	29/09/2016	11/06/2021
DNIR-569	Pfizer Australia Pty Ltd	Gene therapy, Open-Label, Dose-escalation study of SPK-9001 (adeno-associated viral vector with human factor IX gene) in subjects with hemophilia B	This trial aims to assess the safety and tolerability of gene therapy treatment using a genetically modified adeno-associated viral vector encoding human Factor IX in patients with severe Hemophilia B.	Licence issued	8/09/2016	9/09/2026
DNIR-570	CSIRO	Characterisation of the Molecular Determinants of Host Responses and Pathogenicity of Filoviruses	Viral genes of family Filoviridae viruses will be examined to determine their role in pathogenesis, host responses, host range, and cross-species transmission.	Licence issued	1/03/2017	1/03/2027
DNIR-571	Women's and Children's Health Network Incorporated	Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA	This clinical trial aims to assess the safety and efficacy of gene therapy using a genetically modified adeno-associated viral vector encoding human sulfoglucosamine sulfohydrolase (SGSH) in paediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA).	Surrendered	14/03/2017	20/11/2024
DNIR-572	The University of Queensland	Analyses of gut and systemic infection with recombinant listeria	GM L. monocytogenes will be used to study the ability of gut-resident T cells to protect against intestinal Listeria infection.	Surrendered	13/04/2017	17/12/2025

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-573	The University of Melbourne	Molecular Biology of retroviral Replication, Pathogenesis and Productive Infection	To study molecular mechanisms regulating viral gene expression and function, to better understand molecular aspects of viral replication and latency for development of therapeutics	Licence issued	23/05/2017	23/05/2027
DNIR-574	The University of Melbourne	Examination of HIV Latent Infection		Withdrawn		
DNIR-575	The University of Sydney	Fine tuning transplantation tolerance with co-stimulatory molecules	To study immunological tolerance of transplanted organs in mice, using GM AAV as a vector to express proteins that may enhance or block tissue acceptance in the liver of transplant recipients	Licence issued	27/06/2017	27/06/2027
DNIR-576	James Cook University	New strategies for improved tuberculosis vaccines	GM Mycobacterium bovis BCG strains will be used to express known immunogens and virulence factors of Mycobacterium tuberculosis to develop improved tuberculosis vaccine strains and test vaccination regimens in an animal model of human tuberculosis	Licence issued	3/11/2017	3/11/2027
DNIR-577	PSI CRO Australia Pty Ltd	Gene-transfer, open-label, dose-escalation study of SPK-8011 [adeno-associated viral vector with B-domain deleted human factor VIII gene] in individuals with hemophilia A	Gene therapy, open-label, dose-escalation study of SPK-8011 (recombinant adeno-associated viral vector with B-domain deleted human factor VIII gene) in subjects with haemophilia A	Surrendered	17/11/2017	31/10/2023
DNIR-578	University of South Australia	A recombinant viral vaccine vector platform to produce polyclonal antibodies in milk and egg.	To study the efficacy and safety of a GM viral vaccine vector to produce polyclonal antibodies in milk and eggs	Surrendered	20/12/2017	7/01/2026
DNIR-579	Griffith University	Investigating the mode of action of novel drug leads against Giardia duodenalis	GM Giardia duodenalis will be used to study the mode of action of novel anti-Giardia drug candidates and the role of specific G. duodenalis proteins in mediating their effect.	Licence issued	13/12/2017	13/12/2027
DNIR-580	Novotech (Australia) Pty Limited	MVA-NP+M1: a new Influenza vaccine for use in human clinical trials	To assess the safety, tolerability, and efficacy of GM Vaccinia virus (MVA strain) in the prevention of influenza A	Expired	23/01/2018	23/01/2023
DNIR-581	Murdoch Children's Research Institute	Cardiac Regeneration	This study aims to investigate the function of various genes and signalling pathways involved in heart development and regeneration. This project will test whether selected genes implicated in heart development are sufficient to promote cardiac regeneration in adult mice in vivo	Licence issued	13/04/2018	13/04/2028
DNIR-582	Monash University	Genetic manipulation of cells by viral transduction using in vivo models	This study aims to study the growth, spread and treatment response of melanoma. The project will investigate the effect of silencing genes involved in cell growth or differentiation on the development of human melanoma tumours transplanted into mice	Licence issued	10/05/2018	10/05/2028
DNIR-583	Novotech (Australia) Pty Limited	Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for high risk Locally Advanced Cervical Cancer: AIM2CERV.	The study drug, ADXS11-001 is a genetically modified Listeria monocytogenes encoding human papillomavirus antigen. The clinical trial aims to treat subjects with high risk locally advanced cervical cancer following chemotherapy and radiotherapy	Surrendered	16/05/2018	25/11/2019
DNIR-584	CSIRO	Large-scale fermentation of SCV vaccines.	To test and optimise the fermentation conditions, and to manufacture large-scale (> 25 L) volumes of GM Vaccinia virus vaccines.	Surrendered	1/06/2018	15/02/2024

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-585	Novotech (Australia) Pty Limited	Clinical Trial of an oncolytic vaccine for the treatment of cancers caused by the human papilloma virus (HPV)	The proposed clinical trial will investigate the safety, tolerability and efficacy of a two-component 'oncolytic vaccine' for the treatment of human cancers caused by high-risk Human Papilloma Virus (HPV)	Surrendered	23/10/2018	7/12/2022
DNIR-586	The Children's Hospital Westmead	A global study of a single one-time dose of AVXS-101 delivered to paediatric patients with genetically diagnosed and pre-symptomatic Spinal Muscular Atrophy with multiple copies of SMN2	To use a recombinant AAV encoding the human survival motor neuron 1 (SMN1) gene to treat paediatric patients with Spinal Muscular Atrophy (SMA) before development of irreversible injury due to motor neuron loss	Expired	3/08/2018	3/08/2023
DNIR-587	GlaxoSmithKline Australia Pty Ltd	Clinical Trials with Respiratory Syncytial Virus (RSV) Investigational Vaccine ChAd155-RSV	To investigate the safety, tolerability and efficacy of a recombinant ChAd155-RSV as a prophylactic vaccine for prevention of RSV lower respiratory tract infections in infants.	Expired	25/09/2018	25/09/2023
DNIR-588	Janssen-Cilag Pty Ltd	Recombinant Respiratory Syncytial Viral Vaccine (Ad26.RSV.preF) for Clinical Studies	To assess the safety and tolerability a prophylactic RSV vaccine	Expired	20/11/2018	19/11/2023
DNIR-589	The University of Melbourne	Using adeno-associated viral vectors to study striated musculature and related tissues in vitro and in vivo	To use GM AAV to study changes in striated musculature when exposed to single cytokines, to aid in development of treatment for muscle wasting caused by disease or injury	Licence issued	3/12/2018	3/12/2028
DNIR-590	Queensland University of Technology	Development and use of Banana streak virus-based vectors to investigate banana-Fusarium interactions		Withdrawn		
DNIR-591	QIMR Berghofer	Virus-mediated approaches to examine cardiovascular disease in vitro and in vivo	This study aims to determine the role of genes in the regulation of cardiac regeneration and disease by over-expressing the genes in mice using adenovirus and adeno-associated virus vectors	Licence issued	16/01/2019	16/01/2029
DNIR-592	Novotech (Australia) Pty Limited	An Oncolytic Immunotherapy Product for use in Clinical Trials	To study the safety and efficacy of the GM HSV-1 in the treatment of different solid tumour types, in combination with an anti-cancer drug	Expired	23/01/2019	23/01/2024
DNIR-593	Hudson Institute of Medical Research	Endometrial MSC as a cell-based therapy for pelvic organ prolapse (POP) in an ovine model	This application aim to use a replication-defective (RD) lentivirus, encoding the fluorescent protein mCherry, to evaluate the use of endometrial mesenchymal stem cells (eMSC) in a cell-based therapy for Pelvic Organ Prolapse (POP).	Licence issued	25/03/2019	25/03/2029
DNIR-594	Merck Sharp & Dohme (Australia) Pty Ltd	A cytomegalovirus prophylactic vaccine (V160) for use in clinical trials	The GMO V160 is a conditionally replication defective cytomegalovirus (CMV) designed as a vaccine for prevention of CMV infection. The intended clinical programme is to evaluate its efficacy in prevention of CMV infection in adults and children	Expired	1/04/2019	1/04/2024
DNIR-595	Inghams Group Limited	US corn importation for Inghams to produce poultry feed	The applicant intends to import US corn, which is expected to contain GM grain, into Australia for processing to produce poultry feed.	Expired	23/05/2019	23/05/2024
DNIR-596	Ridley Corporation Limited	US corn importation for Ridley to produce stockfeed	The applicant intends to import US corn that may contain GM seed, into Australia for processing into stockfeed.	Expired	31/05/2019	31/05/2024
DNIR-597	Australian National University	Viral mediated approaches to examine cell growth and proliferation		Withdrawn		

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-598	PPD Australia Pty Ltd	A Phase 1, double blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of Dengusil in healthy adults	The proposed clinical trial will evaluate the safety of the GMOs when administered to healthy adults. Secondary objectives are to measure the immune response and viraemia induced by the GMOs	Expired	13/08/2019	13/08/2024
DNIR-599	Medpace Australia Pty Ltd	A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma	To study the safety and efficacy of the GMO in the treatment of malignant pleural mesothelioma, in combination with an anti-cancer drug.	Expired	1/08/2019	1/08/2024
DNIR-600	BioMarin Pharmaceutical Australia Pty Ltd	Studies to evaluate the efficacy and safety of BMN 270, an Adeno-Associated Virus vector-mediated gene transfer of human factor VIII in haemophilia A patients	To assess the efficacy and safety of gene therapy treatment using a GM AAV vector encoding activated human factor VIII in adult patients with severe Haemophilia A.	Licence issued	28/08/2019	28/08/2029
DNIR-601	IQVIA RDS Pty Ltd	BacTRL-IL-12 Phase 1 Trial in Humans with Various Cancers	To evaluate the safety of bacTRL-IL-12, delivered as a single infusion in adults with advanced solid tumours. Secondary objectives are to evaluate the effect of the GMO on tumour size, duration and overall survival rates following infusion and the possible relationship between glycemic exposure with tumoral colonisation and efficacy.	Expired	6/09/2019	6/09/2024
DNIR-602	TheraVir Pty Ltd	A clinical trial with a herpes simplex virus GMO (T3011) in patients with solid tumours.	To study the safety and tolerability of the GMO administered into tumours of cancer patients	Surrendered	26/09/2019	21/06/2024
DNIR-603	Monash University	Limiting EAE through transplantation of HSCs	To use a genetically modified (GM) replication-defective lentivirus to express a therapeutic fusion protein, NgR(310)ecto-myc-Fc, in murine haematopoietic stem cells (HSCs). The modified HSCs (free of virus) will be subsequently used to study the therapeutic benefits of NgR(310)ecto-myc-Fc in a mouse model of progressive multiple sclerosis	Licence issued	21/10/2019	21/10/2029
DNIR-604	Novotech (Australia) Pty Limited	An Immune Stimulating Oncolytic HSV-1 for use in Clinical Trials in Patients with Solid Tumours (VG161)	Clinical trial to study the safety and tolerability use of a genetically modified Herpes Simplex Virus 1 (HSV-1), namely VG161, to treat advanced malignant solid tumours.	Expired	22/10/2019	22/10/2024
DNIR-605	Medpace Australia Pty Ltd	Clinical evaluation of GT005 in patients with age-related macular degeneration	Clinical evaluation of GT005 in patients with age-related macular degeneration	Surrendered	8/01/2020	2/04/2024
DNIR-606	Peter MacCallum Cancer Centre	Clinical Study GO-004: An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors	The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with immune checkpoint blockade in patients with advanced solid tumours.	Expired	15/01/2020	15/01/2025
DNIR-607	Merck Sharp & Dohme (Australia) Pty Ltd	An oncolytic viral therapy V938 in combination with Pembrolizumab (MK-3475) for use in clinical trials.		Re-categorised		
DNIR-608	Clinical Network Services (CNS) Pty Ltd	Clinical trials with a prophylactic influenza A/H3N2 live, M2-deleted, intranasal vaccine (H3N2 M2SR) (with CCI)		Re-categorised		

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-609	Novotech (Australia) Pty Limited	Clinical Trials with Hepatitis Treatment Vaccine (VTP-300)	Clinical trial to study the safety, tolerability and immunogenicity of genetically modified Chimpanzee adenovirus (ChAdOx1-HBV) and vaccinia virus (MVA-HBV), namely VTP-300, to treat patients with chronic hepatitis B infection.	Expired	24/02/2020	24/02/2025
DNIR-610	Novotech (Australia) Pty Limited	Clinical Trials with Zika Chikungunya Vaccine (SCV1002)	A Phase I, open label, single centre, single dose escalation study to investigate the safety, tolerability and immunogenicity of intra-muscular administration of SCV1002 in adult healthy volunteers.	Expired	2/03/2020	2/03/2025
DNIR-611	Monash University	Understanding how Helicobacter pylori causes disease	The aim of this licence application is to examine the role of virulence factors from cancer-associated Helicobacter pylori in causing the disease. The genetically modified (GM) H. pylori strains with and without introduced mutations in the virulence factors will be used for in vitro (cell lines and primary cells) and in vivo (mice) studies.	Licence issued	11/03/2020	11/03/2030
DNIR-612	University of New South Wales	Identification of protective anti-HCV antibodies in subjects that clear infection to inform vaccine design	To generate cell culture derived hepatitis C virus (HCV) variants with different patient-derived viral envelopes. A secondary aim is to characterise the infectivity and susceptibility to neutralisation by patient antibodies for each variant, and to study the fate of the virus in blood mononuclear cells and hepatocytes.	Licence issued	8/05/2020	8/05/2030
DNIR-613	The University of Queensland	Antibiotic resistance gene transfer in bacteria from water sludge	To investigate horizontal transfer of antibiotic resistance genes in environmental samples	Licence issued	28/05/2020	28/05/2030
DNIR-614	QIMR Berghofer	Manufacture and characterisation of a P. falciparum NF54 Inducible Gametocyte Producer (NF54/iGP3) Master Cell Bank for use in Phase I Clinical Trials utilising the Induced Blood Stage Malaria Infection Model	The aim of this licence application is to produce a good manufacturing practice (GMP) grade master cell bank of a genetically modified (GM) Plasmodium parasite, P. falciparum NF54/iGP3 Clone 3, which produces high numbers of gametocytes in vivo in the presence of the antibiotic, trimethoprim and to assess its safety and infectivity in pre-clinical studies.	Licence issued	18/05/2020	18/05/2031
DNIR-615	Novartis Pharmaceuticals Australia Pty Limited	Supply of Luxturna (voretigene neparvovec) for the treatment of patients.	To supply Luxturna to patients suffering from bi-allelic RPE65 mutations	Licence issued	26/05/2020	
DNIR-616	The University of Queensland	Understanding influenza virus pathogenesis	To identify the role of specific mutations in Influenza A virus that increase disease severity	Licence issued	11/06/2020	11/06/2030
DNIR-617	Griffith University	GM HIV that are more infectious than wild type HIV	To assess infectiousness of GM HIV.	Licence issued	9/06/2020	9/06/2030
DNIR-618	CSIRO	Genetic control strategies for plant pathogenic fungi	To determine if new genetic technologies, namely gene drives, can be used to control plant pathogenic fungi	Surrendered	16/07/2020	28/06/2023
DNIR-619	Novotech (Australia) Pty Limited	CodaVax-H1N1, a live-attenuated vaccine for the use in clinical trials for breast cancer	Treatment of breast cancer with a codon-optimised live attenuated genetically modified influenza virus	Expired	28/07/2020	28/07/2025
DNIR-620	Western Sydney Local Health District	Therapeutic treatment of patients with Mycobacterium abscessus disease	This licence is for the treatment of non-tuberculous Mycobacteria infection (NTM) with a cocktail of naturally occurring and a GM bacteriophage	Expired	22/04/2020	22/04/2025
DNIR-621	Novartis Pharmaceuticals Australia Pty Limited	Supply of Zolgensma (Onasemnogene abeparvovec) for the treatment of patients with spinal muscular atrophy (SMA)	This licence authorises the commercial supply of Zolgensma to patients suffering from spinal muscular atrophy	Licence issued	24/08/2020	

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-622	Accelagen Pty Ltd	rBCG Vaccine to reduce incidence and severity of COVID-19 infection in high risk groups	rBCG Vaccine to reduce incidence and severity of COVID-19 infection in high risk groups such as Health care workers and people over 65 with co-morbidity	Expired	9/06/2020	9/06/2022
DNIR-623	PPD Australia Pty Ltd	A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of a GMO in Patients with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)	This trial aims to assess the safety and efficacy of gene therapy treatment using a genetically-modified adeno-associated viral vector encoding human progranulin in patients with frontotemporal dementia	Licence issued	21/09/2020	21/09/2030
DNIR-624	Pfizer Australia Pty Ltd	A clinical trial to evaluate the efficacy and safety of PF-07055480 in adult male participants with moderately severe to severe haemophilia A	Phase III clinical trial with replication deficient GM AAV carrying human factor VIII to treat haemophilia patients	Expired	8/10/2020	8/10/2025
DNIR-625	BioMarin Pharmaceutical Australia Pty Ltd	Clinical trial to determine the safety and efficacy of BMN 307, an Adeno-associated virus vector-mediated gene transfer of human phenylalanine hydroxylase in patients with phenylketonuria	To assess the efficacy, safety and tolerability of a single injection of BMN 307, a gene therapy treatment using GM AAV encoding human phenylalanine hydroxylase to reduce plasma Phe in phenylketonurics with baseline plasma Phe > 600 $\mu\text{mol/l}$	Surrendered	17/09/2020	30/05/2024
DNIR-626	Novotech (Australia) Pty Limited	Clinical Trials with a SARS-CoV-2 oral vaccine (bacTRL-Spike)	Clinical Trials with a SARS-CoV-2 oral vaccine (bacTRL-Spike)	Expired	10/08/2020	10/08/2025
DNIR-627	South Australian Health and Medical Research Institute	Generating mouse models with altered inheritance and sex bias	The aim of this licence application is to develop a genetic method to control invasive pest mice by spreading mutations that cause infertility, embryonic death or bias the sex of offspring	Licence issued	25/09/2020	25/09/2030
DNIR-628	The University of Melbourne	Identification of molecular factors that influence reassortment and pandemic potential of highly pathogenic avian influenza H5 viruses	Identify gene segments, critical regions within gene segments, and functional interactions of gene products that influence reassortment in HPAI H5 viruses	Licence issued	30/09/2020	30/09/2030
DNIR-629	Novotech (Australia) Pty Limited	Clinical trial with ICM-203 for the treatment of arthritis	This trial aims to assess the safety and efficacy of gene therapy treatment using a genetically-modified adeno-associated viral vector encoding transcription factor Nkx3.2 in patients with arthritis	Expired	15/01/2021	15/01/2026
DNIR-630	CSL Innovation Pty Ltd	Human Embryonic Kidney 293 cells containing recombinant ChAdOx1 vector expressing COVID-19 insert	The aim of this dealing is to manufacture and supply frozen bulk drug substance for subsequent formulation operations as part of an overall program for the supply of recombinant antigen for the prevention of COVID-19	Surrendered	2/11/2020	28/02/2023
DNIR-631	Novotech (Australia) Pty Limited	SARS-CoV-2 prophylactic vaccine for use in clinical trials	This Phase I trial aims to assess the safety and efficacy of a vaccine candidate against disease caused by SARS-CoV-2.	Surrendered	28/01/2021	20/04/2022
DNIR-632	Seqirus Pty Ltd	Formulation and Fill/Finish of a recombinant ChAdOx1 vector that expresses the spike protein of SARS-CoV-2	The aim of this dealing is to receive frozen bulk drug substance for subsequent formulation and fill finish operations as part of an overall program for the supply of recombinant antigen for the prevention of COVID-19	Surrendered	14/12/2020	11/05/2023
DNIR-633	Murdoch Children's Research Institute	Administration of AVXS-101 to patients with genetically diagnosed spinal muscular atrophy	To assess the safety and efficacy of a recombinant AAV serotype 9 vector encoding SMN1 in infants with Spinal Muscular Atrophy (SMA)	Expired	29/03/2021	29/03/2026
DNIR-634	The University of Queensland	Dissecting COVID-19 pathogenesis by advanced molecular technologies	To study viral replication, pathogenesis, immune evasion, immunomodulation and drug susceptibility by assessing the effects of targeted mutations in various proteins.	Licence issued	10/06/2021	10/06/2031

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-635	Novotech (Australia) Pty Limited	Clinical Trials with 4D-310 for the treatment of Fabry Disease	This trial aims to assess the safety, tolerability, and pharmacodynamics of 4D-310 in patients with Fabry disease	Expired	4/06/2021	4/06/2026
DNIR-636	Avance Clinical Pty Ltd	Clinical trial to determine the safety and efficacy of SC-Ad6-1, an adenovirus based COVID-19 vaccine	To assess the safety, tolerability, immunogenicity and efficacy of SC-Ad6-1 as a second generation, prophylactic vaccine to prevent COVID-19.	Expired	15/04/2021	15/04/2026
DNIR-637	Janssen-Cilag Pty Ltd	A recombinant COVID-19 vaccine (Ad26.COV2.S) for use in clinical trials	To conduct clinical trials to assess the safety, reactogenicity and immunogenicity of the recombinant COVID-19 vaccine (Ad26.COV2.S) in pregnant women and children.	Surrendered	5/05/2021	18/12/2025
DNIR-638	Avance Clinical Pty Ltd	Serotype 5 Based Recombinant Vector Encoding the Human CYP21A2 Gene to treat Congenital Adrenal Hyperplasia	To test the safety and efficacy of a recombinant AAV serotype 5 vector encoding the human CYP21A2 gene in participants with Congenital Adrenal Hyperplasia (CAH).	Expired	30/06/2021	30/06/2026
DNIR-639	Monash University	Investigating the genetic basis of dengue and chikungunya virus resistance to Wolbachia	Identify genetic determinants to dengue and chikungunya viruses that might confer resistance to the antiviral effects of Wolbachia in infected mosquitoes	Licence issued	25/08/2021	25/08/2031
DNIR-640	Treidlia Biovet Pty Ltd	Generation of recombinant toxin molecules from Clostridium tetani	To manufacture recombinant tetanus toxins for study of their potential to treat muscular disorders	Licence issued	20/08/2021	20/08/2026
DNIR-641	Treidlia Biovet Pty Ltd	Generation of recombinant toxin molecules	To manufacture recombinant ApxIVA toxins in E. coli for use in a vaccine against swine pleuropneumoniae, caused by Actinobacillus pleuropneumoniae	Licence issued	25/08/2021	25/08/2026
DNIR-642	Diagnostic Technology Pty Limited	Recombinant production of Neosaxitoxin and Microcystin in E. coli		Withdrawn		
DNIR-643	Griffith University	Development of heterologous viral envelope pseudotyped virus platforms for research in emerging viral pathogens	The aim of this application is to develop a platform using heterologous viral envelope pseudotyping i.e., the surface of an un-related virus will be decorated with viral surface proteins of pandemic viral pathogens, to examine the function of the surface (envelope or spike) proteins of pandemic viral pathogens	Licence issued	28/09/2021	28/09/2026
DNIR-644	Pfizer Australia Pty Ltd	Establish safety and efficacy of PF- 06939926 in patients with Duchenne Muscular Dystrophy	To test the safety and efficacy of a recombinant AAV serotype 9 vector encoding a miniaturised version of human dystrophin protein in participants with Duchenne muscular dystrophy (DMD)	Licence issued	8/09/2021	8/09/2028
DNIR-645	Peter MacCallum Cancer Centre	Viral immune activating agents as cancer therapeutics		Withdrawn		
DNIR-646	The University of Melbourne	Two types of split gene drive for D.melanogaster lab experiments	The aim of this licence application is to develop and explore split gene drive designs to confer sex biased progeny and insecticide sensitivity in model organism Drosophila as a proof-of-concept	Licence issued	11/10/2021	11/10/2026
DNIR-647	Medpace Australia Pty Ltd	A Phase I/II, multicenter, open-label, single dose, dose ranging study to assess the safety and tolerability of ST-920, an AAV2/6 human alpha galactosidase A gene therapy in subjects with Fabry disease	Clinical trial to assess safety and tolerability of ST-920, an AAV2/6 human alpha-galactosidase A gene therapy to treat Fabry disease	Surrendered	21/10/2021	28/05/2025
DNIR-648	Medpace Australia Pty Ltd	Clinical trial to determine the safety and efficacy of FLT180a, an Adeno-associated virus vector-mediated gene transfer of the Padua variant of human Factor IX in patients with haemophilia B	To assess the safety, tolerability and confirm the dose of FLT180a, a gene therapy treatment for adult male patients with haemophilia B using GM AAV encoding the Padua variant for human Factor IX	Licence issued	1/11/2021	1/11/2026

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-649	The Walter and Eliza Hall Institute of Medical Research	Use of the inducible gametocyte producing P. falciparum line NF54/iGP3 for controlled human malaria infection model	Characterise the GM Plasmodium falciparum NF54/iGP Clone 3 in vitro in cell lines and in vivo in a mouse model using trimethoprim-induced gametocytes to assess safety and infectivity.	Licence issued	10/01/2022	10/01/2027
DNIR-650	Merck Sharp & Dohme (Australia) Pty Ltd	Clinical trial of a live attenuated tetravalent Dengue vaccine (V181) in adults	The proposed clinical trial will evaluate the safety and tolerability of the GMOs when administered to healthy adults. Secondary objectives are to measure the immune response induced by the GMOs.	Licence issued	1/03/2022	1/03/2027
DNIR-651	BioMarin Pharmaceutical Australia Pty Ltd	Clinical Trial with BMN 331 in patients with Hereditary Angioedema	To determine safety, tolerability and efficacy of GM AAV (BMN-331) in patients with Hereditary Angioedema who are deficient in C1 Esterase Inhibitor (C1-INH).	Surrendered	30/03/2022	20/09/2024
DNIR-652	PPD Australia Pty Ltd	A Phase 3 clinical trial with DTX301 in patients with late-onset ornithine transcarbamylase deficiency	Clinical trial to test the safety and efficacy of DTX301 in participants with late-onset ornithine transcarbamylase deficiency.	Surrendered	11/04/2022	5/08/2025
DNIR-653	Novotech (Australia) Pty Limited	An Oncolytic Immunotherapy Product for use in Clinical Trials	The purpose of the clinical trials is to study the safety, tolerability and efficacy of the GMO in the treatment of mucosal solid tumours, as a single agent or in combination with anticancer drugs.	Surrendered	2/05/2022	3/06/2022
DNIR-654	The University of Melbourne	Understanding Coronavirus infection and disease	To study virus host-range, virulence, replicative fitness, transmissibility and susceptibility to antiviral drugs and vaccines, with the aim of developing better vaccines, antiviral drugs, and other treatment regimens for COVID-19.	Licence issued	17/10/2022	17/10/2027
DNIR-655	The Alfred Hospital	Phage therapy for severe lung disease due to Mycobacterium abscessus	This licence is for the treatment of non-tuberculous Mycobacteria infection (NTM) with a cocktail of naturally occurring and a GM bacteriophage.	Licence issued	12/07/2022	12/07/2027
DNIR-656	BioCina Pty Ltd	Expression and Purification of fusion protein targeting tumor specific cells	Large-scale production of GM E. coli expressing a fusion protein for use in cancer treatment.	Licence issued	12/01/2023	12/01/2028
DNIR-657	Seqirus Pty Ltd	Influenza prophylactic vaccine for use in a clinical trial	The proposed Phase 1 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine.	Licence issued	23/01/2023	23/01/2028
DNIR-658	Flinders University	Testing of immortalised cell lines for replication competent retroviruses	This licence authorises the testing of cell lines generated using early retroviral vector technology to demonstrate that they are free of replication competent retroviruses.	Licence issued	23/02/2023	23/02/2028
DNIR-659	CSL Innovation Pty Ltd	Supply of etranacogene dezaparvovec for the treatment of people with haemophilia B	To supply etranacogene dezaparvovec to patients suffering from haemophilia B with an increased bleeding tendency due to deficiency of the blood coagulation protein FIX (congenital Factor IX).	Licence issued	5/04/2023	
DNIR-660	The University of Queensland	Use of recombinant Adeno-associated viral vectors to enable evaluation of human vaccine responses in mice	To use genetically modified adeno-associated viral vectors expressing human cytokines to study immunological responses in mice.	Licence issued	19/04/2023	19/04/2028
DNIR-661	Novotech (Australia) Pty Limited	Clinical trial of genetically modified HSV-1-based vector for the treatment of solid tumours	To evaluate the safety, tolerability, and efficacy of the GMO in participants with solid tumours.	Licence issued	21/04/2023	21/04/2028
DNIR-662	Australian Veterinary Serum Laboratories	Expression of Australian paralysis tick holocyclotoxins in Pichia pastoris for development of therapeutics	To produce purified holocyclotoxins for assessment of antibody therapies and vaccine development for companion animals.	Licence issued	19/05/2023	19/05/2028

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-663	Novotech (Australia) Pty Limited	A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children with SCN1A positive Dravet Syndrome.	This clinical trial aims to assess the safety and efficacy of gene therapy treatment using a genetically modified adeno-associated viral vector in children with SCN1A-positive Dravet Syndrome. The GMO is designed to increase expression of the SCN1A gene in certain types of brain cells, correcting the genetic defect which causes this disorder .	Licence issued	6/06/2023	6/06/2028
DNIR-664	Novotech (Australia) Pty Limited	Clinical trial of genetically modified adeno-associated virus for the treatment of autosomal dominant optic atrophy (ADOA)	To evaluate the safety, tolerability and efficacy of gene therapy in adult patients with ADOA associated with OPA1 mutation	Licence issued	16/06/2023	16/06/2028
DNIR-665	South Australian Health and Medical Research Institute	Generating mouse models with altered inheritance	The aim of this project is to develop a gene drive in a laboratory to control invasive pest mice.	Licence issued	26/06/2023	26/06/2028
DNIR-666	Beyond Drug Development Pty Ltd	Clinical evaluation of VOY-101 in patients with advanced non-neovascular age-related macular degeneration	This clinical trial is to test the safety and preliminary efficacy of a single, unilateral, intravitreal injection of an AAV2 vector therapy in subjects with late-stage non-neovascular age-related macular degeneration (AMD) .	Licence issued	3/07/2023	3/07/2028
DNIR-667	The Children's Hospital Westmead	Clinical trials involving Adeno-associated virus (AAV) gene therapy	To perform a broad range of clinical trials targeting genetic disorders caused by mutations affecting a single gene within a hospital setting. The trials use AAV viral vectors for in vivo administration of gene therapy in eligible patients .	Licence issued	10/08/2023	10/08/2028
DNIR-668	Parexel International Pty Ltd	A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP9001 in Non- Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (EMVISION)	Clinical trial for patient with Duchennes Muscular Dystrophy (DMD)	Licence issued	22/08/2023	22/08/2028
DNIR-669	Janssen-Cilag Pty Ltd	Clinical trial of genetically modified adeno-associated virus for treatment of geographic atrophy secondary to age-related macular degeneration	To evaluate the efficacy and safety of the GMO in patients with geographic atrophy secondary to age-related macular degeneration .	Surrendered	7/08/2023	18/12/2025
DNIR-670	QIMR Berghofer	Gene Drive Anopheles farauti	Laboratory-contained research to develop a gene drive mosquito to control the spread of malaria	Licence issued	25/08/2023	25/08/2028
DNIR-671	Novotech (Australia) Pty Limited	Clinical trial with a genetically modified Salmonella Typhimurium in patients with advanced solid tumours.	To evaluate the safety and preliminary anti-tumour activity of the GMO in patients with metastatic or unresectable solid tumours .	Licence issued	1/09/2023	1/09/2028
DNIR-672	IQVIA RDS Pty Ltd	Clinical trial with Anti-CD19 CAR-T cell therapy in patients with relapsed/refractory B cell non-Hodgkin lymphoma	To evaluate the safety and tolerability of CAR-T cell therapy in patients with B cell non-Hodgkin lymphoma to determine the maximum tolerated dose and recommended Phase 2 dose	Licence issued	11/09/2023	11/09/2028
DNIR-673	CSIRO	Molecular determinants of Newcastle disease virus pathogenicity	This project aims to investigate the molecular basis for differences in pathogenicity associated with Newcastle disease virus strains of differing virulence .	Licence issued	25/09/2023	25/09/2028
DNIR-674	Monash University	Use of mouse lines containing diphtheria toxin genes for cardiovascular studies		Withdrawn		
DNIR-675	Monash University	Use of DTA transgenic mice		Withdrawn		
DNIR-676	Monash University	DTA Expressing Strains for Investigating Immunity in Mucosal Sites		Withdrawn		

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-677	Monash University	Use of transgenic mice expressing Diphtheria Toxin A to study roles of various cellular processes	To use DTA expressing mice to study the roles of various cellular processes.	Licence issued	31/10/2023	31/10/2028
DNIR-678	Novotech (Australia) Pty Limited	Clinical trial of a genetically modified alphavirus replicon-based vaccine for the prevention of influenza	Clinical trial of a genetically modified alphavirus replicon-based vaccine for the prevention of influenza	Licence issued	18/10/2023	18/10/2028
DNIR-679	Graythan Regulatory Services Pty Ltd	Treatment of patients with advanced solid tumours with a genetically modified alphavirus	To determine the safety and tolerability of the GMO alone, and in combination with a checkpoint inhibitor, in patients with advanced cancers.	Licence issued	30/11/2023	30/11/2028
DNIR-680	The University of Melbourne	Vaccinia vectored vaccines against SARS-CoV-2 and Influenza A virus	Assessment of MVA vectored vaccine against IAV and SARS-Cov-2 in mice.	Licence issued	12/12/2023	12/12/2028
DNIR-681	Adelaide University	Testing of mammalian cell lines for replication competent virus associated with prior genetic modification	The purpose of the proposed dealings is to enable the testing of historically generated cell lines, previously transduced with early viral vector technology, with no historical documentation to demonstrate that they are free of replication competent viruses.	Licence issued	16/01/2024	16/01/2029
DNIR-682	Novotech (Australia) Pty Limited	Clinical evaluation of RZ-004 in patients with retinitis pigmentosa	To test the safety and preliminary efficacy of subretinal injection of the gene therapy RZ-004 in participants with retinitis pigmentosa caused by an autosomal dominant RHO mutation.	Licence issued	10/01/2024	10/01/2029
DNIR-683	Novotech (Australia) Pty Limited	Clinical trial of genetically modified alphavirus replicon-based vaccine for the prevention of COVID-19	To evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine against COVID-19	Licence issued	12/01/2024	12/01/2029
DNIR-684	Beyond Drug Development Pty Ltd	A clinical trial to evaluate the safety, tolerability and efficacy of an AAV9 gene therapy in female children with Rett Syndrome	The purpose of the proposed trial is to assess the safety, tolerability and efficacy of an AAV9 based gene therapy in female children aged 4-10 years with Rett Syndrome, associated with mutation in MECP2 gene.	Licence issued	15/01/2024	15/01/2029
DNIR-685	Bioproperties Pty Ltd	Formulation and filling of a genetically modified infectious laryngotracheitis virus for the vaccination of chickens	The purpose of this application is to formulate and fill the genetically modified vaccine for infectious laryngotracheitis virus (ILT) in chickens.	Licence issued	13/02/2024	13/02/2029
DNIR-686	The University of Melbourne	in vitro and in vivo studies with feline alphaherpesvirus-1 derived immunocontraceptives	The applicant aims to construct and investigate the effectiveness of immunocontraceptives based on feline herpesvirus-1, using in vitro and in vivo models.	Licence issued	30/04/2024	30/04/2029
DNIR-687	BioCina Pty Ltd	Expression and Purification of an Epsilon Toxin (ETX) Vaccine Candidate	The aim of this project is to express a genetically modified (GM) toxin in GM E. coli. The purified toxin will be evaluated as a vaccine candidate.	Licence issued	7/03/2024	7/03/2029
DNIR-688	Premier Research (Australia) Pty Ltd	Clinical trial of a treatment for refractory/relapsing B-cell malignancies	A clinical trial to assess the safety and effect of INT2104, a lentiviral vector with a transgene for a chimeric antigen receptor specific for CD20, in a broad population of patients with relapsed or refractory B-cell malignancies.	Licence issued	17/04/2024	17/04/2029
DNIR-689	The University of Sydney	An intracellular VenomORF library expression platform	This study aims to develop a third-generation lentivirus based genomic platform which can be utilised to identify the bioactive proteins of therapeutic value from venom of different organisms.	Licence issued	12/04/2024	12/04/2029
DNIR-690	PPD Australia Pty Ltd	Clinical trial of a genetically modified adeno-associated virus in patients with peripheral manifestations of Gaucher Disease	Clinical trial of genetically modified adeno-associated virus for the treatment of patients with Gaucher disease	Licence issued	19/03/2024	19/03/2029

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-691	The University of Melbourne	Demonstration of split gene drives in zebrafish	To develop a proof of concept study to explore the split gene drive homing mechanism in zebrafish. The intent is to apply the results of this study to control invasive vertebrate species by conferring sex bias	Licence issued	11/06/2024	11/06/2029
DNIR-692	Syneos Health Australia Pty Ltd	A clinical trial to evaluate the safety and efficacy of SPK-8011 in adults with severe or moderately severe haemophilia A	The purpose of the proposed trial is to assess the safety, tolerability and efficacy of an AAV based gene therapy in adults suffering with severe or moderately severe haemophilia A	Surrendered	25/06/2024	21/05/2025
DNIR-693	CSL Innovation Pty Ltd	Clinical trial of etranacogene dezaparvovec in patients with haemophilia B	The purpose of this clinical trial is to evaluate the safety and efficacy of the GMO in adults with haemophilia B	Licence issued	3/05/2024	3/05/2029
DNIR-694	BioCina Pty Ltd	Manufacturing unencapsulated Streptococcus pneumoniae as a whole cell vaccine	The aim of this project is to manufacture the GMO, formulate and fill the GM vaccine for subsequent inactivation.	Licence issued	22/04/2024	22/04/2029
DNIR-695	BioMarin Pharmaceutical Australia Pty Ltd	Supply of Roctavian (valoctocogene roxaparvovec) to patients with severe haemophilia A	Commercial supply of Roctavian for the therapeutic treatment of patients with Severe Haemophilia A	Surrendered	20/08/2024	20/11/2024
DNIR-696	Seqirus Pty Ltd	Clinical trial of self-amplifying mRNA vaccine for pandemic influenza	The proposed Phase 1 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine	Licence issued	31/07/2024	31/07/2029
DNIR-697	Public and Environmental Health Reference Laboratories, Pathology Queensland	Destruction of nonviable Hendra virus (HeV) and Australian Bat Lyssavirus (ABLV) recombinant plasmids	The aim of this dealing is to destroy stored stocks of plasmids encoding full length, partial or GM Hendra virus and Australian Bat Lyssa Virus genomes	Expired	10/09/2024	10/09/2025
DNIR-698	Murdoch Children's Research Institute	A Clinical Trial of ECUR-506 for treatment of Males with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency	The proposed clinical trial will evaluate safety and efficacy of an AAV-based gene therapy for the treatment of OTC deficiency.	Licence issued	19/09/2024	19/09/2029
DNIR-699	Seqirus Pty Ltd	Clinical trial of a multi-valent self-amplifying mRNA vaccine for the prevention of Influenza	The proposed Phase 2 clinical trial will evaluate the safety, reactogenicity and immunogenicity of a self-amplifying mRNA vaccine	Licence issued	31/07/2024	31/07/2029
DNIR-700	TFS Trial Form Support Australia Pty Ltd	Clinical trial of AAV gene therapy (AGTC-501) for X-linked retinitis pigmentosa	The purpose of this clinical trial is to evaluate the efficacy, safety, and tolerability of subretinal injection of the gene therapy AGTC-501 in male participants with X linked retinitis pigmentosa	Licence issued	3/10/2024	3/10/2029
DNIR-701	Source Certain Operations Pty Ltd	Import of corn, soybean and wheat	Import of corn, soybean and wheat seed samples for provenance analysis.	Licence issued	10/10/2024	10/10/2029
DNIR-702	Adelaide University	Engineering bacteria to make bacterial toxins for cancer treatment	Expression of recombinant bacterial toxins in GM E. coli to reduce the viability of bowel cancer cells.	Licence issued	17/10/2024	17/10/2029
DNIR-703	Medpace Australia Pty Ltd	A clinical trial of UB-VV111 in combination with rapamycin for the treatment of relapsed/refractory CD19+ hematologic malignancies	To assess the safety, efficacy, and pharmacokinetics/pharmacodynamics of UB-VV111 in combination with and without rapamycin in adult subjects with relapsed/refractory CD19+ hematologic malignancies.	Licence issued	19/11/2024	19/11/2029
DNIR-704	The Children's Hospital Westmead	A Clinical Trial of ECUR-506 for treatment of Males with Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency	The proposed clinical trial will evaluate safety and efficacy of an AAV-based gene therapy for the treatment of OTC deficiency.	Licence issued	30/10/2024	30/10/2029

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-705	Western Sydney Local Health District	Clinical trial of GM AAV for treatment of genetic XYLT2 deficiency	The purpose of this clinical trial is to test the safety and efficacy of GM AAV in adult patients with genetic XYLT2 deficiency, specifically to test efficacy for brittle bone disease	Licence issued	12/11/2024	12/11/2029
DNIR-706	La Trobe University	Expression of Staphylococcus aureus toxins	The purpose of this project is to express Staphylococcus aureus toxins in E. coli for characterisation of their <u>superantigen mechanisms</u> .	Licence issued	14/01/2025	14/01/2030
DNIR-707	The Royal Children's Hospital	Bermagene geperpavec (B-VEC)	To treat a small number of patients with dystrophic epidermolysis bullosa.	Licence issued	19/12/2024	19/12/2029
DNIR-708	Seqirus Pty Ltd	Preparation of influenza vaccines using attenuated influenza A viruses	The purpose of the dealings is to produce and propagate vaccines against non-seasonal Influenza A, based on an attenuated Influenza A virus, in cell lines at small and large <u>scales and to conduct quality control experiments</u>	Licence issued	22/01/2025	22/01/2030
DNIR-709	BioCina Pty Ltd	Manufacture of genetically modified Salmonella enterica enterica Serovar Typhimurium bacterial strains to derive <u>nanocells</u>	To manufacture genetically modified Salmonella Typhimurium bacteria capable of producing nanocells.	Licence issued	13/01/2025	13/01/2030
DNIR-710	The University of Melbourne	Exploring gene drives in Plasmodium to control malaria	This project aims to develop and investigate gene drives in Plasmodium berghei and Plasmodium falciparum to modulate <u>parasite populations</u>	Licence issued	12/02/2025	12/02/2030
DNIR-711	The University of Melbourne	Understanding seasonal coronavirus infection and disease	The primary aim is to develop genetically modified (GM) HCoV-NL63 strains capable of infecting mice to better understand HCoV-NL63 infection. These studies may assist in the development of better vaccines and antiviral drugs that could be broadly effective against both SARS-CoV-2 and HCoV-NL63.	Licence issued	10/02/2025	10/02/2030
DNIR-712	The Florey Institute of Neuroscience and Mental Health	Prodromal disease characterisation in murine models of familial prion disease	The project is to develop human genetic prion disease in mouse by introducing human genes related to prion disease. This animal model data will provide evidence for a future <u>longitudinal study involving patients</u>	Licence issued	24/02/2025	24/02/2030
DNIR-713	The University of Sydney	A constitutive VenomORF library expression platform	This study aims to develop a third-generation lentivirus genomic platform to characterise the bioactivity of proteins <u>from the venom of different organisms</u> .	Licence issued	10/02/2025	10/02/2030
DNIR-714	IQVIA RDS Pty Ltd	In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma	To assess the safety, tolerability, preliminary efficacy and pharmacokinetics/pharmacodynamics of the GMO in adult <u>patients with relapsed and refractory multiple myeloma</u> .	Licence issued	6/03/2025	6/03/2030
DNIR-715	Valo Therapeutics (Australia) Pty Ltd.	A clinical trial to assess safety and clinical activity of the GMO PeptiCRAD-1 in patients with solid tumours		Cease to consider		
DNIR-716	PPD Australia Pty Ltd	A clinical trial of an AAV-based gene therapy (EPI-321) for the treatment of facioscapulohumeral muscular dystrophy (FSHD) in adults	The purpose of this clinical trial is to assess the safety, tolerability and biological activity of EPI-321 (the GMO) in adult patients with facioscapulohumeral muscular dystrophy (FSHD)	Licence issued	24/03/2025	24/03/2030
DNIR-717	PPD Australia Pty Ltd	Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Refractory Systemic Lupus Erythematosus	To evaluate the safety and tolerability of CAR-T cell therapy in patients with Refractory Systemic Lupus Erythematosus	Surrendered	25/03/2025	7/08/2025

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-718	Adelaide University	Investigating immune evasion mechanisms in cancer	Using genetically modified Murine Leukemia Virus (MLV) to transduce human and murine cells to express different genes in order to understand their effects on immune invasion.	Licence issued	31/03/2025	31/03/2030
DNIR-719	Adelaide University	Use of genetically modified Staphylococcus aureus strain to express an extracellular virulence factor.	To use GM Staphylococcus aureus overexpressing a protease to generate positive controls for comparative analysis.	Licence issued	24/03/2025	24/03/2030
DNIR-720	The University of Newcastle	Characterisation of toxin biosynthesis pathways from environmental microorganisms	This study aims to develop genetically modified microbial hosts to enable heterologous expression of aquatic microbial toxins. Biosynthesis gene clusters involved in the molecular pathway will be characterised for future development of bioactive compounds	Licence issued	12/05/2025	12/05/2030
DNIR-721	QIMR Berghofer	Obesity linked cancer	The aim of the proposed dealings is to modulate gene expression in mammary duct epithelial cells of mice using lentiviral vectors in order to induce ductal carcinogenesis in situ	Licence issued	16/04/2025	16/04/2030
DNIR-722	James Cook University	Production of transgenic Nippostrongylus brasiliensis hookworms that secrete therapeutic foreign molecules	Evaluate the prophylactic and/or therapeutic potential of transgenic hookworms expressing foreign molecules in mice.	Licence issued	28/04/2025	28/04/2030
DNIR-723	Boehringer Ingelheim Pty Ltd	Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors	To evaluate the safety and efficacy of the GM VSV for the treatment of solid tumours.	Licence issued	2/05/2025	2/05/2030
DNIR-724	Novotech (Australia) Pty Limited	Clinical trial of GM AAV for treatment of Amyotrophic Lateral Sclerosis	To test the safety and efficacy of GM AAV for the treatment of Amyotrophic Lateral Sclerosis	Licence issued	30/01/2025	30/01/2030
DNIR-725	ICON Clinical Research Pty Limited	Clinical trial of genetically modified adeno-associated virus for the treatment of haemophilia B	The purpose of this clinical trial is to evaluate the safety and efficacy of genetically modified adeno-associated virus in adult and paediatric patients with haemophilia B	Licence issued	30/04/2025	30/04/2030
DNIR-726	CTI Clinical Trial and Consulting Services Australia Pty Ltd	Clinical trial of GM adeno-associated virus for treatment of frontotemporal dementia	To assess the safety, tolerability and pharmacodynamic effects of a GM AAV in adult participants with frontotemporal dementia (FTD)	Licence issued	13/05/2025	13/05/2030
DNIR-727	Premier Research (Australia) Pty Ltd	A Phase I Study to Evaluate the Safety and Tolerability of a Lentiviral Vector (INT2106) in participants with refractory Generalised Mvasthanien Gravis	To assess the safety and effectivity of INT2106, a lentiviral vector with a transgene for CAR19, in patients with generalised mvasthanien gravis (GMG)	Licence issued	17/06/2025	17/06/2030
DNIR-728	Flinders University	Use of a Diphtheria Toxin Subunit A expressing transgenic mouse model to study molecular and cellular physiology of common human diseases	Use of a Diphtheria Toxin Subunit A expressing transgenic mouse model to study molecular and cellular physiology of common human diseases	Licence issued	2/07/2025	2/07/2030
DNIR-729	The Walter and Eliza Hall Institute of Medical Research	Experimental malaria infection of healthy malaria-naïve adults with the genetically modified Plasmodium falciparum	The study will infect healthy participants with GM Plasmodium falciparum via mosquito bite to create a master cell bank (MCB) for future human clinical trial.	Licence issued	4/07/2025	4/07/2030
DNIR-730	IQVIA RDS Pty Ltd	Phase 3 clinical trial of a new formulation of live attenuated tetravalent dengue vaccine in adults	The Phase III clinical trial aims to evaluate the immunogenicity and safety of 2 doses of a new formulation of the tetravalent dengue vaccine compared to the currently approved commercial vaccine in adults in dengue non-endemic area.	Licence issued	30/07/2025	30/07/2030

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-731	Sanofi-Aventis Australia Pty Ltd	Clinical trial of an adeno-associated viral vector-mediated gene therapy for the treatment of non-congenital myotonic dystrophy type 1	To evaluate the safety, tolerability, and efficacy of the GMO, an adeno-associated viral vector-mediated gene therapy, in participants with non-congenital myotonic dystrophy type 1 (DM1)	Licence issued	14/08/2025	14/08/2030
DNIR-732	Worldwide Clinical Trials Pty Limited	Clinical Study of Vusolimogene Oderparepvec in Patients with Advanced Melanoma	To evaluate the clinical benefits and safety of Vusolimogene Oderparepvec in combination with nivolumab for the treatment of patients with advanced (unresectable, Stage IIIb-IV) melanoma whose disease has progressed while being treated with an antiPD-1 antibody and an anti-CTLA-4 antibody	Licence issued	8/09/2025	8/09/2030
DNIR-733	Worldwide Clinical Trials Pty Limited	Clinical trial of RP2 in Adult Patients with Metastatic Uveal Melanoma	To test the safety and efficacy of RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab in immune checkpoint inhibitor-naïve adult participants with inoperable metastatic uveal melanoma	Licence issued	8/09/2025	8/09/2030
DNIR-734	BioCina Pty Ltd	Expansion of E. coli coded with tetanus toxin and derivatives and manufacture of toxin proteins	Manufacture of GM E. coli master cell banks for supply to client	Licence issued	24/09/2025	24/09/2030
DNIR-735	Bristol-Myers Squibb Australia Pty Ltd	Clinical trial of BMS-986515, healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases	The purpose of this clinical trial is to evaluate the safety and tolerability of BMS-986515 in trial participants with severe, refractory autoimmune diseases.	Licence issued	6/11/2025	6/11/2030
DNIR-736	Viral Vector Manufacturing Facility Pty Ltd	Large scale manufacture of lentiviral and adeno-associated viral vectors	To manufacture a broad range of lentiviral and adeno-associated virus (AAV) vectors in quantities greater than 25 L per vessel. The GMOs will subsequently be formulated, filled and finished for in-house process development and client-based therapeutic use	Licence issued	12/11/2025	12/11/2030
DNIR-737	PPD Australia Pty Ltd	Clinical trial of GM AAV for treatment of geographic atrophy secondary to age-related macular degeneration	To test the safety, tolerability and efficacy of VV-14295 in adults with geographic atrophy secondary to age-related macular degeneration.	Licence issued	5/11/2025	5/11/2030
DNIR-738	Novotech (Australia) Pty Limited	Clinical trial of GM adeno-associated virus for the treatment of congenital myasthenia syndrome	To test the safety and efficacy of GM adeno-associated virus in patients with congenital myasthenic syndrome	Licence issued	2/12/2025	2/12/2028
DNIR-739	Syneos Health Australia Pty Ltd	Clinical trial of 4D-150 in adults with Macular Neovascularisation Secondary to Age-Related Macular Degeneration	This clinical trial is a Phase 3 study designed to evaluate the efficacy, safety, and durability of GM AAV therapy in adults with neovascular age-related macular degeneration (nAMD).	Licence issued	4/12/2025	4/12/2030
DNIR-740	Vow Group Pty Ltd	Manufacture of the cNISTmAb Monoclonal Antibody using the Genetically Modified NISTCHO Cell Line	To demonstrate the large-scale manufacturing capabilities of the GMO cell line platform.	Licence issued	9/12/2025	9/12/2028
DNIR-741	Sanofi-Aventis Australia Pty Ltd	Clinical trial of an adeno-associated viral vector-based gene therapy for the treatment of geographic atrophy secondary to age-related macular degeneration	To evaluate the safety, tolerability and efficacy of SAR446597 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	Licence issued	9/02/2026	9/02/2031
DNIR-742	Adelaide University	Identification and characterisation of Apicomplexan drug and vaccine targets using genetically modified parasites	To characterise the function of currently uncharacterised parasite genes, investigate the effectiveness of developmental drugs on gene targets, and produce reporter lines for use in vaccine development	Licence issued	2/02/2026	2/02/2031
DNIR-743	Vow Group Pty Ltd	Production of therapeutic monoclonal antibodies (mAbs) in Chinese Hamster Ovary (CHO) suspension cell lines	Large-scale manufacturing of monoclonal antibodies using GM CHO cell lines	Licence issued	22/04/2026	22/04/2029

OFFICIAL

OFFICIAL

OGTR ID	Organisation	Project Title	Project Description	Status	Date Issued	Expiry/ Surrender Date
DNIR-744	Adelaide University	Use of non-replicative HCV pseudoparticles to evaluate the efficacy of candidate HCV vaccines	To use genetically modified murine leukemia virus particles pseudotyped with hepatitis C virus envelope proteins in human cell infection assays to evaluate immune responses elicited by candidate hepatitis C vaccines	Licence issued	21/04/2026	21/04/2031
DNIR-745	Adelaide University	AAV gene therapy for treatment of brain tumours	To use genetically modified adeno-associated viral (AAV) vectors expressing human cytokines to study immunological responses in mice.	Licence issued	1/04/2026	1/04/2031
DNIR-746	University of Tasmania	Developing a biocontrol vaccine for pest species	To test immunocontraception vaccines in laboratory rats and mice.	Licence issued	28/04/2026	28/04/2031
DNIR-747	Graythan Regulatory Services Pty Ltd	Clinical trial with a self-amplifying mRNA for the treatment of patients with advanced solid tumours		Withdrawn		
DNIR-748	Medpace Australia Pty Ltd	A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1	To test the safety and efficacy of FLT201 in adult patients with Gaucher Disease Type 1	Licence issued	8/05/2026	8/05/2031
DNIR-749	Medpace Australia Pty Ltd	A Phase 1, Open-Label Multicenter Study of UB-VV500 in Combination with Rapamycin in Relapsed or Refractory Multiple Myeloma	To evaluate the safety and efficacy of UB-VV500 (GMO) in combination with or without rapamycin in adult subjects with relapsed or refractory multiple myeloma.	Licence issued	16/06/2026	16/06/2031
DNIR-750	Medpace Australia Pty Ltd	Clinical trial of GM adeno-associated virus (RJVA-001) in adults with inadequately controlled type 2 diabetes on multiple glucose-lowering agents	To evaluate the safety, tolerability, and preliminary efficacy of RJVA-001 in participants with inadequately controlled type 2 diabetes	Licence issued	21/05/2026	21/05/2031
DNIR-751	Graythan Regulatory Services Pty Ltd	Clinical trial with a self-amplifying mRNA for the treatment of patients with advanced solid tumours	The aim of the clinical trial is to determine the safety and tolerability of a self-amplifying RNA encoding IL-12 alone, and in combination with a checkpoint inhibitor, in patients with advanced solid tumours.	Licence issued	29/04/2026	29/04/2031
DNIR-752	Parexel International Pty Ltd	A Clinical Trial to Investigate the Efficacy of SGT-003 in Ambulant Males with Duchenne Muscular Dystrophy	Investigate the efficacy of a single intravenous dose of SGT-003 as gene therapy in ambulant males with Duchenne muscular dystrophy	Licence issued	22/05/2026	22/05/2031
DNIR-759	University of Tasmania	Using transgenic mice expressing Diphtheria Toxin A chain to investigate cellular processes and organ function	Use of DTA expressing mice to deplete target cell populations in order to assess their contribution to cellular processes and organ function.	Licence issued	18/06/2026	18/06/2031